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ABSTRACT 
 
Caveolae are integral part of the smooth muscle membrane and caveolins, the defining 
proteins of caveolae, act as scaffolding proteins for several G protein-coupled receptor signaling 
molecules and regulate cellular signaling through direct and indirect interactions with signaling 
proteins. Caveolin-1 is the predominant isoform in the smooth muscle and drives the formation 
of caveolae. However, little is known about the role of caveolin-1 in the regulation of excitation-
contraction and excitation-transcription coupling in gastrointestinal smooth muscle. In the 
present study we have characterized muscarinic m2 and m3 receptor signaling in gastric smooth 
muscle and tested the hypothesis that caveolin-1 positively regulates muscarinic receptor 
signaling and contractile protein expression in smooth muscle. The role of caveolae/caveolin-1 in 
the regulation of muscarinic signaling was examined using complementary approaches: a) 
methyl β-cyclodextrin (MβCD) to deplete cholesterol in dispersed muscle cells, b) caveolin-1 
siRNA to suppress caveolin-1 expression in cultured muscle cells, and c) caveolin-1 knockout 
(KO) mice. 
 RT-PCR, western blot and radioligand binding studies demonstrated the selective 
expression of m2 and m3 receptor in gastric smooth muscle cells. Carbachol (CCh), acting via 
m3 receptors caused stimulation of phosphoinositide (PI) hydrolysis, Rho kinase and ZIP kinase 
activity, and induced phosphorylation of MYPT1 (at Thr696) and MLC20 (at Ser19), and muscle 
contraction, and acting via m2 receptors caused inhibition of forskolin stimulated cAMP 
formation. Stimulation of PI hydrolysis, Rho kinase and ZIP kinase activities, phosphorylation of 
MYPT1 and MLC20 phosphorylation and muscle contraction in response to CCh was attenuated 
 XVI 
in dispersed cells treated with MβCD or in cultured cells transfected with caveolin-1 siRNA. 
Similar inhibition of all responses was obtained in gastric muscle cells from caveolin-1 KO mice 
compared to gastric muscle cells to WT mice. Although, caveolin-1 had no effect on m2 receptor 
signaling, agonist-induced internalization of m2, but not m3 receptors was blocked in dispersed 
cells treated with MβCD or in cultured cells transfected with caveolin-1 siRNA. These results 
suggest that caveolin-1 selectively and positively regulates Gq/13-coupled m3 receptor signaling, 
Gi-coupled m2 receptor internalization. The expression of contractile proteins, γ-actin and 
caldesmone and the transcription factors SRF and myocardin that regulate the expression of 
contractile proteins are down regulated, whereas EGF-stimulated EGF receptor phosphorylation 
and ERK1/2 activity are up-regulated in cells transfected with caveolin-1 siRNA. These results 
suggest using pharmacological, molecular and genetic approaches provide conclusive evidence 
that caveolae and caveolin-1 play an important role in orchestrating G protein coupled receptor 
signaling to have dual pro- excitation-contraction and excitation-transcription coupling, and anti-
proliferative role in gastric smooth muscle. 
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CHAPTER I: INTRODUCTION 
 
INTRODUCTION 
 
 
The Gastrointestinal (GI) tract is a complex organ system with tissues that possesses 
distinct structural and functional characteristics. It performs the important task of processing the 
ingested food through digestion, absorption, expulsion of waste products and also protection 
against ingested microbes. It accomplishes these critical functions by the concerted action of the 
neuronal, muscular, immune and glandular tissue systems. The GI tract is highly innervated by 
local intrinsic neurons (the enteric nervous system) and the extrinsic sympathetic and 
parasympathetic nerves. This complex pattern of neural innervations control a variety of gut 
functions ranging from controlling the complex motor activity and propel the intraluminal 
content to the secretion of bioactive agents to facilitate digestion.   
. 
I.  Structure of the Gastrointestinal Tract 
The Gastrointestinal (GI) tract is a long tubular hollow structure with its wall divided into 
four distinct layers that pocesses characteristic morphological and functional property. The 
layering pattern of the gut from inside of the lumen to outside is as follows: mucosa, submucosa, 
muscularis externa, and serosa (Gabella 1987). The enteric nervous system (ENS) is consists of 
two ganglionated plexus within submucosa and muscularis externa. The ENS controls the GI 
function through intrinsic and extrinsic neural reflexes that are mediated through an array of 
messengers and neurotransmitters. The smooth muscle cells of the muscularis externa are aligned 
into two layers: an outer thin longitudinal muscle layer and an inner thick circular muscle layer. 
A large subpopulation of neurons, glial cells, fibroblasts, and interstitial cells of Cajal separates 
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the muscle layers (Kunze and Furness 1999). Smooth muscle cells are responsible for 
contractility of the GI tract. 
I. 1.  Enteric nervous system 
The ENS consists of large number of nerve cell bodies that are found in the myenteric 
plexus located between the two smooth muscle layers and between the circular muscle layer and 
the submucosa (Gershon 1981). The ENS also contain glial cells that play an important role in 
providing support and nutrition to the neurons and are also involved in neurotransmission (Ruhl, 
Nasser et al. 2004). The enteric neural circuitry comprises of three functional classes of neurons 
that form multicomponent neural reflexes, viz motor neurons, interneurons and sensory neurons 
(Brookes 2001).   
I. 1a.  Motor neurons.  Scientific investigation over the past decades has led to the 
identification of both excitatory and inhibitory motor neurons innervating the muscle layers in 
the gut. Commercial availability of selective receptor antagonist led to the identification of 
acetylcholine as a co-transmitter of excitatory motor neurons in addition to tachykinins (Grider 
1989). Excitatory cholinergic transmission is mediated through muscarinic m2 and m3 receptors 
whereas; excitatory transmissions by tachykinin are mediated through NK1 and NK2 receptors 
(Lecci, Altamura et al. 2008). Similar to the excitatory motor neurons, the inhibitory neurons 
also encode for more than one transmitter (10) and include nitric oxide (NO), adenosine 
triphosphate (ATP), vasoactive intestinal peptide (VIP), and pituitary adenylyl cyclase-activating 
peptide (PACAP) (Harmar, Fahrenkrug et al. 2012).  
Another subtype of motor neurons called the secretomotor neurons innervates the 
mucosal layer of the gut and stimulates the secretion from glandular tissue. The secretomotor 
 3 
neurons have their cell bodies generally located in the sub-mucosal plexus and contain 
acetylcholine and VIP as co-transmitters (Carey, Cooke et al. 1985; Reed and Vanner 2007).  
I. 1b.  Interneurons. Physiological and pharmacological studies documented the 
existence of interneurons in the ENS with their cells bodies localized in the myenteric and 
submucosal plexus (Costa, Brookes et al. 1996). Based on structural evidences from guinea pig 
intestine, the interneurons are classified as ascending and descending interneurons (Neal and 
Bornstein 2008). Morphologically, the ascending reflex pathways represent a crosstalk between 
interneurons and excitatory motor neurons that is purely cholinergic acting through nicotinic 
receptors (Tonini and Costa 1990). However, the transmitters involved in the descending reflex 
pathways to relay information between the descending interneurons and the inhibitory motor 
neurons is clearly not elucidated, although, a possible involvement of ATP as a transmitter acting 
through purinergic P2 receptors has been proposed (LePard, Messori et al. 1997; Xue, Farrugia et 
al. 1999).  
I. 1c.  Sensory neurons.  Sensory neurons in the gut, acts as transducers to convey the 
information pertaining to its physical state and chemical milieu including villi movement, 
mucosal distortion, change in local distribution of blood flow, aberration in motility pattern and 
the chemical contents of the lumen, and integrate to the ENS (Furness, Jones et al. 2004). 
Morphologically, sensory neurons have been classified primarily as Dogiel type II neurons, 
which are characterized with multiple processes that form complex neuronal network 
establishing synaptic connections with other sensory neurons, interneurons, and motor neurons 
(Pompolo and Furness 1988). The sensory neurons exhibits well characterized 
electrophysiological properties, displaying broad action potential attributed to the presence of 
voltage gated sodium, calcium and potassium currents (Sanders 2000). Data gathered from recent 
 4 
studies also implicated the involvement of sensory neurons in nociception due to their ability to 
trigger protective measures in response to noxious stimuli (Collins 1996; Lundgren 2002).  
 
I. 1d.  Neurotransmitters in the gastrointestinal tract 
 A variety of neurotransmitters that are expressed in the central nervous system are also 
found in the enteric nervous system of the gut. Some of the most important neurotransmitters 
involved in the gut function are briefly summarized below. 
i) Acetylcholine.  Acetylcholine (ACh) is one of the principal transmitters of the gut 
controlling important functions like motility and secretion (Tobin, Giglio et al. 2009). 
Acetylcholine is synthesized in neurons by the enzyme choline acetyl transferase (ChAT) and 
stored in vesicles where it can be released from nerve terminals upon appropriate stimulation 
(Schemann, Sann et al. 1993; Arvidsson, Riedl et al. 1997; Murthy, Zhou et al. 2003). 
Acetylcholine receptors can be broadly classified into two types nicotinic and muscarinic. Since 
the ENS contains more than 80% of cholinergic neurons, there must be other co-transmitters in 
the gut. The most commonly expressed co transmitter in the gut are neuropeptides (Furness 
2006).     
ii) Neuropeptides. The residual contractile effect in response to cholinergic antagonist 
paralleled the identification of the excitatory neuropeptide, tachykinins. The tachykinin family of 
neuropeptides constitutes substance P and neurokinin A (NKA) and neurokinin B (NKB) that are 
produced as preprotachykinins and undergo transcriptional and translational processing to form 
mature polypeptides. To date the neuropeptide family has been shown to interact with three 
receptors NK-1, NK-2 and NK-3 (Maggio 1988; Satake, Kawada et al. 2003).  In contrast, the 
inhibitory component is mediated by vasoactive intestinal polypeptide (VIP). VIP belongs to a 
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structurally related family of peptides that includes secretin, PACAP and glucagon. On its 
release from nerve terminals, when stimulated, VIP acts on its membrane spanning G-protein 
coupled receptors and triggers the generation of the second messenger, cAMP.  cAMP acts on its 
downstream effectors to mediate the relaxant effects of VIP (Holst, Fahrenkrug et al. 1987). Like 
other GI peptides, VIP is also secreted in its inactive precursor form that is processed to its active 
form through proteolytic cleavage (Grider 1993).   
iii) Gaseous neurotransmitters. Gaseous transmitters are released on demand and 
diffuse across the cell membrane to act on specific intracellular targets.  Nitric oxide (NO) is the 
most well studied gasotransmitter in the ENS, however recently carbon monoxide (CO) and 
hydrogen sulfide (H2S) are gaining importance in regulating some of the GI functions (Kasparek, 
Linden et al. 2008).   
The well defined characteristics of gaseous transmitters are as follows: a) they are 
gaseous molecules with very small atomic radii; b) they are freely diffusible across cellular 
membranes and do not activate cell surface receptors; c) they are synthesized denovo by 
enzymatic action and released on demand in a regulated way; d) they exhibit specific cellular 
functions at physiologically relevant concentrations; e) their cellular effects may or may not be 
dependent on the generation of second messengers; f) they should have very short half-life and 
efficient scavenging mechanisms to remove the transmitter following their action. 
Nitric Oxide (NO). NO is generated as a gaseous product in the conversion of L-arginine 
to L-citruline by the enzymatic action of nitric oxide synthase (NOS). In the GI tract, NO is 
produced mainly by the action of constitutively expressed neuronal NOS (nNOS) and released 
by the inhibitory nitrergic neurons of the enteric nervous system (ENS) (Boehning and Snyder 
2003). Following release NO diffuses through cell membrane and acts on its intracellular targets, 
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such as soluble guanylyl cyclase (sGC) to trigger the formation of cGMP. The cGMP formed 
then acts on several downstream effectors that collectively function to decrease the intracellular 
Ca2+ concentration and leads to hyperpolarization and smooth muscle relaxation (Koh, Sanders 
et al. 1996; Teng, Murthy et al. 1998). NO is the most prominent non-adrenergic, non-
cholinergic neurotransmitter in the gut. Abnormalities in NO production have been correlated 
with many pathophysiological conditions such as achalasia, functional dyspepsia, delayed gastric 
emptying, diabetic gastroperesis and other GI dysmotility disorders (Shah and Kamath 2003).  
Carbon Monoxide (CO).  CO is produced as a catabolite of heme synthesis by the 
enzyme heme oxygenase (HO) along with other by-products such as biliverdin and iron. Release 
of CO by enteric neurons causes smooth muscle relaxation. Apart from stimulating sGC to 
produce cGMP, it also increases cAMP levels that lead to the activation of PKA (Xue, Farrugia 
et al. 2000; Wu and Wang 2005). The activation of second messenger-mediated kinases induces 
smooth muscle relaxation. Coexpression of HO and nNOS in myenteric neurons suggest a 
possible interaction between CO and NO. NOS potentiate CO mediated activation of sGC and 
enhance muscle relaxation. Defects in CO signaling are also associated with inflammatory and 
immune responses (Snyder, Jaffrey et al. 1998; Miller, Reed et al. 2001). 
Hydrogen Sulfide (H2S).  H2S has recently been identified as a gasotransmitter (Li, 
Bhatia et al. 2006). Endogenously, H2S is produced by the action of two enzymes, cystathione γ-
lyase (CSE) and cystathione β-synthase, on L-cysteine. The expression of these enzymes has 
been confirmed in ENS (Linden, Levitt et al. 2010). Following its release, H2S is metabolized by 
several mechanisms including mitochondrial oxidation, cytosolic methylation, and glutathione-
mediated oxidation. H2S function of smooth muscle relaxation is primarily mediated by the 
activation of ATP-sensitive K+ channels that lead to membrane hyperpolarization and subsequent 
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closure of voltage gated Ca2+ channels and relaxation (Ebrahimkhani, Mani et al. 2005). Studies 
have also shown that H2S is involved in inducing chloride secretion in guinea pig and human 
colon (Schicho, Krueger et al. 2006; Pouokam and Diener 2012).   
I. 2.  Interstitial Cells of Cajal (ICCs)  
The GI smooth muscle displays a distinct spontaneous electrical activity originating from 
interstitial cells of Cajal (ICCs). The smooth muscle cells are electrically coupled to ICCs and 
additionally integrate electrical inputs from ENS along with other endocrine and paracrine agents 
to regulate gut motility (JH. 1987; Sanders, Koh et al. 2006). The continuous discharge of 
electrical patterns by virtue of its pacemaker activity, ICCs enhances the open probability of 
voltage gated Ca2+ to induce sustained mode of contraction at different regions of the GI tract 
(Farrugia 1999; Bayguinov, Ward et al. 2007). This intrinsic rhythmic pattern of membrane 
potential in response to excitatory and inhibitory neural inputs is called slow waves. Basically, 
Slow waves function to shift the membrane potential of smooth muscle from a more negative 
potential to a more positive value, that helps to enhance the open probability of the voltage gated 
Ca2+ channels. The periodical influx of Ca2+ generating an inward current due to oscillatory 
opening of voltage gated Ca2+ channels helps to organize the excitation-contraction coupling of 
the muscle into a phasic pattern of contraction and relaxation (Morgan, Muir et al. 1981; 
Camborova, Hubka et al. 2003; Bayguinov, Ward et al. 2007).  
Based on morphological and physiological evidences it has been suggested that 
interstitial cells of Cajal (ICC) are the pacemaker cells of the GI tract. Slow waves are initiated 
from ICCs and conducted to the smooth muscle cells as confirmed by electrical and optical 
recordings performed on ICCs and muscle cells simultaneously. In the absence of ICCs, muscle 
cells no longer shows rhythmicity and do not propagate slow waves. Experimental studies on 
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isolated and cultured ICCs have shown that ICCs express receptors for both excitatory and 
inhibitory transmitter (Ward, Burns et al. 1994; Huizinga, Thuneberg et al. 1995; Iino and 
Horiguchi 2006), the intracellular components and transmembrane ion channels necessary to 
generate spontaneous slow waves (Koh, Sanders et al. 1998). ICCs has also been shown to 
express different types of gap junction proteins including connexins, which help ICCs to form 
well ordered network of electrical coupling with the adjacent smooth muscle cells (Schwentner, 
Oswald et al. 2005). The cellular connectivity that ICC establishes with other ICCs and smooth 
muscle cells are crucial for its pacemaker activity.  
 
I. 3.  Gastrointestinal smooth muscle and its contractile apparatus 
The smooth muscle in the gut produces contractile force to propel food along the length 
of the GI tract. Structurally, smooth muscle cells are about 200 to 300 µm in length and 5 to 15 
µm wide. Unlike skeletal and cardiac muscles, smooth muscles are characterized by the lack of 
cross-striations that gives a smoother appearance in contrast to other types of muscle. 
Intracellular structural bodies such as dense bodies and contractile filaments populates in smooth 
muscle cells (Bitar 2003). Smooth muscle filaments can be categorized into three subtypes: thin 
actin filaments, thick myosin filaments and intermediate filaments. Actin is a 42-kDa protein that 
is ubiquitously expressed in its globular form called G-actin and polymerizes into double helical 
strands and forms filamentous actin or F-actin (Hodgkinson 2000; Rensen, Doevendans et al. 
2007; Tang 2008). Thick filaments are hetero-multimeric proteins formed by the aggregation of 
six different types of polypeptides: 1 pair of myosin heavy chains (MHC) and 2 pairs of myosin 
light chains (MLCs) (Xu, Harder et al. 1996; Burgess, Yu et al. 2007). The MHCs forms a coiled 
structure that terminates in a globular head like structure surrounded by two pair of MLCs, a 20-
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kDa regulatory light chain (MLC20), and a 17-kDa essential light chain (ELC). The globular 
head contains a binding site for actin and actin-activated magnesium-adenosine triphosphatase 
(Mg-ATPase (Kamm and Stull 1989). Smooth muscle also contains thin filament associated 
proteins such as calponin, caldesmon, and smoothelin (Morgan and Gangopadhyay 2001). 
 
I. 4.  Signaling Mechanism Involved in Smooth Muscle Contraction 
“Excitation-contraction coupling” in all muscle is initiated by increase in intracellular 
Ca2+ leading to changes in the activity of, or interactions of, actin and myosin. Actomyosin 
interaction is dependent on phosphorylation of MLC20, which is both necessary and sufficient for 
smooth muscle contraction. Phosphorylation of MLC20 leads to muscle contraction, whereas 
dephosphorylation leads to muscle relaxation. The levels of MLC20 phosphorylation are 
regulated by MLC kinase (MLCK) and MLC phosphatase (MLCP) activity (Horowitz, Menice et 
al. 1996; Webb 2003; Huang, Zhou et al. 2005; Murthy 2006).   
The signaling mechanisms for contraction in visceral smooth muscle is primarily 
mediated by G-protein coupled receptors (GPCRs). The GPCR apparatus consist of three tier 
membrane bound components: i) a seven transmembrane receptor protein, ii) a GTP-binding 
heterotrimeric G protein tethered to the receptor, and iii) membrane bound precursors that 
triggers the generation of one or more cellular signals that initiate cascades leading to activation 
of downstream effectors (Puetz, Lubomirov et al. 2009; Wright, Tripathi et al. 2012). Several 
subtypes of receptor were found to mediate the contractile response in smooth muscle cells and 
include receptors for acetylcholine, peptides (tachykinins, endothelin, motilin), amines 
(histamine, 5-hydoxytryptamine), pyrimidines/purines (UTP, ATP), and lipids (SIP, LPA) 
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(Morini, Kuemmerle et al. 1993; Hellstrom, Murthy et al. 1994; Murthy and Makhlouf 1998; 
Sarna 1999; Zhou and Murthy 2004).  
 
I. 4.1.  Regulation of myosin light chain kinase (MLCK). 
In circular smooth muscle, activation of the receptor by the contractile agonist activates 
Gαq that leads to the activation of phosphoinositide (PI)-specific phospholipase C (PLCβ1). 
Stimulation of membrane bound PLCβ1 triggers the turnover of membrane embedded 
phosphatidylinositol 4,5-bisphosphate (PIP2) that generates two important intracellular second 
messengers; the soluble calcium mobilizing agent IP3 and the surface bound DAG. Soluble 
messenger, IP3 binds to its high affinity receptors IP3R-I on the sarcoplasmic reticulum and 
drives the release of Ca2+ into the intracellular milieu (Murthy, Grider et al. 1991). When Ca2+ 
gets released, it associates with calmodulin to form an active Ca2+-calmodulin complex which 
then binds to and activates MLCK. The activation of MLCK causes phosphorylation of MLC20, 
an obligatory step in smooth muscle contraction. Additionally, Ca2+ influx through voltage-gated 
Ca2+ channels also leads to activation of MLCK, phosphorylation of MLC20 and muscle 
contraction (Makhlouf and Murthy 1997). The initial Ca2+ surge responsible for initiating acto-
myosin interaction is very transient due to the operation of active Ca2+ extrusion and intracellular 
Ca2+ uptake mechanisms. These processes that causes downregulation of cytosolic Ca2+ leads to 
uncoupling of Ca2+-calmodulin complex from MLCK, and results in the inhibition of MLCK 
activity and muscle contraction (Somlyo and Somlyo 1994; Murthy and Makhlouf 1997; Murthy 
2006).  
A number of studies have shown that MLCK itself is regulated by negative feedback 
mechanism through phosphorylation by specific protein kinases. CAMKII is one such kinase that 
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directly phosphorylates MLCK and inhibits its activity (Tansey, Luby-Phelps et al. 1994). 
Recently, another protein kinase called AMP kinase (AMPK) was also shown to phosphorylate 
MLCK at Ser815 that causes significant reduction in its catalytic activity (Horman, Morel et al. 
2008).  
Although, the increase in Ca2+ and MLCK activity is transient, MLC20 phosphorylation 
and muscle contraction are well maintained by Ca2+-independent mechanisms that exclusively 
involve processes that target inhibition of MLC phosphatase (Murthy and Makhlouf 1997; 
Ganitkevich, Hasse et al. 2002; Somlyo and Somlyo 2003). 
 
I. 4.2.  Regulation of myosin light chain phosphatase (MLCP) 
In smooth muscle, regulated inhibition of MLCP is achieved by G-protein mediated 
activation of RhoA. Stimulation of two subsets of G-protein; Gq and G13 in response to a 
contraclite agonist leads to the activation of RhoA. RhoA belongs to a family of small G-proteins 
and in inactive state it is associated with GDP to from RhoA-GDP and localized in the 
cytoplasm. The GDP bound form of RhoA is stabilized by its interaction with another protein 
called guaninine dissociation inhibitor (GDI). Signaling downstream of receptor activation 
stimulates RhoA, a process mediated by several Rho-specific guanine nucleotide exchange 
factors (RhoGEFs). When RhoGEFs is stimulated it promotes the release of GDP and exchange 
GTP in its place (Murthy and Makhlouf 1997; Somlyo and Somlyo 2003; Siehler 2009). RhoA-
GTP is the activated form of RhoA, which then translocate from the cytoplasm and gets tethered 
to the inner leaflet of the plasma membrane and subsequently activates the smooth muscle 
specific isoform of Rho Kinase, Rho kinase II and also the membrane bound phospholipase D 
(PLD) (Murthy, Zhou et al. 2001). 
 12 
When Rho kinase gets stimulated it act on MLCP to inhibit its activity. The MLCP 
holoenzyme comprised of three distinct component; a 110 to 130- kDa regulatory subunit known 
as the myosin phosphatase target subunit 1(MYPT1), a type 1 phosphatase (PP1cδ) of 37 kDa 
which is the catalytic subunit and, finally a 20 kDa subunit whose function is still not known 
(Hartshorne 1998). Rho kinase mediated phosphorylation of MYPT1 at Thr696 promotes 
uncoupling of the catalytic and regulatory subunits of MLCP that ultimately leads to inhibition of 
its catalytic activity (Fukata, Amano et al. 2001). Additionally, targeted phosphorylation of 
Thr853 located within the myosin-binding domain of MYPT1 by Rho kinase, promotes 
dissociation of MLCP from myosin and consequently decreases its efficiency to bind myosin 
(Wooldridge, MacDonald et al. 2004). Zipper interacting protein (ZIP) kinase, also known as the 
MYPT1-associated kinase, has a similar effect like Rho kinase on MYPT1 phosphorylation at 
Thr696 promoting its dissociation from the catalytic subunit and decreasing MLCP activity 
(MacDonald, Borman et al. 2001; Lincoln 2007). 
As noted above, RhoA activation apart from stimulating Rho kinase also stimulates PLD 
activity. PLD hydrolyses phosphatidylcholine to generate phosphatidic acid. The latter gets 
subsequently dephosphorylated to yield DAG that causes prolonged activation of protein kinase 
C (PKC). Smooth muscle typically expresses the ε and δ isoforms of PKC that function to 
phosphorylate an endogenous MLCP inhibitor called CPI-17 (Murthy, Grider et al. 2000; 
Woodsome, Eto et al. 2001). PKC mediated phosphorylation of CPI-17 at Thr38 greatly enhances 
its ability to inhibit MLCP and potentiates muscle contraction (Kitazawa, Eto et al. 2000). This 
dual role of RhoA to activate either Rho kinase or PKC is central to mediate the sustained phase 
of smooth muscle contraction.  
 13 
Lack of inhibition of the sustained phase of smooth muscle contraction in the presence of 
inhibitors specifically targeted to Ca2+/calmodulin dependent MLCK, suggests the involvement 
of Ca2+-independent MLC Kinases during the sustained phase. Moreover, experimental 
evidences demonstrated that contraction in arterial smooth muscle cell by phosphatase inhibitor, 
microcystin-LR in Ca2+ free medium, is significantly abrogated by a non-specific kinase 
inhibitor. All of the above findings exclusively implicate an involvement of Ca2+-independent 
MLCK to phosphorylated MLC20 and caused sustained contraction (MacDonald, Borman et al. 
2001). 
The most well characterized Ca2+-independent kinases in smooth muscle cells are ZIP 
kinase and integrin-linked kinase (ILK). MLC20 phosphorylation at both Ser19 and Thr18 leading 
to contraction of permeabilized preparation of arterial smooth muscle in the presence of 
endogenously purified ZIP kinase and phosphatase inhibitor in Ca2+ free environment confirmed 
the involvement of ZIP kinase as a Ca2+-independent kinase responsible for sustained contraction 
(Niiro and Ikebe 2001; Muranyi, MacDonald et al. 2002). ZIP kinase is a serine/threonine kinase 
and a member of death-associated protein (DAP) kinase family. ZIP kinase has also been shown 
to colocalize with MYPT1 and phosphorylate the MLCP subunit at Thr696 in conjunction with 
Rho kinase (Borman, MacDonald et al. 2002). ILK is also a serine/threonine kinase that operates 
in a Ca2+ independent fashion and found to be associated with MLCP (Zhou, Das et al. 2003). 
ILK causes smooth muscle contraction either by directly phosphorylating MLC20 at Ser19 and 
Thr18 or by working in combination with CPI-17 to inhibit MLCP (Kiss, Muranyi et al. 2002; 
Zhou, Das et al. 2003; Huang, Mahavadi et al. 2006).  
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I. 5.  Signaling Pathways Involved in Smooth Muscle Relaxation 
Relaxation of contracted smooth muscle is mediated by generation of second messengers 
such as cAMP and cGMP, and activation of cAMP-dependent protein kinase (PKA) and cGMP-
dependent protein kinase (PKG), respectively. PKA and PKG, in turn, act on various targets, and 
their action culminates in the reduction of intracellular Ca2+ and/or MLC20 phosphorylation, a 
prerequisite for muscle relaxation. The relaxant neurotransmitter in the gastrointestinal tract 
includes neuronal NO synthase (nNOS) and the peptide neurotransmitter, vasoactive intestinal 
peptide (VIP) and its homologue, pituitary adenylate cyclae-activating peptide (PACAP). 
Activation of soluble guanylyl cyclase by nitric oxide and Gs-coupled VPAC2 receptors by VIP 
or PACAP result in the generation of cGMP and cAMP, respectively. Signaling cascades 
initiated downstream of cGMP and cAMP leads to efficient removal of Ca2+ transients causing 
inactivation of MLCK and subsequent MLC20 dephosphorylation. Muscle relaxation and MLC20 
dephosphorylation can also be achieved by the removal of MLC phosphatase inhibition and 
successive augmentation of its dephosphorylating activity (Webb 2003; Murthy 2006).  
 
I. 5.1. Regulation of Cyclic Nucleotide Levels 
The titre of cAMP and cGMP in gastrointestinal smooth muscle is regulated by a balance 
between their synthesis by cyclases and degradation by phosphodiesterases (PDEs) (Turko, 
Francis et al. 1998).  The cyclic AMP levels in smooth muscle are rapidly degraded by the action 
of cAMP specific PDEs, PDE3 and PDE4, whereas cGMP levels are regulated by cGMP-
specific PDE5.  PKA and PKG exert feedback regulation to fine-tune cAMP and cGMP levels 
via feedback regulation. PKA phosphorylates cAMP specific PDEs to stimulate their activity and 
subsequently promote cAMP degradation. On the other hand PKA mediated inhibitory 
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phosphorylation of adenylyl cyclase V/VI, the predominant isoforms in smooth muscle, also 
reduces the formation of cAMP. Similarly, cGMP levels are regulated via PKG-mediated 
stimulatory phosphorylation of PDE5 that promotes cGMP degradation, and inhibitory 
phosphorylation of sGC that attenuates cGMP generation (Francis, Turko et al. 2001; Murthy 
2001; Murthy, Zhou et al. 2002). 
 
I. 5.2. Molecular targets of PKA and PKG 
In the initial phase of smooth muscle contraction, PKA and PKG induce relaxation 
primarily by terminating the Ca2+ transients and thereby decreasing the sensitivity of MLCK to 
Ca2+. Both PKA and PKG in smooth muscle, inhibit IP3 formation via downregulation of Gαq-
dependent PLCβ1 activity. However the inhibition is not direct via inhibitory phosphorylation of 
Gαq and PLCβ1, but mediated by the combinatorial effect of PKA and PKG induced stimulatory 
phosphorylation of RGS4 and PKA induced phosphorylation of GRK2 that concertedly act to 
inhibit PLCβ1 activity (Huang, Zhou et al. 2007). Similarly, inhibitory phosphorylation of IP3R-
1 on sarcoplasmic reticulum by PKG but not PKA causes blockage of Ca2+ release into the 
cytoplasm (Murthy and Zhou 2003). PKG also phosphorylates sarco-endoplasmic reticulum 
Ca2+/ATPase (SERCA) and enhances Ca2+ uptake from the intracellular milieu into the 
sarcoplasmic store. Furthermore, PKG mediated stimulatory phosphorylation of plasmalemmal 
Ca2+/ATPase augments intracellular Ca2+ extrusion (Cornwell, Pryzwansky et al. 1991). Finally, 
both PKA and PKG inhibit the conductance through membrane bound Ca2+ channels and 
simultaneously activate K+ channels to induce hyperpolarization (Koh, Sanders et al. 1996).    
Relaxation can also be induced by PKA and PKG in a Ca2+ independent manner during 
the sustained phase of contraction. The inhibition of the catalytic activity of MLCP through 
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RhoA pathway is released by PKA and PKG mediated phosphorylation of the molecular targets 
upstream as well as downstream of RhoA. The upstream targets of RhoA by the cyclic 
nucleotides include the Gα13, p115 RhoGEF and RhoA and the downstream targets include Rho 
kinase, and MYPT1. Both PKA and PKG can phosphorylate RhoA at Ser188 and promote its 
translocation from the plasma membrane to the cytosol. The movement of RhoA from membrane 
to cytosol strictly inhibits Rho kinase activity by impeding its physical interaction with 
membrane-bound molecular targets. Therefore, the inhibitory effect of Rho kinase on MLCP via 
MYPT1 phosphoryation is withdrawn. Additionally, the inhibitory effect of CPI-17 on MLCP 
activity is released via inhibition of Rho kinase/PLD activity and PKC mediated phosphorylation 
of CPI-17 (an endogenous MLCP inhibitor) at Thr38 (Sauzeau, Le Jeune et al. 2000; Murthy, 
Zhou et al. 2003; Murthy 2006). Lastly, relaxation mediated via RhoA independent pathway is 
also enhanced by stimulatory phosphrylation and activation of telokin, an endogenous MLCP 
activator (MacDonald, Walker et al. 2000). All of the above effects of cAMP/PKA and 
cGMP/PKG converge to produce enhanced activity of MLCP and accelerated dephosphorylation 
of MLC20, a hallmark for smooth muscle relaxation. 
 
I. 6. Receptor Desensitization and Internalization   
Over the last two decades multiple molecular mechanisms has been proposed to explain 
the regulation of GPCR signaling. Primarily, following activation of the GPCRs by their cognate 
ligands, specific signaling mechanism gets triggered to produce an appropriate cellular response. 
The intensity of the signaling cascade is regulated by reducing the efficacy of the GPCRs to 
transmit signal through a process called desensitization, or by the subsequent removal of the 
activated receptors from the surface to blunt the signaling response through receptor 
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internalization (Drake, Shenoy et al. 2006). Desensitization refers to the process that leads to 
reduce ability of the receptor to get stimulated as a consequence of prior enhanced activation 
(Hausdorff, Caron et al. 1990).  
The term desensitization has traditionally been used to describe events that cause the 
uncoupling of the activated receptors from heterotrimeric G-proteins. In contrast, sensitization 
refers to the process that causes increased ability of the receptor to get stimulated due to low 
activation (Gainetdinov, Premont et al. 2004). GPCRs exhibit desensitization in response to its 
activating ligands to regulate the signaling intensity and promote signaling termination. GPCR 
mediated signaling is regulated at the receptor level majorly by two mechanisms: i) by 
modulating signaling efficacy of the receptors and ii) by upregulating or downregulating the 
number of cell surface receptors. Desensitization process can be further categorized into two 
types: homologous desensitization that is dependent on ligand-receptor interaction and the 
heterologous desensitization that is independent of ligand-receptor interaction (Bohm, Grady et 
al. 1997). 
 
I. 6.1. Molecular mechanism of homologous desensitization 
Ligand bound GPCRs not only activates G-proteins to initiate specific signaling cascades, 
but also the interacting ligand-receptor complex forms a substrate for protein phosphorylation 
(Delom and Fessart 2011). Following receptor activation by the ligand, G protein coupled 
receptor kinase (GRK) gets recruited to the cytoplasmic domain of the activated receptor and 
phosphorylate the receptor at specific sites (Shenoy and Lefkowitz 2003). The GRK family of 
kinases comprised of seven members that has been categorized into three subfamilies, viz. GRK 
1/7, GRK 2/3 and GRK 4/5/6 on the basis of significant overlap of the amino acid sequence and 
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structural homology (Pitcher, Freedman et al. 1998; Willets, Challiss et al. 2003). GRK 2, 3, 5 
and 6 were found to be widely expressed and has been implicated in regulating most of the 
GPCR signaling. The other members of the GRK family GRK 1/7 are exclusively involved in 
signal transduction in visual pathways, whereas GRK4 is only expressed in the testes 
(Gainetdinov, Premont et al. 2000; Penela, Murga et al. 2006).  
GRK mediated phosphorylation of the activated receptor is a prelude to the binding of a 
scaffolding protein called β-arrestin. The driving force of arrestin recruitment comprises of both 
the GRK phosphorylation sites on the receptors and the active ligand-receptor configuration 
(Perry and Lefkowitz 2002). The primary role of arrestin interacting with the activated receptor 
is to dampen the firing of the ligand-receptor complex. The inhibition in signal transmission by 
the ligand-receptor complex is achieved by restricting the Gα subunit from exchanging GTP for 
GDP. Locking the Gα subunit in the GDP conformation prevents the transmission of cellular 
signal to the downstream effectors (Luttrell and Lefkowitz 2002). Among the most well 
characterized arrestins are the nonvisual arrestins called the β arrestins viz. βarrestins-1 and 
βarrestins-2. They are widely expressed in a variety of tissue and play an important role in 
regulating many GPCR signaling machineries. 
 
I. 6.2. Molecular mechanisms of heterologous desensitization 
Heterologous desensitization involves attenuation of the signaling downstream of the 
receptor and precludes physical interaction between the receptor and the ligand (Chuang, 
Iacovelli et al. 1996). An efficient way of receptor uncoupling from the heterotrimeric G-protein 
involves covalent modifications in the structure as imposed by receptor phosphorylation. The 
second messenger dependent kinases such as protein kinase A (PKA) and protein kinase C 
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(PKC) catalyzes transfer of γ-phosphate group of ATP to serine and threonine residues of its 
target proteins (Pierce, Premont et al. 2002). PKA and PKC are activated downstream of GPCR 
signaling and causes generation of second messengers such as cAMP, increase in intracellular 
Ca2+ and diacylglycerol. The second messengers generated activate the downstream kinases and 
transduce signal by stimulating them through prosphorylation (Ferguson 2001). Apart from 
phosphorylating their target effectors, these kinases by virtue of feedback regulation, 
phosphorylates the receptors. Second messenger activated protein kinase mediated 
phosphorylation of the receptors leads to a marked loss of the receptor function. Unlike GRKs 
that selectively phosphorylated agonist bound receptors, second messenger dependent protein 
kinases in contrast, randomly phosphorylates receptors irrespective of the presence or absence of 
the agonist. Moreover, the sites of receptor phosphorylation by these kinases are different from 
those of GRKs (Lefkowitz, Hausdorff et al. 1990). In addition to negatively regulating the 
receptors through phosphorylation, PKA and PKC phosphorylates several other targets such as 
adenylyl cyclase, phospholipase C that collectively contribute to the desensitization process 
(Hamm and Gilchrist 1996).  
 
I. 6.3. Deactivation of G-protein by RGS proteins 
RGS (regulators of G protein signaling) proteins form a distinct class of regulatory 
proteins containing a conserved 120 amino acid sequence called RGS domain that act as GTPase 
activating protein (GAPs). The RGS domain binds specifically to the activated Gα subunit and 
increases the rate of GTP hydrolysis and stabilizing the GDP-bound conformation of the G-
protein. Thus by enhancing the intrinsic GTPase activity of the G-protein, they dampen the 
intensity of signaling pathways (Berman and Gilman 1998; Neubig 2002). Recently it has also 
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been demonstrated that RGS proteins can directly interact with the receptors and modulate their 
activity (Snow, Hall et al. 1998).  
 
I. 7. GPCR internalization 
Agonist-activated receptor internalization into intracellular pockets is an important aspect 
of regulation of GPCR activity. GRK phosphorylation of the activated receptors generates high 
affinity binding sites for β-arrestins (Delom and Fessart 2011). Binding of coat proteins clathrin 
follows binding of β-arrestins to the receptor, which exhibits high affinity to β-arrestins and 
interacts through their carboxy terminal region. Overall, the process involves translocation of β-
arrestins from the cytoplasm to the plasma membrane and bind to the receptor at the site of GRK 
phosphorylation to mediate the process of receptor internalization via both clathrin-dependent 
and clathrin-independent caveolar pathway (Traub 2003). The model pathway for internalization 
is exemplified by β1-adrenergic receptors internalization, which is selectively mediated via 
clathrin-dependent pathway when phosphorylated by GRK, and by clathrin-
independent/caveolar-dependent pathway when phosphorylated by PKA (Rapacciuolo, Suvarna 
et al. 2003). Additionally, lipid modification such as palmitoylation/depalmitoylation of 
receptors has also been shown to play a role in targeting the receptors to lipid rafts for 
internalization (Papoucheva, Dumuis et al. 2004). 
 
 
I. 8.  Regulation of GPCR Signaling by Scaffolding Proteins 
 
Higher degree of specificity in the molecular interaction among multitude of signaling 
proteins forms the basic tenet of the signal transduction process. It is of primary importance to 
study the mechanisms involved in bringing the molecular partners of a signaling cascade in close 
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proximity for accurate and efficient signaling events. Scaffolding proteins forms a special class 
of regulatory proteins that essentially act as molecular glue to gather signaling molecules in close 
proximity that accounts for the precise and efficient signaling mechanisms. Scaffolding proteins 
provides the basic platform that helps in subcellular colocalization of signaling molecules by 
associating with protein components of a signaling cascade and enhancing protein-protein 
interaction for an efficient transmission of cellular signals (Faux and Scott 1996; Wrana and 
Pawson 1997). The hallmark of interaction of a scaffolding protein is defined by the presence of 
a unique signature motif that helps them to interact and bind with their target proteins. The 
function of a scaffolding protein to facilitate signal transduction may not necessarily be restricted 
to mere tethering of signaling molecules to promote the assembly of a signaling complex, but 
also to modulate/regulate the activity of its protein partners. The major function ascribed to 
scaffolding proteins can be broadly classified into two broad areas- firstly, isolating signaling 
molecules of a cascade into a pre-signaling complex and secondly, regulating the activation and 
or inhibition of components of a signaling pathway (Good, Zalatan et al. 2011). Some of the 
important scaffolding proteins involved in the regulation of GPCR signaling are summarized 
below with particular emphasis on caveolin proteins. 
 
I. 8.1. A-Kinase Anchoring Proteins (AKAPs). AKAPs constitute the first family of proteins 
that was recognized with a scaffolding function. AKAP associate with its main host protein, 
PKA along with several other proteins of a signaling pathway and co-localizes them in a specific 
sub-cellular location (Michel and Scott 2002; Pidoux and Tasken 2010). The role of AKAP 
regulation of signaling pathways is exemplified by the activation of Gs-coupled β-adrenergic 
receptors (βAR) by its specific ligand epinephrine, in response to stress to regulate 
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cardiovascular function. To date many AKAP isoforms has been reported in a range of species, 
including yeast, fruitflies, mice and humans. All AKAPs share some common characteristic 
features such as a PKA-binding motif, a localization signal that helps to tether the protein to the 
plasma membrane and the ability to form presignaling protein complex with other components of 
a signaling pathway (Diviani and Scott 2001; Gold, Lygren et al. 2006; Pidoux and Tasken 
2010). 
 
I. 8.2. PDZ-domain containing scaffolding proteins.  PDZ domains are protein-protein 
interaction domains found in several proteins. The name is derived from the initial letters of the 
PSD-95, Dlg, and a ZO-1 protein that contains the sequence repeats from which the initial 
discovery was made. Generally, the interaction between the PDZ domain and its target protein 
though the C-terminal region is constitutive, however, in some instances the interaction also 
entails agonist-dependent receptors activation (Gomperts 1996; Ranganathan and Ross 1997; 
Feng and Zhang 2009). Conclusive evidence exists to support that β2-adrenergic receptors 
interact with proteins containing PDZ-domain that acts as scaffolds to link the receptor to its 
downstream effectors (Hall and Lefkowitz 2002; Valentine and Haggie 2011). Interestingly, 
GRK mediated phophorylation of β2-adrenergic receptors completely disrupt the association of 
the receptor to its PDZ-containing binding partners that clearly shows that GPCRs interaction 
with PDZ-domain containing proteins is critically dependent on GRK phosphorylation. 
Similarly, phosphorylation of inwardly rectifying K+ channels by PKA also disrupts its 
interaction with other PDZ-domain harboring proteins (Cohen, Brenman et al. 1996; Cao, 
Deacon et al. 1999; Fanning and Anderson 1999; Hu, Chen et al. 2002).   
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I. 8.3. Tetratricopeptide repeat (TPR)-bearing scaffolding proteins. This subclass of 
scaffolding proteins have been found to interact with different subtypes of Gα subunits including, 
Gαs and Gαq. The TPR bearing scaffolding proteins been shown to preferentially interact with the 
active conformation of HA-Ras in the absence of the G-protein, Gα16. Although, the 
physiological relevance of this interaction has not been explored in detail (Marty, Browning et al. 
2003; Andreeva, Kutuzov et al. 2007). 
 
I. 8.4. β-arrestins. The aforementioned interactions of GPCR with scaffolding proteins strictly 
entail the presence of specialized sequence motifs embedded either in the receptor or present in 
the scaffolding proteins. The association of GPCRs with β-arrestins exhibits a variation to the 
rule of specific GPCR/scaffold interaction. The family of β-arrestins exist in two isoforms: β-
arrestins1 and β-arrestins2 both are exclusively involved in the desensitization process of the β-
AR. However, recent studies has revealed that β-arrestins can associate with a broad variety of 
GPCRs. G-protein receptor kinase (GRKs) mediated phosphorylation of the activated receptors, 
promotes the receptor association with β-arrestins and causes uncoupling of the receptor from the 
G-protein (Luttrell and Lefkowitz 2002; Lefkowitz and Whalen 2004). Several proteins involved 
in endocytotic pathway such as clathrin are also known to interact with β-arrestins. The 
interactions of β-arrestins with the endocytotic proteins facilitate ligand induced receptor 
internalization. This qualifies β-arrestins as scaffolding protein linking GPCRs with the 
endocytotic machinery to promote internalization. Additionally, β-arrestins are also known to 
interact with tyrosine kinase Src and the interaction is important for activation of Src kinase to 
mediate other signaling events.  Thus, β-arrestins are not only proteins merely involved in GPCR 
internalization but can also function as a protein scaffold to simultaneously stimulate parallel 
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signaling processes (Luttrell, Ferguson et al. 1999; Imamura, Huang et al. 2001; Ma and Pei 
2007). 
 
I. 8.5. Caveolin proteins. Caveolae are 50 to 100 nm omega shaped, cell surface membrane 
invaginations found in many cell types including vascular endothelial cells, muscle cells, 
adipocytes and fibroblasts (Parton and Simons 2007; Volonte, McTiernan et al. 2008). Previous 
studies demonstrated myriad signaling molecules populate in caveolar pits including different 
type of receptors such as GPCRs coupled to heterotrimeric and monomeric G-proteins, receptor 
tyrosine kinases and other growth factor receptors (Wu, Butz et al. 1997; Okamoto, Schlegel et 
al. 1998; Chini and Parenti 2004). Caveolae have been implicated to regulate important cellular 
processes like endocytosis, transcytosis, calcium signaling and several other signal transduction 
events (Minshall, Sessa et al. 2003; Cohen, Hnasko et al. 2004). Caveolae forms a distinct subset 
of lipid rafts that are formed by the dynamic aggregation of cholesterol, glycosphingolipids and 
sphingomyelin (Ortegren, Karlsson et al. 2004). They are also highly enriched with several 
resident proteins of the plasma membrane such as glycophosphatidylinositol (GPI-anchored) and 
other phospholipids (Lisanti, Tang et al. 1993; Lisanti, Scherer et al. 1994).  
The caveolae coat proteins, caveolins serves as markers for identification of the caveolar 
domains and are critical for caveolae function. Caveolins are approximately 22-kDa proteins 
consisting of 178 amino acids with multiple acetylation and phosphorylation sites. Three 
isoforms of caveolin proteins: caveolin-1, caveolin-2 and caveolin-3, has been identified to date 
(Williams and Lisanti 2004; Chidlow and Sessa 2010). Caveolin-1 also known as vesicular 
integral membrane protein (VIP) was the first member of the caveolin gene family to be 
identified (Razani, Woodman et al. 2002; Parton 2003). It displays a wide range of expression 
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pattern in many tissue types including non-muscle and smooth muscle tissues. In smooth muscle, 
the first member of the caveolin family, caveolin-1 alone drives the formation of caveolae and 
forms the major structural components that preferentially interacts with different signaling 
molecules and regulate their function. In contrast, caveolin-2 is nonessential for caveolae 
formation and colocalizes with caveolin-1 for its stable expression. Although, caveolin-2 is not 
essential for caveolae formation, however co-expression and hetero-oligomerization of caveolin-
1 and 2 forms a more deeper and abundant caveolae, indicating a modulatory role of caveolin-2 
in caveolae formation. The last dominant isoform of the caveolin family, caveolin-3 is a muscle 
specific isoform and share high structural and functional similarities with caveolin-1. Unlike 
caveolin-2, caveolin-3 can form caveolar microdomain independent of caveolin-1 (Tang, Scherer 
et al. 1996; Scherer, Lewis et al. 1997; Williams and Lisanti 2004; Mercier, Jasmin et al. 2009).  
Sequence analysis studies have shown that caveolins interact with their binding partners 
through a short stretch of amino acids known as the caveolin scaffolding domain (CSD) 
embedded in the cytosolic N-terminal region spanning from amino acids 82 to 101 (Couet, Li et 
al. 1997; Epand, Sayer et al. 2005). Additionally, the interactions are also guided by a defined 
sequence of amino acids called the caveolin binding motifs (CBM) integrated within the binding 
partners. The most well defined CBM that has been identified contains a short tandem protein 
sequence with aromatic amino acids inserted in a specific pattern (Razani, Woodman et al. 2002; 
Collins, Davis et al. 2012). 
 
I. 8.5a. Regulation of endothelial nitric oxide synthase by caveolin. The interaction of 
caveolin proteins with endothelial nitric oxide synthase (eNOS) has been explored extensively 
(Garcia-Cardena, Fan et al. 1996). Studies demonstrated that interaction of eNOS with CSD of 
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the caveolin protein leads to inhibition of its enzymatic activity. Both caveolin-1 and -3 were 
shown responsible for suppressing the catalytic activity of eNOS. A number of studies also 
supported the hypothesis that decreases in caveolin expression upregulates eNOS activity under 
basal condition (Venema, Ju et al. 1997; Feron and Kelly 2001; Rath, Dessy et al. 2009).   
 
I. 8.5b. Regulation of cAMP/cGMP signaling by caveolin.  The scaffolding domain of 
caveolin-1 and -3 also interacts with specific isoforms of adenylyl cyclase (AC) and inhibit their 
activity (Toya, Schwencke et al. 1998; Willoughby and Cooper 2007). Consequently, disruption 
of caveolae or downregulation of caveolin proteins significantly promotes adenylyl cyclase 
activity (Yamamoto, Okumura et al. 1999; Head, Patel et al. 2006). Additionally, cyclic 
nucleotide phosphodiesterases (PDE), the enzyme responsible for hydrolyzing cAMP and cGMP 
has also been reported to localize in caveolar microdomains (Abrahamsen, Baillie et al. 2004; 
Baillie, Scott et al. 2005). Previous studies have shown that PDE3B isoform is 
compartmentalized in caveolae and its expression was decreased considerably in caveolin-1 
knockout mice (Nilsson, Ahmad et al. 2006). Similar association of PDE5 isoform with caveolae 
was reported and its expression decreased with targeted suppression of caveolin proteins with 
siRNA techniques and also in caveolin-1 knockout mice (Murray F 2006). Although, preliminary 
studies claims that caveolin-1 inhibits the catalytic activity of protein kinase A (PKA), however 
the localization of PKA in caveolae is not very well defined and remains inconclusive (Razani, 
Rubin et al. 1999; Razani and Lisanti 2001).  
 
I. 8.5c. Regulation of receptor tyrosine kinases by caveolins.  Receptor tyrosine kinases 
(RTK), another major class of transmembrane receptor was also reportedly associated with or 
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directly localized in caveolae (Couet, Sargiacomo et al. 1997; Pike 2005). Studies from several 
groups have shown that caveolin proteins regulate the MAP kinase cascade components, which 
forms the downstream effectors of RTK. Studies involving overexpression of caveolin isoforms 
leads to a marked downregulation of the signaling through the MAP kinase pathway (Engelman, 
Chu et al. 1998). In airway and vascular smooth muscle the expression of caveolin-1 was 
markedly reduced in proliferating muscle cells. Consistent with the antiproliferative role of 
caveolins, expression of receptors for growth factors such as EGF and PDGF, and constituent of 
growth factor signaling cascades such as Src, Shc, Grb2 and Ras are localized in caveolae. The 
selective interaction between the caveolin proteins with the members of the MAP kinase cascade 
significantly suppresses their activity (Gosens, Stelmack et al. 2006; Gosens, Stelmack et al. 
2011).  This shows a clear regulation of growth factor signaling by caveolae and its defining 
protein caveolins. 
 
I. 8.5d. Regulation of ion channels by caveolins. Ion channels and transporters play an 
important role in a variety of cellular functions that contribute in maintaining the membrane 
potential and cellular excitability to the release of neurotransmitters. Many groups have reported 
the potential localization of different kinds of ion channels such as Ca2+, K+, Na+, and Cl- in 
caveolar pits (Taggart 2001; Isshiki and Anderson 2003; Bergdahl and Sward 2004). Subcellular 
localization of these transmembrane proteins in rafts and caveolar microdomain are critical for 
their modulation by different cellular signals. The active components of the intracellular calcium 
handling machinery such as Ca2+-ATPase, IP3 receptor, voltage gated calcium channels, 
calmodulin, calcium pumps and transient receptor potential (TRP) channels, are preferentially 
harbored in cholesterol rich plasma membrane domains including caveolae in many cell types 
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(Fujimoto, Miyawaki et al. 1995; Schnitzer, Oh et al. 1995; Darby, Kwan et al. 2000; Lohn, 
Furstenau et al. 2000; Wang, Ye et al. 2005). Subcellular localization of these proteins in 
caveolar domains clearly indicates that caveolae and caveolin proteins conclusively participate in 
the process of intracellular calcium signaling.  
 
I. 8.5e. Regulation of endocytosis by caveolin proteins. Caveolae has been proposed to 
mediate the process of transcytosis in order to shuttle macromolecules across endothelial 
membrane. This process of transcytosis involves GTP-dependent, dynamin-mediated 
internalization of caveolar microdomains from the plasma membrane (Oh, McIntosh et al. 1998; 
Shajahan, Timblin et al. 2004; Predescu, Predescu et al. 2007). Internalization of caveolae is also 
triggered by other signals that include actin polymerization, presence of cholesterol, the presence 
of membrane protruding GMI ganglioside and phosphorylation through kinases (Schnitzer, Liu 
et al. 1995; Mukherjee, Tessema et al. 2006). The role of tyrosine kinase Src is remarkably well 
elucidated to understand its role in the molecular mechanisms of caveolar endocytosis. 
Downregulation of Src using small interfering RNA has resulted in enhanced accumulation of 
caveolar structure at the cellular membrane. Following endocytosis, the caveolar structure is 
maintained as a stable unit that ultimately fuses with other intacellular compartments such as 
caveosome in a RAB5 dependent manner. These intracellular caveolar units can later be recycled 
back to the plasma membrane to restore the caveolar topology on the membrane (Pelkmans, 
Burli et al. 2004; Shajahan, Tiruppathi et al. 2004; Parton and Simons 2007). 
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I. 9. Regulation of smooth muscle function by caveolins 
Studies from several laboratories have reported a very crucial role of caveolae to organise and 
regulate smooth muscle function by modulating cellular processes such as contraction, and 
growth and proliferation. Although, caveolin knockout mice are viable, however, they are more 
prone to develop pathophysiological complications such as cadiomyopathy, enhanced eNOS 
activity and severe pulmonary dysfunction (Drab, Verkade et al. 2001; Zhao, Liu et al. 2002; 
Cohen, Hnasko et al. 2004; Chidlow and Sessa 2010). All these have drawn scientific attention to 
investigate any modulatory effect of caveolae and caveolins in smooth muscle function. Several 
studies demonstrated caveolar colocalization of ion channels and signaling molecules involved in 
contraction (Maguy, Hebert et al. 2006; Balijepalli and Kamp 2008). Recently, caveolae and its 
coat proteins have been shown to play an important role in 5-HT2A and endothelin-1 (ET-1) 
receptor mediated smooth muscle contraction and disruption of caveolae severely compromised 
smooth muscle contractility (Cristofaro, Peters et al. 2007). The involvement of caveolae in 
regulation of L-type Ca2+ channel is controversial. Darby et al provided evidence of caveolar 
enrichment of L-type Ca2+ channels and Ca2+ binding proteins and their direct modulation by 
caveolae to control smooth muscle contractility (Darby, Kwan et al. 2000). However, Lohan et al 
reported that caveolae downregulation has no effect on conductance through L-type Ca2+ 
channels. Caveolae has also been implicated to mediated Ca2+ sensitisation process through its 
interaction with Rho kinase and several isoforms of PKC and regulate arterial smooth muscle 
contraction. Targeted erosion of caveolar pits from arterial smooth muscle cells caused 
significant impairment in muscarinic m2 and m3 receptor mediated airway smooth muscle 
contraction (Schlenz, Kummer et al. 2010). Moreover, response of ileum longitudinal muscle to 
endothelin-1, but not to carbachol or serotonin was reduced in caveolin-1 KO mice, whereas the 
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response of femoral arterial muscle to α1-adrenergic agonist was increased (Shakirova, 
Bonnevier et al. 2006). Thus, it appears that regulation of smooth muscle contraction by 
caveolins is both tissue- and receptor-specific.  
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I. 10. Novelty and Significance  
Caveolae provide an essential platform for signal transduction by G protein-coupled 
receptors in vascular and airway smooth muscle contractile function by integrating the 
contractile signals and intracellular effector pathways. Recent studies using caveolin knockout 
animals demonstrated that caveolae and caveolin-1 play an important role in several diseases 
phenotypes such as diabetes, athresclerosis, cardiac hydpertrophy, pulmonary hypertension and 
bladder dysfunction. Studies in vascular and airway muscle also demonstrated that the 
expression of caveolin-1 was significantly reduced in proliferating muscle cells compared to 
contractile phenotype. Caveolins, therefore, are also important for the maintenance of smooth 
muscle contractile phenotype. Gastrointestinal motility depends on the integrated function of 
enteric neurons, interstitial cells of Cajal and smooth muscle cells. Studies examining the 
involvement of caveolae and caveolin-1 in the regulation of GI motility are limited and, often, 
restricted to the intact tissue or organ. An obvious conclusion form these studies is the 
importance of caveolae and caveolins in the regulation of contractile function. Undoubtedly, the 
next step in the process of the understanding the mechanism by which caveolae and caveolins 
regulate muscle contraction is to understand the regulation of signal transduction pathways 
activated by contractile neurotransmitters in the smooth muscle. The signal transduction 
pathways that regulate muscle contraction short-term also regulate smooth muscle phenotype 
long-term.  In this study we examined the hypothesis that caveolae and caveolin-1 provide a 
critical regulatory environment for excitation-contraction and excitation-trascription coupling in 
the smooth muscle cells. To test this hypothesis we investigated the role of caveolae in the 
regulation of gastric smooth muscle function by the main excitatory neurotransmitter, 
acetylcholine mimetic, carbachol using freshly dispersed muscle cells devoid of neurons and 
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ICC. The role of caveolae and caveolin-1 in m2 and m3 receptor signaling was examined using 
pharmacological, biochemical, molecular and genetic approaches. Our study provides important 
biochemical basis by which caveolin-1 can regulate the integration of extracellular contractile 
stimuli and the downstream intracellular effectors in smooth muscle. For perspective, as 
demonstrated in the present study, caveolin-1 represents an important scaffolding protein in 
orchestrating G protein-coupled receptor signaling to have a dual role in pro- excitation-
contraction and excitation-transcription, and anti-proliferatiion in gastric smooth muscle. These 
results may also help to establish caveolin-1 as a therapeutic target in the treatment of smooth 
muscle complications in GI motility disorders.  
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CHAPTER: II MATERIALS AND METHODS 
II. 1. Materials 
 
 [125I]cAMP, [γ-32]ATP, [3H]myo-inositol, [3H]Scopolamine were obtained from PerkinElmer 
Life Sciences (Boston, MA); methoctramine (muscarinic m2 receptor antagonist) Sigma-Aldrich 
St. Louis, MO; 4-DAMP (muscarinic m3 receptor antagonist) Sigma-Aldrich, (St. Louis, MO); 
Y27632 (Rho kinase inhibitor) Calbiochem, (La Jolla, CA); U73122 (PLC inhibitor) Enzo Life 
Sciences, Inc., NY; PP2 (Src inhibitor) Enzo Life Sciences, Inc., NY; Antibodies: Caveolin-1, 
caveolin-3, phospho-MYPTI, phospho-MLC20, α-actin, γ-actin, caldesmone, β-actin, Rho kinase 
II, ZIP kinase, muscarinic m2 receptor, muscarinic m3 receptor, SRF, myocardin, phospho EGF 
receptor, ERK1/2 were obtained from Santa Cruz biotechnology, Santa Cruz, CA; 
RNAqueousTM kit was obtained from Ambion, Austin, TX; LipofectamineTM 2000 transfection 
reagent, SuperScriptTM II Reverse Transcriptase kit, DH5-α competent cells, were obtained from 
Invitrogen, Carlsbad, CA; Restriction enzymes were obtained from New England Biolabs 
(Ipswich, MA); QIAprepR Spin Miniprep Kit was obtained from QIAGEN Sciences, Maryland; 
PCR reagents were obtained from Applied Biosystems, Roche. Caveolin-1 SiRNA was obtained 
from BD Biosciences, San Jose, CA. pSIREN-DNR-DsRed vector was obtained from Clontech 
Laboratories, Inc. CA; EGF was obtained from BD Biosciences, San Jose, CA. Collagenase CLS 
type II and soybean trypsin inhibitor for cell isolation were obtained from Worthington, 
Freehold, NJ; Western botting materials, Dowex AG-1 X 8 resin (100-200 mesh in formate 
form), chromatography materials and protein assay kit, Tris-HCl ready made gels were all 
obtained from Bio-Rad Laboratories, Hercules, CA; Dulbecco’s modified Eagle’s medium for 
primary cell culture was obtained from Fisher Scientific. All other chemicals were obtained from 
Sigma, St. Louis, MO. 
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Animals 
New Zealand white rabbits (weight: 3-4 lbs) were purchased from RSI Biotechnology, 
Clemmons, NC and killed by injection of euthasol (100 mg/Kg), and caveolin-1 knockout and 
wild type mice (B6129SF2/J) were obtained from the Jackson Laboratory (Bar Harbor, ME) and 
killed by suffocation with CO2. All the procedure was followed as approved by the Institutional 
Animal Care and Use Committee of the Virginia Commonwealth University. The animals were 
housed in the animal facility maintained by the Division of Animal Resources, Virginia 
Commonwealth University. All procedures were conducted in accordance with the Institutional 
Animal Care and Use Committee of the Virginia Commonwealth University. 
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Table 1: Primers for qRT-PCR 
Target Forward Primer 5’-3’ Reverse Primer 5’-3’ 
m1 receptor GGTGGCAGCAGCAGCAGCTCA GCCTCTTGACTGTATTTGGGGAGC 
m2 receptor GTGACTGAAACCTGTGTT GGAGGCTTCTTTTTGGCAGGCTG 
m3 receptor AGCTCCATCCTCAACTC GGTTTTGGGTATGCAGCTGTCAC 
m4 receptor TGAGTCCAGCTCAGGCAGTGCC GTTCCGATACTGGCACAGCA 
m5 receptor GAAAGGAATCAGGCCTCCTGG CCACCAATCGGAACTTATAGGC 
Caveolin-1 GACGCGCACACCAAGGAG GTCACAGTGAAGGTGGTG 
Caveolin-3 GTCTCCAAGTACTGGTGC GGGTTGCAGAAGGTGCGG 
γ-actin ATCAGGCCCGCGACAACTCGT GCCGCCAGTTGTGCTCTAAAAGGT 
Caldesmon CAGAAGGGAAGTCGGTAAATGAAA GGGCAGCTGTCTGAAGTTTATCTTCTT 
β-actin CCCTCCATCGTGCACCGCAA CTCGTCTCGTTTCTGCGCCGT 
GAPDH GCCTGGAGAAAGCTGCTAAGTATG CCTCGGATGCCTGCTTCA 
Myocardin CGGATTCGAAGCTGTTGTCTT AAACCAGGCCCCCTCCC 
SRF TCTCAGGCACCATCCACCAT CCCAGCTTGCTGTCCTATCAC 
SM-MHC TGGACACCATGTCAGGGAAA ATGGACACAAGTGCTAAGCAGTCT 
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II. 1. METHODS 
 
II. 2. 1. Tissue collection and processing 
 
Rabbits were sacrificed by injecting euthasol at a concentration of 100mg/kg of body weight into 
the ear vein. The stomach was rapidly isolated and removed of its content, washed and placed in 
pre-chilled smooth muscle buffer (pH 7.4) with the following composition: 120 mM Nacl, 4 mM 
KCl, 2.6 mM KH2PO4, 2 mM CaCl2, 0.6 mM MgCl2, 25 mM HEPES (N-2-
hydroxyethylpiperazine-N’ 2-ethanesulfonic acid), 14 mM glucose, and 2.1% essential amino 
mixture. 
 
II. 2.2. Preparation of dispersed gastric smooth muscle cells 
The stomach was separated into thin distal fundus and the thicker posterior antrum. Smooth 
muscle cells were isolated by sequential enzymatic collagenase digestion from the circular 
muscle layer followed by filtration and collection through Nitex mesh and centrifugation as 
described previously (Bitar and Makhlouf 1982; Murthy, Zhou et al. 2001). After removal of the 
mucous layer by sharp discussion from both regions, the fundus was chopped and minced 
thoroughly with a pair of sharp scissors and the antrum was sliced into thin pieces using a Stadie-
Riggs tissue slicer. Following tissue processing, they were incubated separately in a solution of 
smooth muscle buffer containing 0.1% collagenase (300U/ml) and 0.001% soybean trypsin 
inhibitor (w/v) for 30 min at 310C in a water bath with a constant supply of 100% oxygen. The 
partially digested tissue was washed twice with collagenase free smooth muscle buffer and the 
smooth muscle cells were allowed to disperse spontaneously for approximately 30 min in the 
enzyme free medium. At the end of digestion and dispersion the cells were harvested by filtration 
through 500µm Nitex mesh and centrifuged twice at 350 g for 10 min to eliminate broken cells 
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and cellular organelles. With an estimated 95% of the cells excluded trypan blue staining after 
counting in a hemocytometer, the experiments were conducted within 2-3 h of cell dispersion.  
 
II. 2.3. Preparation of primary cultures of gastric smooth muscle cells 
The smooth muscle cells dispersed and isolated from rabbit’s stomach were resuspended in 
DMEM culture medium containing the following antibiotics; penicillin (200 U/ml), streptomycin 
(200 U/ml), gentamycin (100mg/ml), amphotericin B (2.5 µg/ ml) along with 10% fetal bovine 
serum (DMEM-10) added through a filtered flask. The muscle cells were then plated at a 
concentration of 5 X 105 cells/ml and incubated at 37oC in a CO2 water-jacketed incubator. The 
cells were allowed to attach to the base of the culture dish and DMEM-10 medium was replaced 
with fresh medium every three days for 2-3 weeks until confluence was attained. When the 
primary cultures of smooth muscle cell were fully confluent, they were trypsinized (0.5 mg 
trypsin/ml) and re-plated at a concentration of 2.5 X 105 cells/ml and further cultured under the 
same conditions. All the experiments were conducted with muscle cells in their first passage. 
Previous studies have confirmed the purity of the primary cultured cells with smooth muscle 
specific marker γ- actin (Teng, Murthy et al. 1998). The cultured muscle cells were starved for 
24 h in serum and antibiotic free medium prior conducting any experiments. 
The project entails conducting experiments on both freshly dispersed gastric smooth muscle cells 
and primary culture of gastric smooth muscle cells. Inspite of the limitations in interpreting the 
experimental data obtained from cultured cells, their use was indispensable for conducting 
molecular studies and introducing genetic manipulations. 
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II. 2.1. Total RNA isolation 
50-100 mg of gastric tissue was isolated from rabbit and mice stomach and transferred to a glass-
Teflon homogenizer with 1 ml of TRIzol (GIBCO BRL). The tissue was properly homogenized 
for 1 min in the polytron. Following homogenization, the content was transferred into a 1.5 ml 
centrifuge tube and 0.2 ml of chloroform was added. Sample tubes were capped securely and 
mixed by inverting the tube for 15 sec. The tubes were incubated at room temperature for 3 min 
and then centrifuged at 12,000 g for approximately 15 min. At the end of centrifugation the 
mixture separates into two distinct layers, a lower red, phenol-chloroform phase and an upper 
clear aqueous phase. Since RNA appears exclusively in the upper aqueous phase, the upper 
phase was carefully transferred into a fresh tube. RNA was precipitated from the aqueous phase 
by mixing with 0.5 ml of isopropyl alcohol followed by incubating the sample at room 
temperature for 2 h. The mixture was then centrifuged at 12,000 g for 10 min at 4oC and the 
precipitated RNA appeared to be a white pellet. The pellet was washed with 0.5 ml of 70% 
ethanol and centrifuged at 7500 g for 10 min at 4oC (Zhang, Li et al. 2012) and completely 
air/vacuum dried using an Integrated Speed-Vac System for 10 min. The dried RNA pellet was 
dissolved in 50-100 µl of DEPC treated water and the concentration was measured with a 
NanoDrop 1000.  
 
II. 2.5.  Real Time PCR  
Real-time PCR was carried out on cDNA samples prepared from total RNA isolate from freshly 
dispersed smooth muscle cells, whole gastric tissue and also primary cultures of gastric cells. 
The experiment was performed using StepOne™ Real-Time PCR System (Applied Biosystem, 
Foster city, CA) and the intercalating dye SYBR green. Optimum PCR conditions were 
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determined on the gradient thermal cycler using the StepOne™ Real-Time PCR System. For 
each cDNA sample, 20 µl by volume of the reaction was mixture was prepared with the 
Quantitect TM SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). The time and 
temperature profile used for each real-time PCR mixture is as follows: 95 ˚C for 5 min; 50 cycles 
of a series consisting of 15 s at 94 ˚C, 30 s at 52 ˚C, 30 s at 72 ˚C; and a final extension of 5 min 
at 72 ˚C. The optimal annealing temperature for each primer set was determined empirically. The 
primary sequence of the primer sets used for the reactions are tabulated as follows: 
 
Each real-time RCR reactions were performed in triplicate. Only one PCR product was generated 
by each primer set and the correct molecular weight was confirmed by electrophoresis on 1.5% 
agarose gel containing 0.1 μg/ml ethidium bromide followed by sequencing of the individual 
bands to finally confirm the identity and integrity of the band. The fluorescent threshold value 
for each data set was calculated using the StepOne™ Real-Time PCR System software. The 
absence of signal in control wells containing water precluded the possibility of formation of 
primer-dimer. 
 
Quantification of gene expression- Usually, two types of data quantification methods are 
applicable in quantitative RT-PCR (qRT-PCR). One, using an absolute quantification method 
that directly measures the levels of expressed genes and the other by a more relative 
quantification method. The absolute quantification approach uses a calibration curve that relates 
the PCR signal to input copy number of the target gene. On the other hand in the relative 
quantification method the PCR signal of the transcript of interest in a treatment group is 
compared to the transcript level of another sample considered as an untreated or control group. 
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Relative quantification of a target gene in reference to another gene also called the housekeeping 
gene whose expression is absolutely unfluctuating under any condition (treatment or control) is 
calculated on the basis of delta delta CT values (CT, also known as CP, is the cycle number at 
which the fluorescence generated within a reaction crosses the threshold). CT is defined as the 
point during the course of a reaction at which there is sufficient accumulation of amplicons. 
There are several mathematical models to calculate the relative expression ratio (R), based on the 
comparison of the diverse cycle differences. One of them includes the delta delta CT method and 
the efficiency corrected calculation model. In these models, the target-gene expression is 
normalized to the expression of one or more non-regulated housekeeping genes. The choice of an 
internal control to normalize the expression of the gene of interest is critical to the interpretation 
of experimental real-time PCR results. The housekeeping gene expression must not be 
influenced by the applied treatment.  
 
 
Delta delta CT method  
 
ΔΔCT = (CT, Tag − CT, HKG) Treatment − (CT, Tag – CT, HKG) Control 
 
                                                          R = 2 −ΔΔCT 
Where, HKG is the housekeeping gene and Tag, the evaluated gene. 
 
Adhering to the criteria for choosing the reference genes in the delta delta method, GAPDH was 
selected as the reference gene. After normalization, the data for one gene or control group were 
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expressed as the fold-change in mRNA expression relative to that obtained for another gene or 
treatment group. 
 
II. 2.6. Western blot analysis 
Smooth muscle cells isolated from rabbit stomach or harvested from primary cultures were 
solubilized in Triton X-100-based lysis buffer containing 20 mM Tris-HCl (pH 8.0), 1 mM DTT, 
100 mM NaCl, 0.5% sodium dodecyl sulphate, 0.75% deoxycholate, 1 mM PMSF, 10 µg/ml of 
leupeptin and 100 µg/ml of aprotinin, in the presence of protease and phosphatase inhibitors. The 
lysates obtained after solubilization was centrifuged at 20000 g for 10 min at 4 °C and the 
supernatant was collected and its protein concentration was determined with a Dc protein assay 
kit from Bio-Rad. Equal amount of protein was resolved by SDS/PAGE gel, followed by an 
eletrophoretic transfer of the protein bands onto a nitrocellulose paper. The blots were then 
blocked with 5% (w/v) non-fat dried milk/TBS-T [tris-buffered saline (pH 7.6) and 0.1% Tween-
20] for 1 h and then incubated overnight at 4 °C with the specific primary antibodies in TBS-T 
and 1% (w/v) non-fat dried milk. Following overnight incubation with primary antibodies, the 
blots were washed thrice with PBST and 0.1% tween and then incubated for 1 h with 
horseradish-peroxidase-conjugated corresponding secondary antibody (1:2000; 10 μg/ml, Pierce) 
in TBS-T /1% (w/v) non-fat dried milk. The immunoreactive proteins were visualized using 
SuperSignal Femto maximum sensitivity substrate kit (Pierce). All washing steps were 
performed with TBS-T. Enhanced chemiluminescence reagent identified the protein bands. 
Quantification of protein bands obtained on western blot was subjected to densitometric analysis 
by the Odyssey software using the median method for calculation of background. The average 
intensity obtained for each band was normalized to that of β-actin for the same lane. The band 
 42 
intensity of each treatment was then calculated as a percent value normalized with the control. 
The percent value of the control was used for statistical analysis.  
 
II. 2.7. Radioligand binding studies 
Dispersed gastric smooth muscle cells were isolated from rabbit stomach and radio-ligand 
binding studies were performed using [3H] scopalamine as described previously (Murthy and 
Makhlouf 1997). The muscle cells were suspended in HEPES medium (pH 7.4) containing 1% 
fetal bovine serum. For total binding, 0.5 ml of cell suspension (106 cells/ml) were aliquot in 
triplicates and incubated at room temperature for 15 min with 1 nM [3H] scopolamine alone. For 
total binding with the specific receptor subtypes the cells were incubated with [3H] scopolamine 
in the presence of methoctramine for total m3 receptor binding or in the presence of 4-DAMP for 
total m2 receptor binding. Following treatment, the bound and free radio-ligand was separated by 
rapid filtration under reduced pressure through 5-µm polycarbonate Nucleopore filters. The 
filters were extensively washed for 4 times with 3 ml of ice-cold HEPES medium containing 
0.2% of bovine serum albumin. Non-specific binding was measured by treating the cells with 
carbachol at a concentration of 10 µM.  Specific binding of the radio-ligand with the receptors 
was obtained by subtracting the non-specific binding from total binging.  
 
II. 2.8. Assay for Phosphoinositide (PI) hydrolysis  
The total inositol phosphates pool from muscle cells was measured by the process of anion 
exchange chromatography using the method of Berridge et al (Murthy and Makhlouf 1991; 
Murthy, Zhou et al. 2003). A volume of 10 milliliters of cell suspension were labeled with myo-
2-[3H] inositol (15 µCi/ml) for 180 min at 31oC. Excess [3H] inositol was removed by 
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centrifuging the muscle cells at 350 g for 10min. After incubating with DMSO and MβCD and 
treatment with CCh (0.1µM) and methoctramine (0.1µM,) the cells was placed in a shaking 
water bath for 1 min. Similar procedure was followed for the other two approaches, caveolin-1 
siRNA targeted cultured smooth muscle cells and gastric tissue obtained from caveolin-1 KO 
mice. Following treatment the reaction was terminated by the addition of 
choloform:methanol:HCl in the ratio of 50:100:1 by volume. After adding equal volume of 
chloroform and water (340 µl), the samples were vortexed and centrifuged at 1000 g for 15 min 
to separate the phases. The upper clear aqueous phase was applied to a column containing 1 ml 
of 1:1 slurry of Dowex AG-1 X8 resin (100-200 mesh in formate form) and distilled water. The 
column was then washed with 10 ml of distilled water followed by 10 ml solution of 5 mM 
sodium tetraborate and 60 mM ammonium formate to remove [3H] glycerophosphoinositol. Total 
inositol phosphates were eluted by applying 6 ml of 0.8 M ammonium formate - 0.1 M formic 
acid. The eluates were collected in scintillation vials and counted in gel phase after addition of 
10 ml of scintillation fluid. The results were expressed as counts per minute per mg of protein.  
 
II. 2.9. Assay for adenylyl cyclase activity 
Adenylyl cyclase activity was measured by the formation of the second messenger cAMP in 
response to the contractile agonist carbachol. Radioimmunoassay using radiolabeled [125I] cAMP 
was performed to measure the level of cAMP production (Murthy and Makhlouf 1997; Murthy 
and Makhlouf 1998; Teng, Grider et al. 2001). Carbachol stimulates muscarinic m2 receptor 
acting via Gαi to inhibit adenylyl cyclase activity. Carbachol induced inhibition of adenylyl 
cyclase activity was monitored as percent reduction of cAMP formation compared to forskolin 
induced cAMP levels. The experiments were performed after the cells were treated with 
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carbachol (CCh: 0.1µM) and the muscarinic m3 receptor antagonist 4-DAMP (0.1µM). One 
milliliter of cell suspension containing approximately 3 x 106 cells/ml was treated with 10µM of 
forskolin either alone or in combination with carbachol (0.1 µM). Following treatment the 
reaction was terminated with cold 6% trichloroacetic acid (v/v) and vortexed vigorously. The 
mixture was then centrifuged and the supernatant was collected and were extracted three times 
with water-saturated diethyl ether to remove the trichloroacetic acid and then lyophilized and 
frozen at -20oC. Before radioimmunoassay, the samples were reconstituted in 50 µl of 50mM 
sodium acetate (pH 6.2) and acetylated with triethylamine/acetic anhydride (2:1 v/v) for 30 min. 
Cyclic AMP was measured in triplicates using 100 µl aliquots and the results was analyzed and 
derived from a standard curve using Prism @ GraphPad program. The results were expressed as 
pmol of cAMP/mg protein. 
 
II. 2.10. Immunokinase assay for Rho kinase and ZIP kinase activity 
Rho kinase and ZIP kinase activities were measured by immunokinase assay as previously 
described (Murthy and Makhlouf 1998; Murthy, Zhou et al. 2001; Zhou and Murthy 2004). 
Muscle cells were divided into two groups, control and experimental group. The control group 
was incubated with DMSO and the experimental group was incubated with MβCD (10mM) each 
for 30 min. After 30 min incubation cells were washed three times with smooth muscle buffer 
and equal amount of cells (3x106 cells/ml) were treated with carbachol (0.1 µM) and Rho Kinase 
inhibitor, Y27632 (1 µM) for 10 minutes and the reaction was terminated by rapid centrigugation 
at 25000 g for 15 mins at 4oC. The same treatment process was followed for other two 
approaches, caveolin-1 siRNA transfected cultured gastric muscle cells and cells obtained from 
caveolin-1 knockout mice. Following treatment the cells were lysed with lysis buffer containing 
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50mM Tris-HCl (pH 7.5), 150mM NaCl, 0.1% SDS, 0.5%sodium deoxycholate, 1%NP-40, 
10mM sodium pyrophosphate, and protease inhibitor cocktail (2 µl/ml, BD Biosciences). The 
homogenates were further centrifuged at 10,000 rpm for 10 min at 4oC. The supernatant 
containing cytosolic protein after being transferred to a new 1.5 ml tube was mixed with 5 µl of 
Rho Kinase antibody and incubated for 2 hrs at 4oC. 
At the completion of two hours, protein A/G agarose beads were added to each tube and the 
mixture was reincubated at 4oC for overnight and washed 3 times with lysis buffer. The pellet 
was resuspended in 50 µl of kinase buffer containing 100mM Tris-HCl (pH7.4), 1M KCl, 50mM 
MgCl2, 10mM EDTA, and 1mM DTT. Twenty microlitres of Rho kinase immunoprecipitates 
were added to the reaction mixture containing 100 mM Tris- HCl (pH7.4), 1M KCl, 50 mM 
MgCl2, 1mM DTT, 1mM ATP, and 10 µCi of [γ- 32P] ATP (3000 Ci/mol) along with 1µg of 
myelin basic protein, followed by incubation for 15 mins at 37oC. Phosphorylation of myelin 
basic protein was absorbed onto phosphocellulose disks, and free radioactivity was removed by 
washing 3 times with 75mM H3PO4. The amount of radioactivity on the disks was measured by 
liquid scintillation. The results are expressed as counts per minute per milligram protein (31). 
 
II. 2.11. Transfection of caveolin-1 siRNA into cultured gastric smooth muscle cells 
Primary culture of gastric smooth cells was grown at 80-90% confluence and serum starved for 
overnight. The caveolin-1 specific siRNA was subcloned into the pSIREN-DNR-DsRed 
expression vector. The recombinant vector was diluted with Opti-MEM R and mixed gently. 
After dilution of the plasmid vector into Opti-MEM the mixture was incubated for 5 min at room 
temperature. Similarly, the transfection agent LipofectamineTM 2000 was also diluted in opti-
MEM and mixed gently. The diluted recombinant plasmid and the diluted LipofectamineTM 2000 
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reagent was mixed together and further incubated at room temperature for 20 min. After 20 min, 
the mixture were added to cultured muscle cells and kept for 48 h for sucessful knockdown of 
caveolin-1 protein. The transfection efficiency was monitored by the expression of the red 
fluorescent protein integrated into the vector, by TRITC filters. The control cells were 
transfected with vector alone. Imaging using fluorescent microscopy confirmed 80% transfection 
efficiency. Following each transfection method, cell lysates were collected and the protein level 
was confirmed by western blot analysis (Zhou, Das et al. 2003; Huang, Zhou et al. 2007).  
 
II. 2.12. Sucrose Density Centrifugation of gastric cells  
Rabbit gastric smooth muscle cells in their first passage were maintained in culture. Once the 
cells attained 70-80 % confluence, the medium was aspirated and the plates were washed with 
ice cold PBS. At the end of third wash, PBS was completely removed and 1 ml of 1% Triton-X 
100 buffer was applied to each plate enough to cover the plates. The cells were then scrapped off 
using a cell scraper and transferred into a prechilled Dounce (glass-glass) homogenizer. 
Following homogenization, the cell lysate was subjected to sucrose density centrifugation to 
separate caveolar and non- caveolar fraction. The principle of separation was based on the 
unique lipid enrichment of the caveolar fraction such as sphingolipids and cholesterol, which 
makes these fractions more buoyant compared to other cellular content.  
After homogenization, 2 ml of the sample was mixed with 2 ml of 90 % MBS/Triton X-100 
buffer in an ultracentrifuge tube to prepare a sucrose layer of 45%. 4 ml each of 35% and 5 % 
sucrose prepared in MBS/Triton X-100 buffer was carefully layered on top of the 45% sucrose 
layer. Following the preparation of the sucrose density layer, the tube was perfectly balanced and 
centrifuged for 16-20 h at 39,000 rpm at 40C in a SW41Ti rotor (Beckman). After the 
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centrifugation, the tubes were carefully removed from the bucket and the samples were collected 
from top to bottom in 1 ml fractions. Each fraction collected was analyzed by SDS-PAGE. The 
caveolar fractions were probed with a caveolin-1 specific antibody (Murthy and Makhlouf 2000; 
Ostrom and Insel 2006).  
 
II. 2.13. Receptor Internalization by radioligand binding studies 
Dispersed gastric smooth muscle cells and cultured cells were used to study the effect of 
caveolin-1 on muscarinic m2 and m3 receptor internalization. Receptor internalization was 
measured by radio-ligand binding studies using [3H] scopolamine (Murthy, Grider et al. 2000). 
The muscle cells were suspended in HEPES medium (pH 7.4) containing 1% fetal bovine serum. 
For total binding, 0.5 ml of cell suspension (106 cells/ml) were aliquot in triplicates and 
incubated at room temperature for 15 min with 1 nM [3H] scopolamine alone or with [3H] 
scopolamine and 0.1 µM carbachol in the presence of muscarinic m2 and m3 receptor 
antagonists, methoctramine and 4-DAMP respectively. Receptor internalization was induced by 
pre-treating the cells with CCh (0.1 µM) for 20 min. Following incubation the bound and free 
radio-ligand was separated by rapid filtration under reduced pressure through 5 µm 
polycarbonate Nucleopore filters. The filters were extensively washed for 4 times with 3 ml of 
ice-cold HEPES medium containing 0.2% of bovine serum albumin. Total binding was again 
measured using similar protocol after receptor internalization. Non-specific binding was 
calculated by treating the cells with CCh at a concentration of 10 µM (100 times).  Specific 
binding of the radio-ligand for the receptors was obtained by subtracting the non-specific binding 
from total binging.  
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II. 2.14. Measurement of smooth muscle cell contraction by scanning micrometry 
Freshly dispersed gastric smooth muscle cells were incubated with DMSO and methyl β-
cyclodextrin (MβCD) (10 mM) separately each for 30 min. Dispersed cells was also isolated 
from caveolin-1 KO and WT mice. Following incubation and cell isolation, aliquots of 0.4 ml of 
cell suspension were treated with CCh (0.1µM) in the presence of m2 receptor antagonist 
methoctramine (0.1µM). After treatment the reactions were terminated using 8% acrolein at a 
final concentration 0.1% that helps to kill and fixed the cells without affecting the cell length. 
The resting cell length was determined in control experiments with muscle cell suspension 
treated with 100 µl of 0.1% bovine serum albumin without the agonists and antagonist. The peak 
contraction was derived from the concentration response curve after various treatments. The 
mean length of 50 smooth muscle cells treated with CCh and methoctramine were measured by 
scanning micrometry as described previously (Murthy, Zhou et al. 2003) and compared to the 
mean length of untreated cells. The contractile response was expressed as the percent decrease in 
mean cell length compared to the control cell length. 
 
II. 2.15. In-cell western 
Culture of smooth muscle cells were grown in 96 well plate (0.1 X 106 cells/well) and treated 
with carbachol (CCh: 0.1 µM) and methoctramine (0.1 µM). Following treatment the medium 
was aspirated and washed three times with 1XPBS and immediately fixed by adding 150 µl of 
fixing solution to each well. After 20 min of fixation at room temperature without shaking, the 
solution was removed and 200 µl of Triton washing solution was added to each well and placed 
on a shaker for 5 min. The washing step was repeated for 4 more times. Following extensive 
washing 150 µl of Odyssey blocking buffer was added to each well and incubated for 2 h at 
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room temperature on a shaker. After blocking, the primary antibody (1:200 dilution) was 
dissolved in 50 µl of blocking buffer and added to each well. The plate was incubated with the 
primary antibody on a shaker at a gentle speed at 40C for 2 h. Following incubation with primary 
antibody the wells were washed with Tween washing solution for five times and 50 50 µl of the 
specific secondary antibody containing Sapphire and DRAQ5 for background detection was 
added for 1 h at room temperature. The plate was washed 5 times with 200 µl of Tween washing 
solution and scanned under Licor-Odyssey imaging system using both 700 and 800 nm channels.  
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Statistical Analysis 
 
 
The results were expressed as means + S.E of n experiments and analysed for statistical 
significance using Student t-test for paired and unpaired values. Each experiment was performed 
on cells and tissues obtained from different animals. Difference of responses among different 
groups were tested and confirmed for significance using Fisher’s protected least significance 
difference test. The results were analysed using GraphPad software, San Diego, CA. A 
probability of P< 0.05 was considered significance.  
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CHAPTER III: RESULTS 
III. 1.  Signaling transduction by muscarinic receptors 
 Molecular, pharmacological and immunohistochemical studies demonstrated that at 
least five different muscarinic acetylcholine (ACh) receptors (m1-m5) are expressed in 
mammalian tissues and their expression is tissue- and species-specific. In vascular and visceral 
smooth muscle ACh interacts mainly with m2 and m3 receptors; m3 receptors are coupled via 
Gq with phosphoinositide (PI) hydrolysis and inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ 
release, whereas m2 receptors are coupled via Gi with inhibition of adenylyl cyclase (Migeon, 
Thomas et al. 1995; Schramm, Arjona et al. 1995; Morel, Macrez et al. 1997; Murthy, Zhou et al. 
2003; Tran, Matsui et al. 2006). Our initial studies characterized the expression of muscarinic 
receptors and the receptor-specific signaling pathways activated by carbachol (acetylcholine 
mimetic) in rabbit gastric smooth muscle cells.   
 
III. 1a. Expression of muscarinic m2 and m3 receptors in gastric smooth muscle  
Specific primers for muscarinic m1, m2, m3 and m4 receptors were designed based on the 
conserved sequences in human, rabbit, rat, and mouse cDNAs and used for identification of 
muscarinic receptor mRNA expression. Muscarinic m2 and m3, but not m1 and m4 receptors 
were detected by RT-PCR on RNA extracted from cultures of gastric smooth muscle cells in first 
passage (Fig. 1). When experiments were done in the absence of reverse transcriptase (RT), there 
was no amplification of either m2 or m3 receptors. Use of m1, m2, m3 and m4 receptor cDNA’s 
as positive control resulted in an amplification of mRNA with receptor specific primers. As 
shown previously, the use of confluent cultures of smooth muscle in first passage ensured the 
absence of neural, endothelial, or interstitial cell contaminants (Teng, Murthy et al. 1998) and the 
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presence of PCR product in cultured muscle cells demonstrate the specific expression of m2 and 
m3 mRNA in smooth muscle cells. 
Further confirmation for the expression of m2 and m3 receptors was obtained by western 
blot analysis using selective antibody to m2 and m3 receptors. The results demonstrated the 
expression of both m2 and m3 receptors of predicted size 52 kDa and 66 kDa respectively in the 
homogenates of isolated smooth muscle cells (Fig. 1). The results are consistent with the 
selective expression of  m2 and m3 receptors in vascular and other visceral smooth muscle  (Lin, 
Kajimura et al. 1997; Belmonte 2005; Gericke, Sniatecki et al. 2011). 
Selective expression of m2 and m3 receptors in gastric smooth muscle cells was further 
confirmed by radioligand binding studies using [3H]Scopolamine as muscarinic agonist. Specific 
binding was calculated as the difference between the total binding in the absence of acetylcholine 
(ACh) and non-specific binding in the presence of (10 µM) ACh. Total binding was 2,105±302 
cpm/mg protein and the non-specific binding was 22±4% of the total binding (456±65 cpm/mg 
protein). Incubation of cells with the selective m2 receptor antagonist, methoctramine (0.1 µM) 
inhibited specific binding by 69±3%, whereas incubation of cells with the selective m3 receptor 
antagonist 4-DAMP (0.1 µM) inhibited specific binding by 32±4%. Incubation of cells with both 
methoctramine and 4-DAMP abolished the specific binding of [3H]Scopolamine (Fig. 2). The 
results suggest that the gastric smooth muscle cells express only m2 and m3 receptors and the 
expression of m2 receptors are more abundant than m3 receptors. The radioligand binding studies 
are consistent with the selective expression of m2 and m3 receptor mRNA and proteins in these 
cells.  
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III. 2. Signaling pathways coupled to m2 and m3 receptors in gastric smooth muscle 
 Previous radioligand binding and pharmacological studies in gastrointestinal smooth 
muscle cells had demonstrated a high selectivity of methoctramine for m2 receptors and 4-
DAMP for m3 receptors (Murthy and Makhlouf 2000). This made it possible to use these 
antagonists to examine signaling pathways initiated by m2 and m3 receptors. The signaling 
pathways activated by m2 receptors are examined in response to carbachol (CCh: 0.1 µM) in the 
presence of 4-DAMP (0.1 µM), whereas the signaling pathways activated by m3 receptors are 
examined in response to CCh in the presence of methoctramine (0.1 µM). The concentrations of 
CCh and antagonists were selected based on our previous studies in isolated gastrointestinal 
smooth muscle cells.  Since previous studies have demonstrated that m3 receptors are coupled 
with Gq /G13 and m2 receptors are coupled to pertussis toxin (PTx)-sensitive Gi  (Murthy 2008),  
in the present study, PTx was also used as an additional tool to identify pathways initiated by m2 
and m3 receptors. 
 
III. 2a. Gq-coupled muscarinic m3 receptor signaling 
Acetylcholine was shown previously to stimulate PI hydrolysis, IP3 formation and Ca2+ release 
via Gαq in dispersed intestinal smooth muscle cells (Murthy 2008). In the present study, CCh-
stimulated PI-specific phospholipase C (PLC) activity (PI hydrolysis) in the presence of m2 
receptor antagonist methoctramine (0.1 µM) was measured as readout of m3-coupled Gq activity.  
Incubation of freshly dispersed smooth muscle cells from rabbit stomach with CCh (0.1 µM) in  
the presence of methoctramine (0.1 µM) caused a significant increase in PI hydrolysis 
(3,075±532 cpm/mg protein) compared to the basal PI hydrolysis (400±83 cpm/mg protein). The 
increase in PI hydrolysis was significantly inhibited in the presence of selective m3 receptor 
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antagonist 4-DAMP (843±121 cpm/mg protein; 84±5% decrease compared to control CCh 
response, p<0.001). Pretreatment of cells with U73122 (1 µM), a selective inhibitor of PI 
hydrolysis blocked CCh-induced increase in PI hydrolysis (87±6% inhibition, p<0.001) (Fig. 3). 
 
III. 2b. G13-coupled muscarinic m3 receptor signaling   
Acetylcholine was shown previously to stimulate RhoA and RhoA-dependent Rho kinase 
activity via Gα13 in dispersed intestinal smooth-muscle cells (Murthy, Zhou et al. 2003).  In the 
present study, stimulation of Rho kinase and zipper interacting protein (ZIP) kinase activity in 
response to CCh was measured as readout of m3-coupled G13 activity.   
Rho kinase.  Incubation of freshly dispersed gastric smooth muscle cells with CCh (0.1 
µM) for 10 min caused a significant stimulation of Rho kinase activity (33,582±2412 cpm/mg 
protein) compared to basal activity (9,006±1683 cpm/mg protein). Pretreatment of cells with 
Y27632 (1 µM), the specific inhibitor of Rho kinase blocked the increase in Rho kinase activity 
(88±5% inhibition, p<0.001). Pretreatment of cells with 4-DAMP (0.1 µM) also blocked the 
increase in Rho kinase activity in response to CCh (12,649±1443 cpm/mg protein; 85±7% 
decrease compared to CCh response, p<0.001), whereas pretreatment of cells with 
methoctramine (0.1 µM) had no significant effect on the increase in Rho kinase activity 
(30,829±3406 cpm/mg protein; 9±6% inhibition) (Fig. 4). These results suggest that CCh-
stimulated Rho kinase activity was mediated via m3 receptors.   
ZIP kinase.  Incubation of freshly dispersed smooth muscle cells with CCh (0.1 µM) for 
10 min caused a significant stimulation of ZIP kinase activity (21,328±2757 cpm/mg protein) 
compared to basal activity (4,446±1207 cpm/mg protein). Pretreatment of cells with Y27632 (1 
µM), the specific inhibitor of Rho kinase significantly inhibited the increase in ZIP kinase 
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activity (7,467±1397 cpm/mg protein; 83±6% inhibition, p<0.001). These results suggest that 
ZIP kinase activity is downstream of Rho kinase activity. Pretreatment of cells with 4-DAMP 
blocked the increase in ZIP kinase activity in response to CCh (7,610±1192 cpm/mg protein; 
80±5% decrease compared to CCh response, p<0.001), whereas pretreatment of cells with 
methoctramine (0.1 µM) had no significant effect on the increase in ZIP kinase activity 
(21,549±2868 cpm/mg protein) (Fig. 5). These results suggest that CCh-stimulated ZIP kinase 
activity was mediated via m3 receptors and is dependent on stimulation of Rho kinase activity.   
 
III. 2c. Gi-coupled muscarinic m2 receptor signaling 
 Previous studies in vascular and visceral smooth muscle have shown that ACh interacts 
with Gi-coupled m2 receptors and inhibits adenylyl cyclase activity (Zhang, Horowitz et al. 
1991; Murthy and Makhlouf 1997; Hakonarson and Grunstein 1998). In the present study, 
inhibition of forskolin-stimulated cAMP formation was measured as readout of m2-coupled Gi 
activity. Forskolin (10 µM) caused an increase in cAMP formation in dispersed muscle cells 
(24.0±2.3 pmol/mg protein) compared to basal levels of cAMP (2.5±0.5 pmol/mg protein). The 
increase in cAMP by forskolin (10 µM) was significantly inhibited (8.0±1.7 pmol/mg protein; 
74±3% inhibition, p<0.001) in the presence of CCh (0.1 µM), and the inhibition was 
significantly reversed by pretreatment of cells with methoctramine (0.1 µM) (9±4% inhibition), 
whereas pretreatment of cells with 4-DAMP had no significant effect on the inhibition of cAMP  
formation (67±7% inhibition) (Fig. 6). Pretreatment of muscle cells with PTx (400 ng/ml) 
abolished the inhibitory effect of CCh on cAMP formation consistent with the stimulation of Gi 
proteins by m2 receptor activation (23.5±3.2 pmol/mg protein; 4±2% inhibition, NS) (Fig. 6).  
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III. 2d. m3 receptor-mediated muscle contraction  
As shown previously in intestinal muscle, treatment of dispersed muscle cells with CCh (0.1 
µM) for 30 s caused muscle contraction (28±3% decrease in muscle cell length from basal 
muscle cell length of 112±4 µm) (Murthy, Zhou et al. 2003). Pretreatment of muscle cells with 
4-DAMP (0.1 µM) abolished CCh-induced contraction (4±2% decrease in cell length), whereas 
pretreatment of cells with methoctramine (0.1 µM) had no significant effect on muscle 
contraction (25±3% decrease in cell length) (Fig. 7). These results are consistent with the 
previous reports demonstrating selective involvement of m3 receptors in smooth muscle 
contraction. More than 90% of the contraction in response to CCh was blocked in 
gastrointestinal and urinary bladder muscle from m3 receptor knockout (KO) mice, whereas 
contraction was minimally affected in m2 receptor KO mice (Stengel, Yamada et al. 2002). 
 In summary, gastric muscle cells express both m2 and m3 receptors: expression of m2 
receptors was more abundant than m3 receptors.  Carbachol, acting via m3 receptors caused 
stimulation of PI hydrolysis, Rho kinase and ZIP kinase activity, and induced muscle 
contraction, and acting via m2 receptors caused inhibition of forskolin-stimulated cAMP 
formation (Fig. 8.).  
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Fig. 1. Selective expression of muscarinic m2 and m3 receptors in gastric smooth muscle 
cells.  
Upper panel: mRNA Expression: Total RNA was isolated from cultured gastric smooth 
muscle cells (first passage) and reverse transcribed using 2µg of total RNA. The cDNA was 
amplified with specific primers for different muscarinic receptor subtypes m1 to m4. 
Experiments were done in the presence or absence of reverse transcriptase (RT). PCR products 
corresponding to m2 and m3 receptor were obtained with the specific primers and further 
confirmed with control cDNAs. Primers corresponding to m1 and m4 receptors did not amplify 
any specific bands from RNA isolated from muscle cells, but amplified a specific product from 
control cDNA. Results show representative PCR products separated by electrophoresis in 
agarose gel containing ethidium bromide and visualized under a chemiImager fluorescence 
system. 
Lower panel: Protein expression: Freshly dispersed mucle cells were homogenized in 
lysis buffer and lysates containing equal amounts of total proteins were separated on SDS-PAGE 
and the expression of muscarinic receptors was analysed using selective antibody to m2 (1:1000) 
and m3 (1:1000) receptors and the band corresponding to 52 kDa and 66 kDa, respectively was 
detected by chemiluminiscence. The representative western blot shows the presence of 
muscarinic m2 and m3 receptors.     
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Fig.2. Selective expression of muscarinic m2 and m3 receptors by radioligand binding 
studies.  
Freshly dispersed gastric smooth muscle cells were incubated with [3H]scopolamine for 15 
minutes at room temperature and the amount of radioactive [3H]scopolamine bound to cells was 
measured by liquid scintillation. Specific binding was measured as the difference between the 
total binding (cpm/mg protein) measured in the absence of 10 µM carbachol (CCh) and non-
specific binding (cpm/mg protein) measured in the presence of 10 µM CCh. Cells were incubated 
in the presence of 4-DAMP (0.1 µM) to measure binding to m2 receptors or in the presence of 
methoctramine (0.1 µM) to measure binding to m3 receptors.  Results are expressed as % specific 
binding. Values are means ± S.E of 5 experiments.  
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Fig. 3. m3 receptor-dependent stimulation of phosphoinositide (PI) hydrolysis in gastric 
muscle   
Freshly dispersed muscle cells labelled with myo-[3H]inositol were incubated with carbachol 
(CCh; 0.1 µM) plus methoctramine (0.1 µM) for 60 seconds.  In some experiments cells were 
pretreated with 4-DAMP (0.1 µM) or the selective PI hydrolysis inhibitor U73122 (1 µM) for 10 
min. Total [3H]inositol phosphates were separated by ion-exchange chromatography and 
radioactivity counted by liquid scintillation. Results are expressed as total [3H]inositol phosphate 
formation in cpm/mg protein. Values are means ± S.E. of 4 experiments. ** Significant increase 
in response to CCh (P<0.001). 
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Fig. 4. m3 receptor-dependent stimulation of Rho Kinase activity in gastric muscle.   
Freshly dispersed gastric muscle cells were incubated with carbachol (CCh, 0.1 µM) for 10 min 
in the presence or absence of 4-DAMP (0.1 µM), methoctramine (0.1 µM), or the selective Rho 
kinase inhibitor Y27632 (1 µM). Rho kinase activity was measured using [γ-32P]ATP by 
immunokinase assay. Rho kinase activity was stimulated by CCh and inhibited by 4-DAMP and 
Y27632, but not by methoctramine.  Results are expressed as cpm/mg protein. Values are means 
± S.E of 5 experiments. ** Significant increase in response to CCh (P<0.001). 
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Fig. 5. m3 receptor-dependent stimulation of zipper interacting protein (ZIP) Kinase 
activity in gastric muscle.   
Freshly dispersed gastric muscle cells were incubated with carbachol (CCh, 0.1 µM) for 10 min 
in the presence or absence of 4-DAMP (0.1 µM), methoctramine (0.1 µM), or the selective Rho 
kinase inhibitor Y27632 (1 µM). ZIP kinase activity was measured using [γ-32P]ATP by 
immunokinase assay. ZIP kinase activity was stimulated by CCh and inhibited by 4-DAMP and 
Y27632, but not by methoctramine.  Results are expressed as cpm/mg protein. Values are means 
± S.E of 5 experiments. ** Significant increase in response to CCh (P<0.001). 
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Fig. 6. m2 receptor-dependent inhibition of adenylyl cyclase activity in gastric muscle.   
Adenylyl cyclase activity was measured as cAMP formation in freshly dispersed muscle cells in 
the presence of 100 µM isobutylmethylxanthine (IBMX).  Muscle cells were treated with 
forskolin (FSK, 10 µM) in the presence or absence of CCh (0.1 µM) for 60 s and cAMP was 
measured by radioimmunoassay. In some experiments, cells were pre treated with 4-DAMP or 
methoctramine for 10 min or pertussis toxin (400 ng/ml) for 60 min, and then treated with 
forskolin (10 µM) and CCh for 60 s. Results are computed from a standard curve using Prizm@ 
and expressed as pmol cAMP/mg protein.  Values are means ± S.E. of 4 experiments. ** 
Significant inhibition of forskolin-stimulated cAMP formation (P<0.001). 
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Fig.7. m3 receptor-dependent muscle contraction in gastric muscle.  
Freshly dispersed gastric smooth cells were treated separately with CCh (0.1 µM) for 30 s.  The 
mean length of 50 muscle cells was measured by scanning micrometry and was compared with 
the length of untreated muscle cells. In some experiments, cells were pre treated with 4-DAMP or 
methoctramine for 10 min or pertussis toxin (PTx, 400 ng/ml) for 60 min, and then treated with 
CCh for 30 s.  Results were expressed as percent decrease in cell length from control length 
(112±4 µm). Values are means ± S.E of 6 experiments. ** Significant decrease in muscle cell 
length in response to CCh (P<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
 
 
 
Fig 8: Signaling pathways activated by m2 and m3 receptors in gastric muscle cells.  
Gastric muscle cells express m2 and m3 receptors. m2 receptors are coupled to inhibition of 
adenylyl cyclase (AC) activity and cAMP formation via a pertussis toxin (PTx)-sensitive G 
protein, whereas m3 receptors are coupled to stimulation of PI hydrolysis and Rho kinase and 
ZIP kinase activity via PTx-insensitive G protein(s), and muscle contraction.  
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III. 3. Regulation of Gq-coupled muscarinic m3 receptor signaling by caveolae and 
caveolin-1. 
 Mature contractile smooth muscle is characterized by the presence of abundant 
caveolae. Recent in vitro and in vivo studies from several investigators suggest that caveolae and 
caveolins modulate vascular and visceral smooth muscle function (Hardin and Vallejo 2006). 
The role of caveolae/caveolin-1 in the regulation of muscarinic signaling was examined using 
three complimentary approaches: a) methyl β-cyclodextrin (MβCD) treatment to deplete 
cholesterol in dispersed muscle cells, b) caveolin-1 siRNA to suppress caveolin-1 expression in 
cultured muscle cells, and c) caveolin-1 knockout (KO) mice.  
 Expression of caveolin-1 and caveolin-3 were examined by qRT-PCR using specific 
primers. mRNA expression of caveolin-1 was nearly 13-fold higher than caveolin-3 in gastric 
smooth muscle (Fig. 9). This is consistent with previous studies in both visceral and airway 
smooth muscle showing that the relative mRNA expression levels were 15:1:1 for caveolin-1, 
caveolin-2 and cavelolin-3, respectively (Shakirova, Bonnevier et al. 2006).  
 
III. 3a. Inhibition of carbachol-stimulated PI hydrolysis by methyl β-cyclodextrin.  
Freshly dispersed gastric smooth muscle cells labeled with [3H]myo-inositol were divided 
into control and experimental group. The control group was incubated with DMSO and the 
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30 
min. Previous studies have demonstrated that treatment of several types of cells with MβCD 
depletes cholesterol and disrupts caveolae (Patel, Murray et al. 2008). After 30 min, cells were 
treated with CCh (0.1 µM) for 1 min in the presence of the m2 receptor antagonist 
methoctramine (0.1 µM) and PI hydrolysis was measured as described in Methods. The basal 
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levels of PI hydrolysis in both groups are similar (366±88 cpm/mg protein in control cell vs. 
305±62 cpm/mg protein in cells treated with MβCD). Treatment of control cells with CCh (0.1 
µM) caused a significant increase in PI hydrolysis (2,566±394 cpm/mg protein; 603±54% 
increase above basal). Carbachol (0.1 µM) also caused an increase in PI hydrolysis in cells 
treated with MβCD (1,381±95 cpm/mg protein; 352±38% increase above basal); however, the 
increase was significantly attenuated (42±3% inhibition, p<0.01) compared to CCh response in 
control cells (Fig. 10). The selective PI-specific PLC inhibitor, U73122 (1 µM) blocked CCh-
stimulated PI hydrolysis in both control cells and in cells treated with MβCD to a similar extent 
(Fig. 10). These results suggest that caveolae positively regulates Gq-mediated PI hydrolysis in 
gastric smooth muscle. 
 
III. 3b. Inhibition of carbachol-stimulated PI hydrolysis by caveolin-1 siRNA.  
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-
DNR-DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 
48 h. Suppression of caveolin-1 expression was verified by western blot analysis and 
immunofluorescence. After plasmid transfection, cultured cells were labeled with [3H] myo-
inositol, and then treated with the contractile agonist CCh (0.1 µM) in the presence of m2 
receptor antagonist methoctramine (0.1 µM) for 1 min to measure PI hydrolysis. The basal levels 
of PI hydrolysis in both groups were similar (396±75 cpm/mg protein in control cell vs. 343±113 
cpm/mg in cells treated with caveolin-1 siRNA). Treatment of control cells with CCh (0.1 µM) 
caused a significant increase in PI hydrolysis (2,813±288 cpm/mg protein; 610±8% increase 
above basal, p<0.001). Carbachol also caused an increase in PI hydrolysis in cells transfected 
with caveolin-1 siRNA (1,470±243 cpm/mg protein; 328±5% increase above basal); however, 
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the increase was significantly attenuated (46±4% inhibition, p<0.01) compared to CCh response 
in control cells (Fig. 11). The selective PI-specific PLC inhibitor, U73122 (1 µM) blocked CCh-
stimulated PI hydrolysis in both control cells and in cells transfected with caveolin-1 siRNA 
(Fig. 11). These results suggest that caveolin-1 positively regulates Gq-mediated PI hydrolysis in 
gastric smooth muscle.   
 
III. 3c. Inhibition of carbachol-stimulated PI hydrolysis by caveolin-1 KO.   
Gastric muscle was isolated from wild type and caveolin-1 KO mice and labeled with 
[3H] myo-inositol for 4 h and then treated with CCh (0.1 µM) in the presence of m2 receptor 
antagonist methoctramine (0.1 µM) for 1 min to measure PI hydrolysis. The basal levels of PI 
hydrolysis in gastric muscle from wild type (WT) and caveolin-1 KO mice were similar 
(457±104 cpm/mg protein in WT mice vs. 384±97 cpm/mg protein in caveolin-1 KO mice).   
Treatment of muscle from wild type mice with CCh caused a significant increase in PI 
hydrolysis (2,714±191cpm/mg protein: 500±15% increase above basal, p<0.001). Carbachol also 
caused an increase in PI hydrolysis in muscle from caveolin-1 KO mice (1,577±218 cpm/mg 
protein; 310±18% increase above basal, p<0.001), however, the increase was significantly 
attenuated (38±7% inhibition, p<0.01) compared to CCh response in wild type mice (Fig. 12). 
U73122 (1 µM) blocked CCh-stimulated PI hydrolysis in both wild type and caveolin-1 KO 
mice. These results provide conclusive evidence that caveolin-1 positively regulates Gq-
mediated PI hydrolysis in gastric muscle. 
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III. 3d. Inhibition of carbachol-stimulated initial MLC20 phosphorylation and muscle 
contraction by MβCD and caveolin-1 KO.   
Previous studies in gastrointestinal muscle have shown that initial contraction is mediated 
by stimulation of PI hydrolysis, generation of IP3, IP3-dependnet Ca2+ release, and 
Ca2+/calmodulin-dependent activation of MLCK and phosphorylation of MLC20 at Ser19 (Murthy 
2006). Since there is decrease in PI hydrolysis by disruption of caveolae with MβCD, we tested 
the effect of MβCD on CCh-induced MLC20 phosphorylation and contraction in freshly 
dispersed muscle cells. MLC20 phosphorylation was measured by in-cell western using phospho-
specific (Ser19) antibody. Treatment of cells with CCh (0.1 µM) significantly increased MLC20 
phosphorylation (210±36% increase, p<0.001). Carbachol also caused an increase in MLC20 
phosphorylation in cells treated with MβCD (114±35% increase, p<0.001); however, the increase 
was significantly attenuated (46±9% inhibition, p<0.01) compared to CCh response in control 
cells (Fig. 13).   
Treatment of cells with MβCD (10 mM) had no significant effect on basal muscle cell 
length (control: 115±4 µm vs. MβCD treated: 111±5 µm). Consistent with the increase in PI 
hydrolysis and MLC20 phosphorylation, treatment of freshly dispersed muscle cell with CCh (0.1 
µM) induced muscle contraction (29±3% decrease in muscle cell length). Carbachol also caused 
muscle contraction in cells treated with MβCD (14±1% decrease in cell length); however, 
contraction was significantly attenuated (51±4±% inhibition, p<0.01) compared to CCh response 
in control cells (Fig. 14). MβCD induced decrease in muscle contraction is consistent with its 
inhibitory effect on CCh-induced PI hydrolysis and MLC20 phosphorylation in dispersed muscle 
cells.  The specific involvement of caveolin-1 in CCh-induced muscle contraction was examined 
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using caveolin-1 KO mice. Basal lengths of gastric muscle cells isolated from WT mice were 
similar to that of caveolin-1 KO mice (WT: 92±5 µm; KO: 98±4 µm). Carbachol (0.1 µM) 
caused a significant contraction (29±2% decrease in muscle cell length) in gastric muscle cells 
isolated from WT mice that was similar to contraction in isolated rabbit gastric muscle cells 
(29±3% decrease in cell length). Carbachol (0.1 µM) also caused muscle contraction in muscle 
cells isolated from caveolin-1 KO mice (16±2% decrease in muscle cell length), however, 
contraction was significantly attenuated (44±4% inhibition, p<0.01) compared to CCh response 
in WT mice, and the attenuation was similar to that obtained in rabbit gastric muscle cells treated 
with MβCD, suggesting that caveolin-1 positively regulates initial Ca2+-dependent muscle 
contraction (Fig. 14).  
In summary, stimulation of PI hydrolysis, MLC20 phosphorylation and muscle 
contraction in response to CCh was attenuated in dispersed cells treated with MβCD or in 
cultured cells transfected with caveolin-1 siRNA. Similar inhibition of PI hydrolysis and muscle 
contraction was obtained in gastric muscle cells from caveolin-1 KO mice compared to gastric 
muscle cells of WT mice. These results suggest that caveolin-1 positively regulates Gq-coupled 
m3 receptor signaling. 
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Fig. 9. Expression of caveolin-1 and -3 in gastric smooth muscle.   
Total RNA was isolated from cultured gastric smooth muscle cells (first passage) using 
RNAqueous kit (Ambion, Austin, TX). The RNA was subsequently treated with DNAase and 
reverse transcribed using 2µg of total RNA by qScript cDNA prep kits (Quanta, Gaithersburg, 
MD). The cDNA prepared was used for quantitative real-time PCR (qRT-PCR) to measure real-
time expression levels of caveolin-1 and 3 transcripts. For each cDNA sample, a 20 µl reaction 
volume was prepared using QuantitectTM SYBRgreen PCR mastermix (Qiagen, Mississauga, 
ON). Real-time PCR reaction mixtures were prepared in triplicates. Each primer set yielded only 
one PCR product whose identity and integrity was confirmed by sequence analysis of the 
individual bands. Standard curves were generated from a dilution series of cDNA and the data 
was quantified using 2∆∆Ct method based on GAPDH amplification. The GAPDH thresholds 
remain constant. Relative quantification of a target gene in relation to a reference gene was 
calculated on the basis of delta delta CT values. Results demonstrated that caveolin-1 expression 
was 15 folds higher than caveolin-3 isoform. Values are means ± S.E of three experiments. 
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Fig.10. Inhibition of carbachol-stimulated PI hydrolysis by methyl β-cyclodextrin.  
Freshly dispersed gastric smooth muscle cells were labelled with [3H]myo-inositol and divided 
into control and experimental group. The control group was incubated with DMSO and the 
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30 
min. After 30 min, cells were treated with CCh (0.1 µM) plus methoctramine (0.1 µM) for 60 s.  
In some experiments cells were pretreated with a selective PI hydrolysis inhibitor U73122 (1 
µM) for 10 min and then with CCh plus methoctramine. PI hydrolysis (formation of water 
soluble [3H]inositols) was measured as formation of water soluble [3H]inositol phosphates by 
ion exchange chromatography and the radioactivity counted by liquid scintillation. Results are 
expressed as cpm/mg protein. Values are means ± S.E of three experiments. ## Significant 
inhibition of CCh response in MβCD treated cells compared to CCh response in control cells 
(P<0.01).  
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Fig. 11. Inhibition of carbachol-stimulated PI hydrolysis by caveolin-1 siRNA.  
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNR-
DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h. 
After plasmid transfection, cultured cells were labeled with [3H]myo-inositol, and then treated 
with CCh (0.1 µM) plus methoctramine (0.1 µM) for 60 s.  In some experiments, cell were 
pretreated with a selective PI hydrolysis inhibitor U73122 (1 µM) for 10 min and then treated 
with CCh plus methoctramine. PI hydrolysis (formation of water soluble [3H] inositols) was 
measured as formation of water soluble [3H]inositol phosphates by ion exchange 
chromatography and the radioactivity counted by liquid scintillation. Results are expressed as 
cpm/mg protein. Values are means ± S.E of three experiments. ## Significant inhibition of CCh 
response in cells trasnfected with caveolin-1 siRNA compared to CCh response in cells 
transfected with vector alone (P<0.01). Inset showing transfection of siRNA verified by 
immunofluorescence and knockdown of caveolin-1 expression by caveolin-1 siRNA verified by 
western blot analysis. 
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Fig.12. Inhibition of carbachol-stimulated PI hydrolysis by caveolin-1 KO.  
Gastric muscle isolated from wild type and caveolin-1 KO mice were labelled with [3H]myo-
inositol and then treated with CCh (0.1 µM) plus methoctramine (0.1 µM) for 60 s. In some 
experiments cell were pretreated with a selective PI hydrolysis inhibitor U73122 (1µM) for 10 
min and then treated with CCh plus methoctramine. PI hydrolysis (formation of water soluble 
[3H] inositols) was measured as formation of water soluble [3H]inositol phosphates by ion 
exchange chromatography and the radioactivity counted by liquid scintillation. Results are 
expressed as cpm/mg protein. Values are means ± S.E of three experiments. ## Significant 
inhibition of CCh response in caveolin-1 KO mice compared to CCh response in wild type mice 
(P<0.01). 
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Fig. 13. Inhibition of carbachol-stimulated initial MLC20 phosphorylation by MβCD    
Primary culture of gastric smooth muscle cells was grown on a 96 well plate and divided into 
control and experimental group. The control group was incubated with DMSO and the 
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30 
min. After 30 min, wells in each group were treated with CCh (0.1µM) plus methoctramine 
(0.1µM) for 30s. MLC20 phosphorylation was measured by in-cell western using phospho-
specific (Ser19) antibody. Results are expressed as percent phosphorylation. Values are means ± 
S.E of three experiments. ** Significant inhibition of CCh response in MβCD treated cells 
compared to CCh response in control cells (P<0.05). 
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Fig. 14. Inhibition of carbachol-stimulated initial muscle contraction by MβCD and 
caveolin-1 KO.   
Left panel: Freshly dispersed smooth muscle cells from rabbit stomach were divided into 
control and experimental group. The control group was incubated with DMSO and the 
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30 
min. After 30 min, cells were treated with CCh (0.1 µM) plus methoctramine (0.1 µM) for 30 s. 
Right panel: Gastric muscle cells were isolated from caveolin-1 KO mice and WT mice were 
separately treated with CCh (0.1 µM) plus methoctramine (0.1 µM) for 30 s.   
The mean length of 50 muscle cells was measured by scanning micrometry and compared 
with the length of untreated muscle cells.  Results were expressed as percent decrease in cell 
length from control length (rabbit stomach: control (115±4 mm) and MβCD treated (111±5 µm); 
mouse stomach: wild type (92±5 µm) and caveolin-1 KO (98±4 µm)). Values are means ± S.E of 
5-6 experiments.  ** Significant inhibition of CCh response in MβCD treated cells and in muscle 
cells isolated from caveolin-1 KO mice compared to CCh response in DMSO treated cells and 
muscle cells isolated from wild type mice (P<0.05).  
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III. 4. Regulation of G13-coupled m3 receptor signaling by caveolae and caveolin-1. 
 Previous studies have demonstrated that muscarinic m3 receptors are coupled to 
stimulation of Rho kinase and ZIP kinase activity via G13/RhoA (Murthy, Zhou et al. 2003). 
Stimulation of Rho kinase and ZIP kinase activity in response to m3 receptor activation was 
confirmed in gastric muscle cells in the present study. To examine whether caveolae and 
caveolin-1 also regulated G13/RhoA pathway, stimulation of Rho kinase and ZIP kinase activity 
in response to CCh was measured in freshly dispersed muscle cells treated in the presence or 
absence of MβCD, cultured muscle cells transfected with control siRNA and caveolin-1 siRNA, 
and in gastric muscle from WT and caveolin-1 KO mice.     
 
III. 4a. Inhibition of carbachol-stimulated Rho kinase activity by methyl β-cyclodextrin.  
Freshly dispersed gastric smooth muscle cells were divided into control and experimental 
group. The control group was incubated with DMSO and the experimental group was incubated 
with methyl β-cyclodextrin (MβCD) (10 mM) each for 30 min. After 30 min, cells were treated 
with CCh (0.1 µM) for 10 min, and Rho kinase activity was measured by immunokinase assay as 
described in Methods. The basal levels of Rho kinase activity in both groups are similar 
(8,411±1584 cpm/mg protein in control cells vs. 8,431±1600 cpm/mg protein in cells treated 
with MβCD).  Treatment of control cells with CCh (0.1 µM) caused a significant increase in Rho 
kinase activity (33,505 cpm/mg protein; 298±18% increase above basal, p<0.001). Carbachol 
also caused an increase in Rho kinase activity in cells treated with MβCD (19,570±2039 cpm/mg 
protein; 132±6% increase above basal, p<0.001), however, the increase was significantly 
attenuated (54±6% inhibition, p<0.001) compared to CCh response in control cells (Fig. 15). The 
selective Rho kinase inhibitor, Y27632 (1 µM) blocked CCh-stimulated Rho kinase activity in 
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both control cells and in cells treated with MβCD (Fig. 15). These results suggest that caveolae 
positively regulates G13/RhoA-mediated Rho kinase activity in gastric muscle cells.  
 
III . 4b. Inhibition of carbachol-stimulated Rho kinase activity by caveolin-1 siRNA.  
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-
DNR-DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 
48 h. Suppression of caveolin-1 expression was verified by western blot analysis and 
immunofluoresence. Muscle cells were treated with CCh (0.1 µM) for 10 min, and Rho kinase 
activity was measured by immunokinase assay as descried in Methods. The basal levels of Rho 
kinase activity in both groups are similar (7,582±1217 cpm/mg protein in control cells vs. 
8,126±1906 cpm/mg protein in cells transfected with caveolin-1 siRNA). Treatment of control 
cells with CCh caused a significant increase in Rho kinase activity (33,288±4549 cpm/mg 
protein; 239±8% increase above basal, p<0.001).  Carbachol (0.1 µM) also caused an increase in 
Rho kinase activity in cells transfected with caveolin-1 siRNA (21,579±3842 cpm/mg protein; 
165±6% increase above basal, p<0.001); however, the increase was significantly attenuated 
(31±4 % inhibition, p<0.01) compared to CCh response in control cells (Fig. 16). The selective 
Rho kinase inhibitor, Y27632 (1 µM), blocked CCh-stimulated Rho kinase activity in both 
control cells and in cells transfected with caveolin-1 siRNA (Fig. 16). These results suggest that 
caveolin-1 positively regulates G13/RhoA-mediated Rho kinase activity in gastric muscle cells.  
 
III . 4c. Inhibition of carbachol-stimulated Rho kinase activity by caveolin-1 KO.   
Gastric muscle was isolated from wild type and caveolin-1 knockout mice and Rho 
kinase activity in response to CCh (0.1 µM) was measured by immunokinase assay. The basal 
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levels of Rho kinase activity in gastric muscle from control and caveolin-1 KO mice were similar 
(7460±1895 cpm/mg protein in WT mice vs. 7,150±1338 cpm/mg protein in caveolin-1 KO 
mice). Treatment of muscle from WT mice with CCh (0.1 µM) caused a significant increase in 
Rho kinase activity (30,033 cpm/mg protein: 302±10% increase above basal, p<0.001). 
Carbachol (0.1 µM) also caused an increase in Rho kinase activity in muscle from caveolin-1 
KO mice (19,090±2049 cpm/mg protein; 166 ± 5% increase above basal, p<0.001); however, the 
increase was significantly attenuated (45±8% inhibition, p<0.01) compared to CCh response in 
WT mice (Fig. 17). The selective Rho kinase inhibitor, Y27632 (1 µM), blocked CCh-stimulated 
Rho kinase activity in both WT and caveolin-1 KO mice (Fig.17). These results provide 
conclusive evidence that caveolin-1 positively regulates G13/RhoA-mediated Rho kinase activity 
in gastric muscle. 
 
III . 4d. Inhibition of carbachol-stimulated ZIP kinase activity by methyl β-cyclodextrin.  
Freshly dispersed muscle cells incubated in the presence or absence of MβCD (10 mM) 
for 30 min were treated with CCh (0.1 µM) for 10 min, and ZIP kinase activity was measured by 
immunokinase assay as descried in Methods. The basal level of ZIP kinase activity was similar 
in the presence or absence of MβCD (4,058±921cpm/mg protein in control cells vs. 4,039±975 
cpm/mg protein in cells treated with MβCD). Treatment of control cells with CCh (0.1 µM) 
caused a significant increase in ZIP kinase activity (19,726±2213 cpm/mg protein; 386±11% 
increase above basal, p<0.001). Carbachol (0.1 µM) also caused an increase in ZIP kinase 
activity in cells treated with MβCD (12,028±2013 cpm/mg protein; 197±12% increase above 
basal, p<0.001), however, the increase was significantly attenuated (48±6% inhibition, p<0.01) 
compared to CCh response in control cells (Fig. 18). The selective Rho kinase inhibitor, Y27632  
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(0.1 µM) blocked CCh-stimulated ZIP kinase activity in both control cells and in cells treated 
with MβCD, suggesting that ZIP kinase activity is downstream of Rho kinase activity (Fig. 18). 
These results suggest that caveolae positively regulates G13/RhoA-mediated ZIP kinase activity 
in gastric muscle cells.  
 
III . 4e. Inhibition of carbachol-stimulated ZIP kinase activity by caveolin-1 siRNA.  
Muscle cells transfected with control siRNA or caveolin-1 siRNA were treated with CCh 
(0.1 µM) for 10 min, and ZIP kinase activity was measured by immunokinase assay as described 
in Methods. The basal level of ZIP kinase activity was not affected by the transfection of 
caveolin-1 siRNA (3,609±1016 cpm/mg protein in control cell vs. 4,206±1127 cpm/mg protein 
in cells transfected with caveolin-1 siRNA). Treatment of control cells with CCh (0.1 µM) 
caused a significant increase in ZIP kinase activity (21,414±3043 cpm/mg protein; 493±25% 
increase above basal, p<0.001).  Carbachol (0.1 µM) also caused an increase in ZIP kinase 
activity in cells treated with caveolin-1 siRNA (12,507±2201 cpm/mg protein; 194±21% 
increase above basal, p<0.001), however, the increase was significantly attenuated (59±6% 
inhibition, p<0.01) compared to CCh response in control cells (Fig. 19). Y27632 (1 µM) blocked 
CCh-stimulated ZIP kinase activity in both control cells and in cells transfected with caveolin-1 
siRNA. These results suggest that caveolin-1 positively regulates G13/RhoA-mediated ZIP 
kinase activity in gastric muscle cells.  
 
III. 4f. Inhibition of carbachol-stimulated ZIP kinase activity by caveolin-1 KO.   
Gastric muscle was isolated from wild type and caveolin-1 KO mice and ZIP kinase 
activity in response to CCh (0.1 µM) was measured by immunokinase assay. The basal levels of 
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ZIP kinase activity in gastric muscle from control and caveolin-1 KO mice were similar 
(3,136±644 cpm/mg protein in WT mice vs. 3,515±755 cpm/mg in caveolin-1 KO mice).   
Treatment of muscle from WT mice with CCh (0.1 µM) caused a significant increase in ZIP 
kinase activity (18,003±2941 cpm/mg protein: 474±17% increase above basal, p<0.001).  
Carbachol (0.1 µM) also caused an increase in ZIP kinase activity in muscle from caveolin-1 KO 
mice (11,213±1701 cpm/mg protein; 219±16% increase above basal, p<0.001); however, the 
increase was significantly attenuated (54±6% inhibition, p<0.01) compared to CCh response in 
WT mice (Fig. 20). Y27632 (1 µM) blocked CCh-stimulated Rho kinase activity in both WT and 
caveolin-1 KO mice (Fig. 20). These results provide conclusive evidence that caveolin-1 
positively regulates G13/RhoA-mediated ZIP kinase activity in gastric muscle. 
 
III. 4g. Inhibition of carbachol-stimulated MYPT1 phosphorylation and sustained muscle 
contraction by MβCD and caveolin-1 KO.   
Previous studies in gastrointestinal muscle have demonstrated that sustained contraction 
is mediated by stimulation of Rho-dependent pathways involving phosphorylation of MYPT1 
(regulatory subunit of MLC phosphatase) at Thr696 by Rho kinase/ZIP kinase and CPI-17 
(endogenous MLC phosphatase inhibitor) at Thr38 by PKC. Phosphorylation of MYPT1 and CPI-
17 leads to inhibition of MLC phosphatase activity, increase in MLC20 phosphorylation and 
sustained muscle contraction (Murthy, Grider et al. 2000). Since there is decrease in Rho 
kinase/ZIP kinase activity by disruption of caveolae with MβCD, we tested the hypothesis that 
MYPT1 phosphorylation and sustained muscle contraction are positively regulated by caveolin-
1. The effect of MβCD (10 mM) on CCh-induced MYPT1 phosphorylation and contraction in 
freshly dispersed muscle cells was examined.  MYPT1 phosphorylation was measured by in-cell 
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western using phospho-specific (Thr696) antibody. Treatment of cells with CCh (0.1 µM) for 10 
min significantly increased MYPT1 phosphorylation (314±43% increase, p<0.001). Carbachol 
also caused an increase in MYPT1 phosphorylation in cells treated with MβCD (126±15% 
increase, p<0.001); however, the increase was significantly attenuated (58±10% inhibition, 
p<0.01) compared to CCh response in control cells (Fig. 21).   
Treatment of cells with MβCD (10 mM) had no significant effect on basal muscle cell 
length (control: 115±4 µm vs. MβCD treated: 111±5 µm). Consistent with the increase in Rho 
kinase and ZIP kinase activity and MYPT1 phosphorylation, treatment of freshly dispersed 
muscle cell with CCh (0.1µM) induced sustained (measured at 10 min) muscle contraction 
(22±3% decrease in muscle cell length). Carbachol also caused muscle contraction in cells 
treated with MβCD (11±2% decrease in cell length); however, contraction was significantly 
attenuated (49±3% inhibition, p<0.01) compared to CCh response in control cells (Fig. 22).  
MβCD-induced decrease in muscle contraction is consistent with its inhibitory effect on CCh-
induced Rho kinase/ZIP kinase activity and MYPT1 phosphorylation in dispersed muscle cells.   
The specific involvement of caveolin-1 in CCh-induced sustained muscle contraction was 
examined using caveolin-1 KO mice. Basal lengths of gastric muscle cells isolated from WT 
mice were similar to that of caveolin-1 KO mice (WT: 92±5 µm; KO: 98±4 µm). Carbachol 
(0.1µM) caused a significant contraction (21±2% decrease in muscle cell length) in gastric 
muscle cells isolated from WT mice that was similar to the contraction in isolated rabbit gastric 
muscle cells (22±3% decrease in cell length). Carbachol (0.1 µM) also caused muscle 
contraction in muscle cells isolated from caveolin-1 KO mice (13±2% decrease in muscle cell 
length), however, contraction was significantly attenuated (39±3 inhibition, p<0.01) compared to 
CCh response in WT mice, and the attenuation was similar to that obtained in rabbit gastric 
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muscle cells treated with MβCD (Fig. 22), suggesting that caveolin-1 positively regulates RhoA-
dependent sustained contraction in gastric muscle. 
In summary, stimulation of Rho kinase and ZIP kinase activity, MYPT1 phosphorylation 
and muscle contraction in response to CCh was attenuated in dispersed cells treated with MβCD 
or in cultured cells transfected with caveolin-1 siRNA. Similar inhibition of Rho kinase and ZIP 
kinase activity and muscle contraction was obtained in gastric muscle cells from caveolin-1 KO 
mice compared to gastric muscle cells of WT mice. These results suggest that caveolin-1 
positively regulates G13-coupled m3 receptor signaling. 
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Fig. 15. Inhibition of carbachol-stimulated Rho kinase activity by methyl β-cyclodextrin.  
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group. 
The control group was incubated with DMSO and the experimental group was incubated with 
methyl β-cyclodextrin (MβCD) (10 mM) each for 30 min.  After 30 min, cells were treated with 
CCh (0.1 µM) for 10 min in the presence or absence of a selective Rho kinase inhibitor Y27632 
(1 µM). Rho kinase activity was measured using [γ-32P]ATP by immunokinase assay. Results are 
expressed as cpm/mg protein.  Values are means ± S.E of 6 experiments. ## Significant 
inhibition of CCh response in MβCD treated cells compared to CCh response in control cells 
(P<0.01).  
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Fig. 16. Inhibition of carbachol-stimulated Rho kinase activity by caveolin-1 siRNA.  
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNR-
DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h. 
After plasmid transfection, cells were treated with CCh (0.1 µM) for 10 min in the presence or 
absence of a selective Rho kinase inhibitor, Y27632. Rho kinase activity was measured using [γ-
32P]ATP by immunokinase assay. Results are expressed as cpm/mg protein. Values are means ± 
S.E of 4 experiments. ## Significant inhibition of CCh response in cells transfected with 
caveolin-1 siRNA compared to CCh response in cells transfected with control pSIREN-DNR-
DsRed vector (P<0.01).  
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Fig. 17. Inhibition of carbachol-stimulated Rho kinase activity by caveolin-1 KO.  
Gastric muscle isolated from wild type and caveolin-1 KO mice were treated with CCh (0.1 µM) 
for 10 min in the presence or absence of Y27632 (1 µM). Rho kinase activity was measured 
using [γ-32P]ATP by immunokinase assay. Results are expressed as cpm/mg protein.  Values are 
means ± S.E of 3 experiments. ## Significant inhibition of CCh response in caveolin-1 KO mice 
compared to CCh response in wild type mice (P<0.01).  
 
 
 
 
 
 
 
 
 
 
 
 
 102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 103 
 
 
 
 
 
Fig. 18. Inhibition of carbachol-stimulated zipper interacting protein (ZIP) kinase activity 
by methyl β-cyclodextrin.  
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group. 
The control group was incubated with DMSO and the experimental group was incubated with 
methyl β-cyclodextrin (MβCD) (10 mM) each for 30 min. After 30 min, cells were treated with 
CCh (0.1 µM) for 10 min in the presence or absence of a selective Rho kinase inhibitor Y27632 
(1 µM). ZIP kinase activity was measured using [γ-32P]ATP by immunokinase assay. Results are 
expressed as cpm/mg protein. Values are means ± S.E of 6 experiments. ## Significant inhibition 
of CCh response in MβCD treated cells compared to CCh response in control cells (P<0.01).  
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Fig. 19. Inhibition of carbachol-stimulated zipper interacting protein (ZIP) kinase activity 
by caveolin-1 siRNA.  
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNR-
DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h. 
After plasmid transfection, cells were treated with CCh (0.1 µM) for 10 min in the presence or 
absence of a selective Rho kinase inhibitor, Y27632. ZIP kinase activity was measured using [γ-
32P]ATP by immunokinase assay. Results are expressed as cpm/mg protein. Values are means ± 
S.E of 4 experiments. ## Significant inhibition of CCh response in cells transfected with 
caveolin-1 siRNA compared to CCh response in control cells (P<0.01).  
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Fig. 20. Inhibition of carbachol-stimulated zipper interacting protein (ZIP) kinase activity 
by caveolin-1 KO.  
Gastric muscle isolated from wild type and caveolin-1 KO mice were treated with CCh (0.1 µM) 
for 10 min in the presence or absence of Y27632 (1 µM). ZIP kinase activity was measured 
using [γ-32P]ATP by immunokinase assay. Results are expressed as cpm/mg protein.  Values are 
means ± S.E of 3 experiments. ## Significant inhibition of CCh response in caveolin-1 KO mice 
compared to CCh response in wild type mice (P<0.01).  
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Fig. 21. Inhibition of carbachol-stimulated MYPT1 phosphorylation by MβCD    
Primary culture of gastric smooth muscle cells was grown on a 96 well plate and divided into 
control and experimental group. The control group was incubated with DMSO and the 
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30 
min. After 30 min, wells in each group were treated with CCh (0.1 µM) for 10 min and MYPT1 
phosphorylation was measured by in-cell western using phospho-specific (Thr696) antibody. 
Results are expressed as percent phosphorylation. Values are means ± S.E of 4 experiments. ** 
Significant inhibition of CCh response in MβCD treated cells compared to CCh response in 
control cells (P<0.01).  
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Fig. 22. Inhibition of carbachol-stimulated sustained muscle contraction by MβCD and 
caveolin-1 KO.   
Left panel: Freshly dispersed smooth muscle cells from rabbit stomach were divided into 
control and experimental group. The control group was incubated with DMSO and the 
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30 
min. After 30 min, cells were treated with CCh (0.1 µM) plus methoctramine (0.1 µM) for 10 
min. Right panel: Gastric muscle cells were isolated from caveolin-1 KO mice and WT mice 
were separately treated with CCh (0.1 µM) plus methoctramine for 10 min.   
The mean length of 50 muscle cells was measured by scanning micrometry and compared 
with the length of untreated muscle cells. Results were expressed as percent decrease in cell 
length from control length (rabbit stomach: control (115±4 µm) and MβCD treated (111±5 µm); 
mouse stomach: wild type (92±5 µm) and caveolin-1 KO (98±4 µm)). Values are means ± S.E of 
5-6 experiments. ** Significant inhibition of CCh response in MβCD treated cells and in muscle 
cells isolated from caveolin-1 KO mice compared to CCh response in DMSO treated cells and 
muscle cells from wild type mice (P<0.01). 
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III. 5. Regulation of Gi-coupled muscarinic m2 receptor signaling by caveolin-1. 
 Studies from our group and several others have demonstrated that muscarinic m2 
receptors are coupled to inhibition of adenylyl cyclase activity (AC) via activation of Gαi 
proteins. To examine whether caveolae and caveolin-1 also regulate Gi-coupled adenylyl cyclase 
activity, inhibition of forskolin-stimulated cAMP formation in response to CCh was measured 
using three approaches mentioned above.     
 
III. 5a. Lack of effect on m2-mediated inhibition of adenylyl cyclase activity by methyl β-
cyclodextrin.  
Freshly dispersed gastric smooth muscle cells were divided into control and experimental 
group. The control group was incubated with DMSO and the experimental group was incubated 
with methyl β-cyclodextrin (MβCD) (10 mM) each for 30 min. After 30 min, cells were treated 
with forskolin (10 µM) for 10 min in the presence or absence of CCh (0.1 µM), and adenylyl 
cyclase activity was measured as increase in cAMP formation by radioimmunoassay as described 
in Methods. The basal levels of cAMP were similar in both groups (3.9±1.2 pmol/mg protein in 
control cell vs. 3.8±0.8 pmol/mg protein in cells treated with MβCD). Treatment of cells with 
forskolin (10 µM) caused an increase in cAMP formation and the increase was similar in both 
groups (531±34% increase above basal in control cells and 479±32% increase above basal in 
cells treated with MβCD) (Fig. 23). These results suggest that caveolae has no significant effect 
on adenylyl cyclase activity in gastric muscle cells. Carbachol (0.1 µM) caused a significant 
inhibition of forskolin-stimulated cAMP formation in control cells (168±20% increase in cAMP 
above basal, and 68±5% attenuation compared to response to forskolin alone, p<0.001) and in 
cells treated with MβCD  (142±16% increase above basal, and 71±6% attenuation compared to 
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forskolin alone, p<0.001). The inhibition of forskolin-stimulated cAMP by CCh is similar in 
control cells and in cells treated with MβCD (Fig. 23), suggesting that caveolae has no effect on 
m2-coupled Gi activity in gastric muscle cells.   
 
III. 5b. Lack of effect on m2-mediated inhibition of adenylyl cyclase (AC) activity by 
caveolin-1 siRNA.   
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-
DNR-DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 
48 h. Suppression of caveolin-1 expression was verified by western blot analysis and 
immunofluorescence. Muscle cells were treated with forskolin (10 µM) for 10 min in the 
presence or absence of CCh (0.1 µM), and adenylyl cyclase activity was measured. The basal 
levels of cAMP were similar in both groups (2.7±0.8 pmol/mg protein in control cell vs. 2.5±0.6 
pmol/mg protein in cells transfected with caveolin-1 siRNA). Treatment of cells with forskolin 
(10 µM) caused an increase in cAMP formation and the increase was similar in both groups 
(738±42% increase above basal in control cells and 682±54% increase above basal in cells 
transfected with caveolin-1 siRNA) (Fig. 24). These results suggest that caveolin-1 has no 
significant effect on adenylyl cyclase activity in gastric muscle cells. Carbachol caused a 
significant inhibition of forskolin-stimulated cAMP formation in control cells (218±18% 
increase in cAMP above basal, and 70±6% attenuation compared to response to forskolin alone, 
p<0.001) and in cells transfected with caveolin-1 siRNA (221±19% increase above basal, and 
67±6% attenuation compared to forskolin alone, p<0.001). The inhibition of forskolin-stimulated 
cAMP by CCh is similar in control cells and in cells transfected with caveolin-1 siRNA (Fig. 
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24), also suggesting that caveolin-1 has no effect on m2-coupled Gi activity in gastric muscle 
cells. 
III. 5c. Lack of effect on m2-mediated inhibition of adenylyl cyclase (AC) activity by 
caveolin-1 knockout.   
Gastric muscle was isolated from wild type and caveolin-1 KO mice and inhibition of 
forskolin-stimulated cAMP formation and AC activity in response to CCh (0.1 µM) was 
measured. The basal levels of cAMP were similar in both groups (3.7±1.0 pmol/mg protein in 
WT mice vs. 3.9±0.6 pmol/mg protein in KO mice). Treatment of cells with forskolin (10 µM) 
caused an increase in cAMP formation and the increase was similar in both groups (584±35% 
increase above basal in WT mice and 541±27% increase above basal in KO mice). These results 
suggest that caveolin-1 has no significant effect on adenylyl cyclase activity in gastric muscle 
cells. Carbachol (0.1 µM) caused a significant inhibition of forskolin-stimulated cAMP 
formation in gastric cells isolated from caveolin-1 KO mice (154±12% increase in cAMP above 
basal, and 73±4% attenuation compared to response to forskolin alone, p<0.001) and in cells 
isolated from WT mice (143±13% increase above basal, and 72±9% attenuation compared to 
forskolin alone, p<0.001) (Fig. 25). The inhibition of forskolin-stimulated cAMP by CCh is 
similar in WT mice and caveolin-1 KO mice (Fig. 25), suggesting that caveolin-1 has no effect 
on m2-coupled Gi activity in gastric muscle cells. 
 
In summary, activation of AC activity by forskolin or inhibition of forskolin-stimulated AC 
activity by CCh was not affected in dispersed cells treated with MβCD or in cultured muscle 
cells transfected with caveolin-1 siRNA. Similarly, activation of AC activity or inhibition of 
forskolin-stimulated AC activity by CCh was not affected by caveolin-1 KO. These results 
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suggest that caveolin-1 has no effect on Gi-coupled m2 receptor signaling. This is in contrast to 
the positive regulation of Gq/13-coupled m3 receptor signaling by caveolin-1. 
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Fig. 23. Lack of effect on m2-mediated inhibition of adenylyl cyclase activity by methyl β-
cyclodextrin.  
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group. 
The control group was incubated with DMSO and the experimental group was incubated with 
methyl β-cyclodextrin (MβCD) (10 mM) each for 30 min. After 30 min, cells were treated with 
forskolin (10 µM) for 10 min in the presence or absence of CCh (0.1 µM) and adenylyl cyclase 
activity was measured as increase in cAMP formation by radioimmunoassay. Forskolin caused 
an increase in cAMP formation and the increase was similar in both groups. Carbachol caused a 
significant inhibition of forskolin-stimulated cAMP formation and the extent of inhibition was 
similar in control cells and in cells treated with MβCD.  Results are expressed as pmol/mg 
protein. Values are means ± S.E of 4 experiments. ** Significant inhibition of forskolin-
stimulated cAMP formation by CCh in both control and MβCD treated cells (P<0.001). 
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Fig. 24. Lack of effect on m2-mediated inhibition of adenylyl cyclase activity by caveolin-1 
siRNA.  
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNR-
DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h. 
After plasmid transfection, cells were treated with forskolin (10 µM) for 10 min in the presence 
or absence of CCh (0.1 µM) and adenylyl cyclase activity was measured as increase in cAMP 
formation by radioimmunoassay. Forskolin caused an increase in cAMP formation and the 
increase was similar in both groups. Carbachol caused a significant inhibition of forskolin-
stimulated cAMP formation and the extent of inhibition was similar in control cells and in cells 
transfected with caveolin-1 siRNA. Results are expressed as pmol/mg protein. Values are means 
± S.E of 4 experiments. ** Significant inhibition of forskolin-stimulated cAMP by CCh in both 
control and caveolin-1 siRNA transfected cells (P<0.001). 
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Fig. 25. Lack of effect on m2-mediated inhibition of adenylyl cyclase (AC) activity by 
caveolin-1 KO.   
Gastric muscle isolated from wild type and caveolin-1 KO mice were treated with forskolin (10 
µM) for 10 min in the presence or absence of CCh (0.1 µM) and adenylyl cyclase activity was 
measured as increase in cAMP formation by radioimmunoassay. Forskolin caused an increase in 
cAMP formation and the increase was similar in both groups. Carbachol caused a significant 
inhibition of forskolin-stimulated cAMP formation and the extent of inhibition was similar in 
wild type and caveolin-1 KO mice.  Results are expressed as pmol/mg protein. Values are means 
± S.E of 4 experiments. ** Significant inhibition of forskolin-stimulated cAMP formation by 
CCh in muscle cells from both wild type and caveolin-1 KO mice (P<0.001). 
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III. 6.  Regulation of muscarinic m2 and m3 receptor internalization by caveolin-1. 
 Differential regulation of m2 and m3 receptor signaling raised the possibility that 
caveolin-1 is selectively associated with m3 receptors, but not m2 receptors. To examine this 
notion, association of m3 and m2 receptors with caveolin-1 was examined by western blot 
analysis of muscle homogenates fractionated by sucrose density gradient centrifugation. As 
shown previously caveolin-1 was selectively present in low buoyant fractions 4-5. In the un-
stimulated state both m2 and m3 receptors are present in high-density gradient fractions 9-12 and 
absent from the caveolar fractions 4-5. However, treatment of cells with CCh for 10 min caused 
translocation of m2, but not m3 receptors to caveolar fractions (Fig 26).   
 Since internalization of several G protein-coupled receptors utilize both clathrin and 
clathrin-independent viz. caveolae-dependent pathways, we tested the hypothesis that m2 
receptors are selectively internalized via caveolae-dependent pathway (Fig. 27). Internalization 
was measured as decrease in radiolignad ([3H]Scopolamine) binding to surface receptors after 
pretreatment of cells with CCh (0.1 µM)  for 20 min. Previous studies have shown that 20-min 
treatment with ligand causes maximum internalization of G protein coupled receptors such as  
VAPC2, and CB1 receptors (Mahavadi S 2004; Murthy, Mahavadi et al. 2008). The role of 
caveolae/cavelin-1 in the regulation of internalization was examined using MβCD in freshly 
dispersed muscle cells and caveolin-1 siRNA in cultured muscle cells. Limited yield of muscle 
cells from control and caveolin-1 KO mice precluded the use of this approach for binding 
studies. An essential step in the caveolae-dependent internalization process involves activation of 
Src kinase and phosphorylation of caveolar coat proteins at Tyr14 (Fagerholm, Ortegren et al. 
2009). A selective Src kinase inhibitor PP2 was used as an additional tool to examine the 
caveolae-dependent pathway.   
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 Specific binding was calculated as the difference between binding in the absence and in 
the presence (non-specific binding) of (10 µM) CCh. Binding to m2 receptors was examined in 
the presence of m3 receptor antagonist, 4-DAMP (0.1 µM), whereas binding to m3 receptor was 
examined in the presence of m2 receptor antagonist methoctramine (0.1 µM). Binding to m2 
receptors or m3 receptors was expressed as percent of both total (m2 and m3 receptor) specific 
binding. 
 
III. 6a. Inhibition of m2 receptor internalization by methyl β-cyclodextrin.   
 Freshly dispersed gastric smooth muscle cells were divided into control and 
experimental group. The control group was incubated with DMSO and the experimental group 
was incubated with MβCD (10 mM) each for 30 min. Each group was further divided into two 
sets and one set in each group was incubated with CCh (0.1 µM) for 20 min and after that the 
cells are washed and used for radioligand binding studies.     
 Binding to m2 receptors was 68±5% of total specific binding (1,782±154 cpm/mg 
protein) in control cells and 66±5% of total specific binding (1,628±186 cpm/ mg protein) in 
cells treated with MβCD. These results suggest that either total binding or binding to m2 
receptors was not affected by treatment of cells with MβCD. To examine m2 receptor 
internalization, muscle cells were treated with CCh (0.1 µM) for 20 min, washed free of ligand, 
and then binding was measured in the presence of m3 receptor antagonist 4-DAMP (0.1 µM). 
Treatment of control cells with CCh attenuated binding to m2 receptors to 21±4% of total 
binding (69±5% attenuation compared to control m2 receptor binding) reflecting internalization 
of m2 receptors.  In contract, when cells are pretreated with MβCD, CCh treatment had no 
significant effect on binding to m2 receptor (62±7% of total specific binding), which is similar to 
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binding to m2 receptors in the absence of CCh treatment (66±5% of total specific binding) (Fig. 
28).  These results suggest that m2 receptor internalization was mediated via caveolar-dependent 
pathway in gastric smooth muscle. 
 
III. 6b. Inhibition of m2 receptor internalization by caveolin-1 siRNA.   
 Primary culture of gastric smooth muscle cells were transfected with control pSIREN-
DNR-DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 
48 h. Suppression of caveolin-1 expression was verified by western blot analysis and 
immunofluorescence. Each group was further divided into two sets and one set in each group 
was incubated with CCh (0.1 µM) for 20 min and after that the cells are washed and used for 
radioligand binding studies.   
 Binding to m2 receptors was 67±6% of total specific binding (1,814±205 cpm/mg 
protein) in control cells and 66±3% of total specific binding (1,758±254 cpm/ mg protein) in 
cells transfected with caveolin-1 siRNA.  These results suggest that either total binding or 
binding to m2 receptors was not affected by transfection of cells with caveolin-1 siRNA. To 
examine m2 receptor internalization, muscle cells were treated with CCh (0.1 µM) for 20 min, 
washed free of ligand, and then binding was measured in the presence of m3 receptor antagonist 
4-DAMP (0.1 µM). Treatment of control cells with CCh (0.1 µM) attenuated binding to m2 
receptors to 26±5% of total binding (61±6% attenuation compared to control m2 receptor 
binding) reflecting internalization of m2 receptors. In contrast, cells transfected with caveolin-1 
siRNA, CCh treatment had no significant effect on binding to m2 receptor (64±6% of total 
specific binding), which is similar to binding to m2 receptors in the absence of CCh treatment 
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(67±6% of total specific binding) (Fig. 29). These results suggest that m2 receptor internalization 
was mediated via caveolin-1-dependent pathway in gastric smooth muscle. 
 
III. 6c. Inhibition of m2 receptor internalization by Src kinase inhibitor, PP2.   
 To examine the involvement of Src kinase in m2 receptor internalization, a selective 
Src kinase inhibitor PP2 (1 µM) was used.  Binding to m2 receptors was 67±8% of total specific 
binding (1689±225 cpm/mg protein) in control cells and 64±5% of total specific binding 
(1567±196 cpm/mg protein) in cells treated with PP2. These results suggest that either total 
binding or binding to m2 receptors was not affected by PP2. Treatment of control cells with CCh 
(0.1 µM) attenuated binding to m2 receptors to 25±5% of total binding (63±4% attenuation 
compared to control m2 receptor binding) reflecting internalization of m2 receptors. In contrast, 
cells pretreated with PP2, CCh (0.1 µM) treatment had no significant effect on binding to m2 
receptor (59±7% of total specific binding), which is similar to binding to m2 receptors in the 
absence of CCh treatment (67±8% of total specific binding) (Fig. 30). These results suggest that 
m2 receptor internalization was mediated via caveolin-1-dependent pathway involving Src 
kinase in gastric smooth muscle. 
 
III. 6d. Lack of effect on m3 receptor internalization by methyl β-cyclodextrin.   
 Freshly dispersed gastric smooth muscle cells were divided into control and 
experimental group. The control group was incubated with DMSO and the experimental group 
was incubated with MβCD (10 mM) each for 30 min. Each group was further divided into two 
sets and one set in each group was incubated with CCh (0.1 µM) for 20 min and after that the 
cells were washed and used for radioligand binding studies. Binding to m3 receptors was 
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examined in the presence of methoctramine (0.1 µM) and expressed as percent of total specific 
binding. 
 Binding to m3 receptors was 30±4% of total specific binding (1,782±154 cpm/mg 
protein) in control cells and 28±4% of total specific binding (1,628±186 cpm/ mg protein) in 
cells treated with MβCD. These results suggest that binding to m3 receptors was not affected by 
treatment of cells with MβCD. Pretreatment of control cells with CCh (0.1 µM) attenuated 
binding to m3 receptors to 10±2% of total binding (66±4% attenuation compared to control m3 
receptor binding) in control cells and to 11±2% of total binding (61±3% attenuation) in cell 
treated with MβCD (Fig. 31). The decrease in binding to m3 receptor reflected internalization of 
m3 receptors and this was not affected by MβCD, suggesting that m3 receptor internalization 
was mediated via caveolae-independent pathway in gastric smooth muscle. 
 
III. 6e. Lack of effect on m3 receptor internalization by caveolin-1 siRNA.   
 Primary culture of gastric smooth muscle cells were transfected with control pSIREN-
DNR-DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 
48 h. Suppression of caveolin-1 expression was verified by western blot analysis and 
immunofluorescence. Each group was further divided into two sets and one set in each group 
was incubated with CCh (0.1 µM) for 20 min and after that the cells are washed and used for 
radioligand binding studies. Binding to m3 receptors was examined in the presence of 
methoctramine (0.1 µM) and expressed as percent of total specific binding. 
 Binding to m3 receptors was 33±4% of total specific binding (1,814±205 cpm/mg 
protein) in control cells and 31±2% of total specific binding (1,758±254 cpm/ mg protein) in 
cells transfected with caveolin-1 siRNA. These results suggest that binding to m3 receptors were 
 128 
not affected by transfection of cells with caveolin-1 siRNA. Pretreatment of control cells with 
CCh attenuated binding to m3 receptors to 10±3% of total binding (69±5% attenuation compared 
to control m3 receptor binding) in control cells and to 11±3% of total binding (64±4% 
attenuation) in cells transfected with caveolin-1 siRNA (Fig. 32). The decrease in binding to m3 
receptor reflected internalization of m3 receptors and this was not affected by caveolin-1 siRNA, 
suggesting that m3 receptor internalization was mediated via caveolin-1-independent pathway in 
gastric muscle. 
 
III. 6f. Lack of effect on m3 receptor internalization by Src inhibitor, PP2.   
 To examine the involvement of Src kinase in m3 receptor internalization, a selective 
Src kinase inhibitor PP2 (1 µM) was used. Binding to m3 receptors was 31±4% of total specific 
binding (1689±225 cpm/mg protein) in control cells and 29±4% of total specific binding 
(1567±196 cpm/mg protein) in cells treated with PP2. These results suggest that binding to m3 
receptors were not affected by treatment of cells with PP2. Pretreatment of control cells with 
CCh (0.1 µM) attenuated binding to m3 receptors to 11±2% of total binding (64±5% attenuation 
compared to control m3 receptor binding) in control cells and to 16±4% of total binding (45±5% 
attenuation) in cells transfected with caveolin-1 siRNA (Fig. 33). The decrease in binding to m3 
receptor reflected internalization of m3 receptors and this was minimally, but significantly, 
affected by PP2, suggesting that m3 receptor internalization was partly mediated via Src kinase-
independent pathway in gastric smooth muscle. 
 
 In summary, pretreatment of muscle cells with CCh caused internalization of both m2 
and m3 receptors. Internalization of m2, but not m3 receptors was blocked in dispersed cells 
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treated with MβCD or in cultured muscle cells transfected with caveolin-1 siRNA. These results 
suggest that caveolin-1 positively regulates m2, but not m3 receptor internalization in gastric 
muscle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 130 
 
 
 
Fig. 26. Localization of muscarinic m2 and m3 receptors in caveolar and non-caveolar 
fractions.  
Freshly dispersed muscle cells were used for caveolae isolation using sucrose density gradient 
centrifugation. After centrifugation, 1 ml fractions were collected from the top. The density of 
buoyancy increases with the increase in fraction number. Equal amount of protein were subjected 
to electrophoresis. Localization of caveoin-1 and m2 and m3 receptors in different fractions was 
examined by western blot analysis using specific antibody. Caveolin-1 is localized in low 
buoyant fraction 4-and 5. In the basal state both m2 and m3 receptors are present in high buoyant 
fraction 9-12 and upon treatment of cells with CCh for 15 min, m2 but not m3 receptors are 
translocated to caveolar fractions. Results shown are representative of 3 different experiments   
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Fig. 27. Pathways for receptor internalization. 
Internalization of G protein-coupled receptors is mediated by two major pathways: Clathrin-
dependent pathway and clathrin-independent or caveolar-mediated pathway. Clathrin–dependent 
pathway involves phosphorylation of receptors by G protein coupled receptor kinases (GRKs) 
followed by binding of  -arrestin to the phosphorylated receptor, recruitment of clathrin to β-
arresitn-bound receptors and formation of clathrin-coated pits and fission of clathrin pits with the 
help of dynamin. Caveolar-mediated pathway is independent of clathrins. Following receptor 
clustering in caveolar microdomains, Src mediated phosphorylation of caveolin-1 at Tyr14 leads 
to caveolae-detachment and internalization of receptors. 
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Fig. 28. Inhibition of m2 receptor internalization by methyl β cyclodextrin.  
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group. 
The control group was incubated with DMSO and the experimental group was incubated with 
MβCD (10 mM) each for 30 min. Each group was further divided into two sets and one set in 
each group was incubated with CCh (0.1 µM) for 20 min in the presence of 4-DAMP (0.1 µM) 
to induce m2 receptor internalization. The cells are washed and incubated with [3H]Scopolamine 
in the absence of 4-DAMP to measure binding to both m2 and m3 receptors (total) or in the 
presence of 4-DAMP to measure binding to m2 receptors. Specific binding was calculated as the 
difference between the binding in the absence of CCh and non-specific binding in the presence 
of 10 µM CCh. Decrease in specific binding after CCh pretreatment represents receptor 
internalization. Results are expressed as percent of total (m2 and m3) specific binding. Values 
are means ± S.E of three experiments. ** Significant decrease in binding compared to control 
binding in the absence of CCh pretreatment (P<0.001).   
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Fig. 29. Inhibition of m2 receptor internalization by caveolin-1 siRNA.  
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNR-
DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h. 
Each group was further divided into two sets and one set in each group was incubated with CCh 
(0.1 µM) for 20 min in the presence of 4-DAMP (0.1 µM) to induce m2 receptor internalisation. 
The cells are washed and incubated with [3H]Scopolamine in the absence of 4-DAMP to 
measure binding to both m2 and m3 receptors (total) or in the presence of 4-DAMP to measure 
binding to m2 receptors. Specific binding was calculated as the difference between the binding in 
the absence of CCh and non-specific binding in the presence of 10 µM CCh. Decrease in specific 
binding after CCh pretreatment represents receptor internalization. Results are expressed as 
percent of total (m2 and m3) specific binding. Values are means ± S.E of three experiments. ** 
Significant decrease in binding compared to control binding in the absence of CCh pretreatment 
(P<0.001). 
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Fig. 30. Inhibition of m2 receptor internalization by Src kinase inhibitor, PP2.  
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group. 
The control group was incubated with DMSO and the experimental group was incubated with a 
selective Src kinase inhibitor PP2 (1 µM). Each group was further divided into two sets and one 
set in each group was incubated with CCh (0.1 µM) for 20 min in the presence of 4-DAMP (0.1 
µM) to induce m2 receptor internalisation. The cells are washed and incubated with 
[3H]scopolamine in the absence of 4-DAMP to measure binding to both m2 and m3 receptors 
(total) or in the presence of 4-DAMP to measure binding to m2 receptors. Specific binding was 
calculated as the difference between the binding in the absence of CCh and non-specific binding 
in the presence of 10 µM CCh. Decrease in specific binding after CCh pretreatment represents 
receptor internalization. Results are expressed as percent of total (m2 and m3) specific binding.  
Values are means ± S.E of three experiments. ** Significant decrease in binding compared to 
control binding in the absence of CCh pretreatment (P<0.001). 
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Fig. 31. Lack of effect on m3 receptor internalization by methyl β cyclodextrin.  
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group. 
The control group was incubated with DMSO and the experimental group was incubated with 
MβCD (10 mM) each for 30 min. Each group was further divided into two sets and one set in 
each group was incubated with CCh (0.1 µM) for 20 min in the presence of methoctramine (0.1 
µM) to induce m3 receptor internalisation. The cells are washed and incubated with 
[3H]Scopolamine in the absence of methoctramine to measure binding to both m2 and m3 
receptors (total) or in the presence of methoctramine to measure binding to m3 receptors.  
Specific binding was calculated as the difference between the binding in the absence of CCh and 
non-specific binding in the presence of 10 µM CCh. Decrease in specific binding after CCh 
pretreatment represents receptor internalization. Results are expressed as percent of total (m2 and 
m3) specific binding.  Values are means ± S.E of three experiments. ** Significant decrease in 
binding compared to control binding in the absence of CCh pretreatment (P<0.001). 
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Fig. 32. Lack of effect on m3 receptor internalization by caveolin-1 siRNA.   
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNR-
DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h. 
Each group was further divided into two sets and one set in each group was incubated with CCh 
(0.1 µM) for 20 min in the presence of methoctramine (0.1 µM) to induce m3 receptor 
internalisation. The cells are washed and incubated with [3H]Scopolamine in the absence of 
methoctramine to measure binding to both m2 and m3 receptors (total) or in the presence of 
methoctramine to measure binding to m3 receptors. Specific binding was calculated as the 
difference between the binding in the absence of CCh and non-specific binding in the presence 
of 10 µM CCh. Decrease in specific binding after CCh pretreatment represents receptor 
internalization.  Results are expressed as percent of total (m2 and m3) specific binding.  Values 
are means ± S.E of three experiments. ** Significant decrease in binding compared to control 
binding in the absence of CCh pretreatment (P<0.001). 
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Fig. 33. Lack of effect on m3 receptor internalization by Src inhibitor, PP2.   
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group. 
The control group was incubated with DMSO and the experimental group was incubated with a 
selective Src kinase inhibitor PP2 (1 µM). Each group was further divided into two sets and one 
set in each group was incubated with CCh (0.1 µM) for 20 min in the presence of methoctramine 
(0.1 µM) to induce m3 receptor internalisation. The cells are washed and incubated with 
[3H]Scopolamine in the absence of methoctramine to measure binding to both m2 and m3 
receptors (total) or in the presence of methoctramine to measure binding to m3 receptors.  
Specific binding was calculated as the difference between the binding in the absence of CCh and 
non-specific binding in the presence of 10 µM CCh. Decrease in specific binding after CCh 
pretreatment represents receptor internalization. Results are expressed as percent of total (m2 and 
m3) specific binding.  Values are means ± S.E of three experiments. ** Significant decrease in 
binding compared to control binding in the absence of CCh pretreatment (P<0.001). 
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III. 7. Regulation of excitation-transcription coupling by caveolin-1.  
 Modulation of smooth muscle phenotype occurs as results of modulation of signaling 
pathways that regulate smooth muscle contractile proteins such as smooth muscle γ-actin (SM-γ 
actin), SM-myosin heavy chain (SM-MHC), calponin, and caldesmon. Expression of contractile 
proteins is regulated by the key transcriptional factors such as serum response factor (SRF) and 
transcriptional co-activators such as myocardin (Pipes, Creemers et al. 2006). The Ca2+ and 
RhoA/Rho kinase pathways have been associated with the regulation of SRF/myocardin activity. 
Recent studies have revealed that the number of caveolae, and their marker protein caveolin-1 is 
greatly increased as smooth muscle cells acquire a contractile phenotype (Gosens, Stelmack et al. 
2011) (Fig. 34). Since there is decrease in RhoA/Rho kinase pathway with caveolin-1 
suppression, we tested the hypothesis that caveolin-1 positively regulates contractile protein 
expression in smooth muscle. Expression of SRF, myocardin, γ-actin and caldesmon was 
measured by real time RT-PCR and western blot in cultured muscle cells transfected with control 
siRNA or caveolin-1 siRNA. mRNA expression of contractile proteins such as γ-actin and 
caldesmon (Fig. 36) and the transcription factors SRF (% inhibition) and myocardin (% 
inhibition) (Fig. 35) are significantly inhibited in cells transfected with caveolin-1 siRNA 
compared to cells transfected with control siRNA. This inhibition of mRNA expression 
paralleled inhibition of protein expression of γ-actin, caldesmon, SRF and myocardin in cells 
transfected with caveolin-1 siRNA compared to cells transfected with control siRNA. These 
results suggest that a positive regulation of contractile proteins expression and the transcription 
factors that regulate contractile protein expression is exerted by caveolin-1 in gastric smooth 
muscle. The decrease in the expression of contractile proteins by caveolin-1 suppression is 
accompanied by an increase in proliferative signals such as epidermal growth factor receptor 
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phosphorylation and ERK1/2 activity. Basal level of EGF receptor phosphorylation was 
significantly higher (65±13% increase) in cells transfected with caveolin-1 siRNA. Treatment 
with EGF caused a significant increase (138±18% increase above basal levels, p<0.01) in EGF 
receptor phosphorylation in control cells. The effect of EGF was significantly augmented in cells 
transfected with caveolin-1 siRNA (218±21% increase above basal, 58±6% augmentation 
compared to EGF response in control cells) (Fig. 37). Consistent with increase in EGF receptor 
phosphorylation, basal ERK1/2 activity was significantly higher in cells transfected with 
caveolin-1 siRNA (control cells 1430±138 cpm/mg protein; 2336±351 cpm/mg protein; 62±4% 
increase, p<0.01). Treatment with EGF caused a significant increase (151±13% increase above 
basal levels, p<0.01) in ERK1/2 activity in control cells. The effect of EGF was significantly 
augmented in cells transfected with caveolin-1 siRNA (235±21 increase above basal, 57±4% 
augmentation compared to EGF response in control cells) (Fig. 38). 
 
 In summary, expression of contractile proteins, γ-actin and caldesmon and the 
transcription factors SRF and myocardin that regulate the expression of contractile proteins are 
down regulated in cells transfected with caveolin-1 siRNA.  This is accompanied by an increase 
in basal and EGF-stimulated EGF receptor phosphorylation and ERK1/2 activity in cells 
transfected with caveolin-1siRNA. These results suggest that caveolin-1 negatively regulates 
proliferative phenotype and positively regulates contractile phenotype in gastric muscle. 
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Fig. 34. Excitation-contraction coupling in smooth muscle. 
Expression of smooth muscle specific genes is essential for maintaining its contractile 
phenotype. Ca2+ and RhoA-dependent signaling pathways positively regulate the expression of 
smooth muscle specific genes through transcription factors such as serum response factor (SRF) 
and myocardin that selectively binds to CArG elements on promoter region. In contrast, 
signaling through growth factors promotes smooth muscle proliferation by suppressing SRF and 
myocardin activity.  
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Fig. 35. Inhibition of serum response factor (SRF) and myocardin expression by caveolin-1 
siRNA.  
Total RNA was isolated from smooth muscle cells transfected with control pSIREN-DNR-
DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA 
transfected cells using RNAqueous prep kits (Ambion, Austin, Tx) and reverse transcribed using 
2 µg of total RNA using qScript cDNA prep kits (Quanta, Gaithersburg, MD). The cDNA was 
amplified with specific primers for serum responsive factor (SRF) and myocardin. Quantitative 
real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels of SRF and 
myocardin. For each cDNA sample, real-time PCR was conducted in a 20-μl-reaction volume 
containing Quantitect
TM 
SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). Real-time 
PCR reactions were performed in triplicate. Results are expressed as fold differences in gene 
expression in caveolin-1 siRNA transfected cells relative to that in control cells transfected with 
the vector alone. Values represent the means ±SE of 3 separate experiments.  Inset:  Culture 
muscle cell lysates containing equal amounts of total proteins were separated with SDS-PAGE 
and expression of SRF and myocardin was analyzed using selective antibody. Results are 
expressed as fold differences in SRF or myocardin protein expression in caveolin-1 siRNA 
transfected cells relative to that in vector-transfected cells. Values represent the means ±SE of 3 
separate experiments. *Significant inhibition of expression in caveolin-1 siRNA transfected cells 
compared to expression in control cells (p<0.05). 
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Fig. 36. Inhibition of γ-actin and caldesmon expression by caveolin-1 siRNA.  
Total RNA was isolated from smooth muscle cells transfected with control pSIREN-DNR-
DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA 
transfected cells using RNAqueous prep kits (Ambion, Austin, Tx) and reverse transcribed using 
2 µg of total RNA using qScript cDNA prep kits (Quanta, Gaithersburg, MD).  The cDNA was 
amplified with specific primers for γ-actin and caldesmon. Quantitative real-time polymerase 
chain reaction (qRT-PCR) was used to measure RNA levels of SRF and myocardin. For each 
cDNA sample, real-time PCR was conducted in a 20-μl-reaction volume containing Quantitect
TM 
SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). Real-time PCR reactions were 
performed in triplicate. Results are expressed as fold differences in gene expression in caveolin-1 
siRNA transfected cells relative to that in control cells transfected with the vector alone. Values 
represent the means ±S.E of 3 separate experiments. Inset: Culture muscle cell lysates 
containing equal amounts of total proteins were separated with SDS-PAGE and expression of γ-
actin and caldesmon was analyzed using selective antibody. Results are expressed as fold 
differences in SRF or myocardin protein expression in caveolin-1 siRNA transfected cells 
relative to that in control vector-transfected cells.  Values represent the means ±S.E of 3 separate 
experiments. * Significant inhibition of expression in caveolin-1 siRNA transfected cells 
compared to expression in control cells (p<0.05). 
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Fig. 37. Augmentation of EGF receptor phosphorylation by caveolin-1 siRNA. 
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNR-
DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h. 
Following transfection cells were treated with EGF (1 ng/ml) for 5 min.  Cell lysates containing 
equal amounts of total proteins were separated on SDS-PAGE and the phosphorylation of EGF 
receptor was analysed using phospho-specific (Tyr1068) antibody. Blots shown are representative 
of 3 different experiments. The bar graphs show quantification of the EFG receptor 
phosphorylation by densitometry. Values represent the means ±S.E of 3 separate experiments. * 
Significant increase in EGF receptor phosphorylation compared to basal phosphorylation 
(p<0.01). ** Significant increase in EGF receptor phosphorylation in response to EGF in cells 
transfected with caveolin-1 siRNA compared to response in control cells transfected with the 
vector alone (p<0.05). 
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Fig. 38. Augmentation of ERK1/2 activity by caveolin-1 siRNA. 
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNR-
DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h. 
Following transfection cells were treated with EGF (1ng/ml) for 5 min and ERK1/2 activity was 
measured using [γ-32P]ATP by immunokinase assay. Results are expressed as cpm/mg protein. 
Values represent the means ±S.E of 3 separate experiments. ** Significant increase in ERK1/2 
activity compared to basal activity (p<0.01). * Significant increase in ERK1/2 activity in 
response to EGF in cells transfected with caveolin-1 siRNA compared to response to EGF in 
control cells (p<0.05). 
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CHAPTER IV: DISCUSSION 
IV. DISCUSSION 
 
 The fundamental phenomenon of contraction in smooth muscle cells of the 
gastrointestinal tract is critical for propelling the intraluminal content from the orad to the caudad 
direction. Contraction is initiated by the release of contractile transmitters that mainly constitutes 
acetylcholine and tachykinins that are derived from enteric excitatory motor neurons. The 
signaling pathways activated by the contractile agonists also play an important role in the 
regulation of smooth muscle contractile phenotype by transcriptional and translational regulation 
of contractile protein expression. Both excitation-contraction and excitation-transcription 
coupling are, in turn, regulated by cell-extrinsic (extracellular matrix) and cell-intrinsic proteins.   
Caveolae are integral parts of the smooth muscle membrane and several studies have 
demonstrated that caveolae act as signaling platforms or scaffolds that regulate cellular signaling 
through direct and indirect interaction with signaling proteins. All three main components of G 
protein coupled receptor system (receptor, G proteins and effector enzymes) are localized at the 
plasma membrane and their co-localization with caveolae is well suited for efficient transduction 
of signaling events. Caveolae contain the protein caveolins, and all three gene products of the 
caveolin proteins (caveolin-1, caveolin-2 and caveolin-3) are expressed in smooth muscle 
(Taggart 2001).  Previous studies in both visceral and airway smooth muscle have shown that the 
relative mRNA expression levels were 15:1:1 for caveolin-1, caveolin-2 and cavelolin-3, 
respectively (Shakirova, Bonnevier et al. 2006). Caveolin-1 is the predominant isoform in the 
smooth muscle and drives the formation of caveolae.  However, little is known about the role of 
caveolin-1 in the regulation of excitation-contraction and excitation-transcription coupling in 
gastrointestinal smooth muscle. In the present study we initially characterized m2 and m3 
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receptor signaling in gastric smooth muscle and then examined the role of caveolin-1 in the 
regulation of signaling pathways mediated by muscarinic receptors. Since selective receptor-
specific ligands are not available, m2 receptor-selective antagonist, methoctramine and m3 
receptor-selective antagonist 4-DAMP were used to analyze the receptor-specific signaling. 
Previous studies in intestinal muscle have demonstrated that m3 are coupled to stimulation of 
PLC-β (PI hydrolysis) via Gq and RhoA-dependent activation of Rho kinase/ZIP kinase via G13, 
whereas m2 receptors are coupled to inhibition of adenylyl cyclase via Gi (Murthy, Zhou et al. 
2003; Uchiyama and Chess-Williams 2004). Similarly, m3-mediated stimulation of PI 
hydrolysis, and Rho kinase and ZIP kinase activity, and m2-mediated inhibition of AC activity 
was obtained in gastric muscle cells. Hence, these enzyme activities were used as readouts of 
Gq/13-coupled m3 receptor activity and Gi-coupled m2 receptor activity to examine the role of 
caveolae/caveolin-1 on receptor-effectors coupling. Increase in MLC20 phosphorylation, a 
biochemical correlate, and decrease in muscle cell length were used as readouts of muscle 
function. Expression of key transcription factors such as SRF and myocardin and contractile 
proteins such as γ-actin, and caldesmon, and proliferative signals such as phosphorylation of 
EGF receptor and stimulation of ERK1/2 activity were measured as readouts to examine the role 
of caveolin-1 in the regulation of contractile phenotype. The role of caveolae/caveolin-1 was 
examined using three complimentary approaches: a) methyl β-cyclodextrin (MβCD) to deplete 
cholesterol in freshly dispersed muscle cells, b) caveolin-1 siRNA to suppress caveolin-1 
expression in cultured muscle cells, and c) caveolin-1 knockout (KO) mice.   
 
 
 
 160 
IV. 1.  Signaling transduction by muscarinic receptors 
 Five distinct muscarinic receptors (m1-m5), derived from distinct gene products, have 
been characterized in mammalian tissues. Our initial studies characterized the expression of 
muscarinic receptors and the receptor-specific signaling pathways activated by CCh in rabbit 
gastric smooth muscle cells. Gastric smooth muscle expresses selectively m2 and m3 receptors 
and this was confirmed by RT-PCR, western blot and radioligand binding studies. Expression of 
m2 receptors is much greater (~70%) than m3 receptors (~30%). Although vascular, visceral and 
airway smooth muscle cells express mostly m2 and m3 receptors, the relative expression of m2 
and m3 receptors varies depending on the tissue. In general, the expression of m2 receptors is 
more abundant than m3 receptors (Eglen, Reddy et al. 1994; Niihashi, Esumi et al. 2000; Wang, 
Han et al. 2001; Murthy, Zhou et al. 2003). Although the expression of m2 receptors is abundant 
than m3 receptors, contraction is exclusively mediated by m3 receptors in gastric muscle cells 
(Kitazawa, Hirama et al. 2008). Similar selective involvement of m3 receptors in contraction was 
demonstrated in vascular and other visceral smooth muscle cells. The contribution of m2 
receptors to mediate muscle contraction varies depending on the smooth muscle tissue. Using 
receptor selective antagonists and transgenic mice, it was demonstrated that more than 90% of 
the contraction in response to CCh was mediated via m3 receptors in intestinal and bladder 
muscle, whereas only 50% contraction was mediated via m3 receptors in airway muscle and the 
remaining contraction was mediated via m2 receptors (Boulanger, Morrison et al. 1994; Chess-
Williams, Chapple et al. 2001; Stengel, Yamada et al. 2002).   
 In the present study, we have demonstrated that CCh-stimulated PI hydrolysis and Rho 
Kinase and ZIP kinase activity were blocked by the selective m3 receptor antagonist, 4-DAMP, 
whereas CCh-induced inhibition of AC activity was blocked by the selective m2 receptor 
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antagonist, methoctramine and pertussis toxin. These results are consistent with the muscarinic 
receptor signaling in other visceral and vascular smooth muscle (Singer, Vang et al. 2002; 
Gerthoffer 2005; Unno, Matsuyama et al. 2006). Receptor-specific coupling to G proteins and 
activation of signaling pathways are not unique to muscarinic m2 and m3 receptors.  Previous 
studies in smooth muscle have shown that similar receptor-specific coupling to distinct G 
proteins and signaling with 5-HT (5-HT2 and 5-HT4) receptors, adenosine (A2 and A1) 
receptors, shingosine-1-phosphate (S1P1 and S1P2) receptors, neuropeptide (NPY1 and NPY2) 
receptors, and endothelin (ETA and ETB) receptors (Kuemmerle, Murthy et al. 1995; Murthy and 
Makhlouf 1995; Murthy and Makhlouf 1998; Hersch, Huang et al. 2004; Misra, Murthy et al. 
2004; Zhou and Murthy 2004). 
Excitatory neurotransmitters such as acetylcholine and tachykinins mobilize intracellular 
Ca2+ via Gαq-dependent stimulation of PLC-β1. Activation of PLC-β1 hydrolyzes 
phosphatidylinositol 4,5 bisphosphate (PIP2) to generate two messengers: IP3, which releases 
Ca2+ from intracellular stores via binding to specific receptors, and diacylglycerol (DAG), which 
activates various PKC isoforms. Increase in cytosolic Ca2+ results in activation of 
Ca2+/calmodulin-dependent MLC kinase and subsequent phosphorylation of MLC20, an essential 
step in smooth muscle contraction (Murthy 2006; Deng, Ding et al. 2011). The selective m3 
receptor antagonist, 4-DAMP, blocks acetylcholine-induced PI hydrolysis and initial muscle 
contraction. 
Contractile agonists that activate Gq also activate G13: both G proteins activate RhoA via 
distinct guanine nucleotide exchange factors (GEFs), and their involvement in smooth muscle is 
receptor-specific. Muscarinic m3 and CCK-A receptors activate RhoA via Gα13 only, whereas 
S1P2 and motilin receptors activate RhoA via both Gαq and Gα13 (Murthy, Zhou et al. 2001; Le 
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Page, Bi et al. 2003; Murthy, Zhou et al. 2003; Suzuki, Hajicek et al. 2009; Sabbatini, Bi et al. 
2010). Activated RhoA, in turn stimulates Rho kinase, a serine/threonine protein kinase that 
belongs to family of enzymes including myotonic dystrophy protein kinase (DMP kinase), 
Cdc42-binding kinase, and citron kinase (Riento and Ridley 2003; Wansink, van Herpen et al. 
2003). Rho kinase phosphorylates the regulatory subunit of MLC phosphatase, MYPT1, at Thr696 
and inhibits catalytic activity resulting in increase in MLC20 phosphorylation and sustained 
contraction (Fukata, Amano et al. 2001). ZIP kinase, a member of death-associated protein 
kinase family, was also shown to phosphorylate MYPT1 at Thr696, albeit with a greater potency, 
and also MLC20 in vitro in a Ca2+-independent mechanism (Borman, MacDonald et al. 2002; 
Endo, Surks et al. 2004). However, the physiological significance of ZIP kinase in vivo is 
unclear. Stimulation of ZIP kinase activity by CCh and inhibition by the selective Rho kinase 
inhibitor, Y27632 provide evidence that the contractile agonist activate ZIP kinase and its 
activity is dependent on Rho kinase suggesting that Rho kinase is an upstream kinase. However, 
Rho kinase does not phosphorylate ZIP kinase in vitro suggesting that activation of ZIP kinase 
by Rho kinase may be indirect via one or more kinases (Graves, Winkfield et al. 2005). 
Carbachol-induced stimulation of Rho kinase and ZIP kinase activity and sustained contraction 
were also inhibited by 4-DAMP and Y27632, suggesting that sustained contraction was also 
exclusively mediated by m3 receptors. The results with Y27632 imply the involvement of Rho 
kinase pathway, but the relative roles of Rho kinase vs. ZIP kinase, in direct phosphorylation of 
MYPT1 to mediate contraction is unknown and awaits further studies with specific ZIP kinase 
inhibitors.  
 Muscarinic m2 receptors are coupled to inhibition of AC activity and this is consistent 
with the expression of AC V and VI isoforms in gastric smooth muscle cells. Gi proteins inhibit 
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AC V/VI isoforms and this is in contrast with the activation of AC II/IV forms that are not 
inhibited by Gi proteins (Murthy and Makhlouf 1997; Murthy and Makhlouf 1998; Wansink, van 
Herpen et al. 2003). Although m2 receptors are not directly coupled to muscle contraction, 
activation of these receptors is shown to augment m3 receptor-mediated contraction. This is 
partly due to inhibition of RGS4, an activator of Gαq-GTPase, and activation of Gαq-dependent 
PLC-β1 activity by m2-mediated stimulation of PI3-kinase activity (Hu, Li et al. 2009). The 
augmentation is attributed to inhibition of cAMP formation by m2 receptor activation. The 
physiological significance of decrease in cAMP formation was viewed as functional antagonism 
of on-going relaxation mediated by cAMP-dependent protein kinase (PKA) and facilitation of 
contraction via Gq/G13-coupled pathways.  
 
 In conclusion, m3 receptors are coupled to stimulation of PI hydrolysis, and Rho 
kinase and ZIP kinase activity, and muscle contraction, whereas m2 receptors are coupled to 
inhibition of AC activity in gastric smooth muscle.  
 
IV. 2. Regulation of m2 and m3 receptor signaling by caveolae and caveolin-1. 
Caveolae and their main membrane proteins, caveolins, concentrate receptors, G proteins, 
effector enzymes, and associated signaling molecules so as to facilitate coordinated generation and 
degradation of second messengers. Caveolins contain a caveolin-scaffolding domain that binds 
signaling molecules via a characteristic caveolin-binding domain in these molecules. Caveolae 
contain abundant cholesterol and sphingolipids and the cholesterol is necessary for caveolae 
structure and function. Depletion of cholesterol with pharmacological treatments alters signaling by 
both tyrosine kinase- and G protein-coupled receptors (GPCRs) (Chini and Parenti 2004; Matthews, 
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Taggart et al. 2005; Patel, Murray et al. 2008). The effect of caveolae and caveolins on smooth 
muscle contraction appears to be receptor- and ligand-specific. In general caveolae and caveolins 
appear to facilitate vascular smooth muscle contraction via G protein coupled receptors, and inhibit 
proliferation via tyrosine kinase-coupled receptors (Insel, Head et al. 2005; de Laurentiis, Donovan 
et al. 2007). The effect of caveolae and caveolins on muscarinic m3 and m2 receptor-mediated 
signaling is not clear.    
In the present study, the role of caveolae/caveolin-1 in the regulation of m2 and m3 receptor 
signaling was analyzed using pharmacological (MβCD), molecular (caveolin-1 siRNA) and genetic 
(caveolin-1 knockout) approaches. A novel aspect of these studies is that similarity of results 
obtained with all three approaches.  MβCD, a water-soluble heptasaccharide, binds cholesterol with 
high specificity and has been used extensively as cholesterol depleting pharmacological agent.  
Depletion of cholesterol by MβCD results in disruption of caveolae and affects plasma membrane 
signaling pathways. The exact mechanism by which cholesterol removal affects signaling pathways 
is not clear, however, cholesterol replenishment restores the plasma membrane signaling (Ostrom 
and Insel 2006). The efficiency and specificity of MβCD treatment was confirmed in vascular and 
airway smooth muscle by the significant decrease in caveolae and lack of effect of MβCD on other 
cellular structures (Gosens, Stelmack et al. 2007). The intact depolarization-induced response of 
MβCD treated cells to KCl also excluded the non-selective damage of the plasma membrane (Dreja, 
Voldstedlund et al. 2002). Although use of MβCD and other cholesterol chelating drugs remains a 
mainstay to study the function of caveolae, the effects of MβCD could be non-specific than 
molecular approaches. Disruption of caveolae by MβCD can affect signaling by redistribution of 
proteins, and thus changing their relative local concentrations or by changing the chemical 
environment of the membrane. To more precisely understand the role of caveolin-1, the most 
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abundant isoform of caveolin in smooth muscle, we used the caveolin-1 siRNA approach to 
suppress caveolin-1 expression and to examine the specific role of caveolin-1 in muscarinic 
signaling. Transfection of siRNA was analyzed by immunocytochemistry and suppression of 
caveolin-1 expression was analyzed by western blot.  We also took the advantage of using caveolin-
1 KO mice as they became available commercially.  Cavelolin-1 KO mice have provided excellent 
animal models to examine the physiological significance of caveolae.  These mice have been used 
in previous studies to examine the role of caveolin-1 in the regulation of vascular and visceral 
muscle function (Zhao, Liu et al. 2002; Schwencke, Schmeisser et al. 2005; Insel and Patel 2007; 
Sathish, Yang et al. 2011). Despite the importance of caveolin-1 in the formation of caveolae and 
signal transduction, caveoin-1 KO mice are viable raising the possibility of compensatory 
mechanisms.   
Our studies indicate that the effect of caveolae and caveolin-1 on muscarinic receptor 
signaling appears to be receptor-and signaling-specific. Caveolae and caveolin-1 facilitate 
Gq/G13-coupled m3 receptor signaling, but not Gi-coupled m2 receptor signaling.  In contrast, 
caveolae and caveolin-1 facilitate m2 receptor, but not m3 receptor internalization.   
 
IV. 2a. Regulation of Gq-coupled m3 receptor signaling by caveolin-1. 
Carbachol-induced stimulation of PI hydrolysis in the presence of methoctramine was 
measured as readout of Gq-coupled m3 receptor signaling.  Carbachol-induced PI hydrolysis was 
significantly inhibited by the disruption of caveolae in freshly dispersed cells and by the 
suppression of caveolin-1 in cultured muscle cells. Similar decrease in PI hydrolysis was 
obtained in gastric muscle from caveolin-1 KO mice. These results suggest that caveolin-1 
positively regulates Gq-coupled m3 receptor signaling. This could lead to decrease in IP3 
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formation, IP3-induced Ca2+ release, and Ca2+/calmodulin-dependent MLC kinase activity, 
MLC20 phosphorylaiton and muscle contraction in response to CCh. Consistent with this notion, 
CCh-induced MLC20 phosphorylation and contraction was significantly reduced in cells treated 
with MβCD. Similar decrease in contraction was also observed in muscle cells obtained from 
caveolin-1 KO mice. These results are similar to recent data from studies with vascular and 
airway smooth muscle cells, where disruption of caveolae with MβCD leads to reduced 
contraction in response to contractile agonists such as endothelin-1, serotonin, α1 adrenergic 
receptor agonist, and acetylcholine (Cristofaro, Peters et al. 2007; Gosens, Stelmack et al. 2007). 
However, studies by Shakirova et al. showed that the effect of caveolin-1 was agonist- and 
tissue-specific. Response of ileum longitudinal muscle to endothelin-1, but not to carbachol or 
serotonin was reduced in caveolin-1 KO mice, whereas the response of femoral arterial muscle to 
α1-adrenergic agonist was increased (Okamoto, Schlegel et al. 1998; Shakirova, Bonnevier et al. 
2006).    
Collectively, our results provide conclusive evidence that caveolin-1 facilitates Gq-
coupled m3 receptor signaling and muscle contraction in response to contractile agonists such as 
CCh. Although, it is not clear whether caveolin-1 targets m3 receptor, or Gαq or PLC-β1 isoform 
to facilitate the effect. Analysis of m3 receptor expression in sucrose density gradient fractions 
showed that m3 receptors are not associated with caveolin-1. This suggests that distal 
components of m3 receptor may be spatially associated with caveolin-1. Previous studies have 
shown that Gαq protein contain caveolin binding motif and directly interacts with caveolin-1 
proteins (Sengupta, Philip et al. 2008; Allen, Yu et al. 2009; Guo, Golebiewska et al. 2011). 
Thus, it is possible that the interaction of Gαq with caveolin-1 augments PI hydrolysis. In support 
to this notion, PI hydrolysis in response to substance P, which interacts with Gq-coupled 
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neurokinin receptor, was also inhibited by MβCD. It is also important to note that in smooth 
muscle caveolae contains proteins that are not only important for GPCR signaling, but also ion 
channel and pumps involved in Ca2+ homeostasis. Recent studies demonstrated that KCl-induced 
contraction was similar in wild type and caveolin-1 KO mice suggesting that caveolin-1 KO does 
not affect the membrane-depolarization process (Shakirova, Bonnevier et al. 2006). 
In conclusion, the results described here indicate a significant role for caveolin-1 in 
regulation of Gq-coupled PLC-β1 activity and muscle function. Further work examining the 
localization of Gαq proteins and PLC-β1 isoforms in caveolae and their interaction with 
caveolin-1 may reveal more precise understanding of the mechanism regulating PI hydrolysis 
and contraction.   
 
IV. 2b.  Regulation of G13-coupled m3 receptor signaling by caveolin-1. 
Stimulation of Rho kinase and ZIP kinase activity in response to CCh was measured as 
readouts of G13-coupled m3 receptor signaling. Previous studies in intestinal smooth muscle 
have shown that acetylcholine-stimulated Rho kinase activity is downstream of G13/RhoA 
signaling (Buyukafsar and Levent 2003; Murthy, Zhou et al. 2003; Rattan, Puri et al. 2003). Our 
studies provide evidence that contractile agonists such as carbachol also stimulate ZIP kinase 
activity and its activation is downstream of Rho kinase.   
Carbachol-stimulated Rho kinase and ZIP kinase activity was significantly inhibited by 
the disruption of caveolae in freshly dispersed cells and by the suppression of caveolin-1 in 
cultured muscle cells. Similar decrease in Rho kinase and ZIP kinase activity was obtained in 
gastric muscle from caveolin-1 KO mice. One of the downstream targets of Rho kinase and ZIP 
kinase is MYPT1. Both kinases phosphorylate MYPT1 at Thr696 leading to inhibition of MLC 
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phosphatase, increase in MLC20 phosphorylation and muscle contraction. Thus, inhibition of 
Rho kinase and ZIP kinase activity could lead to decrease in MYPT1 phosphorylation and 
muscle contraction in response to CCh. Consistent with this notion, CCh-induced MYPT1 
phosphorylation at Thr696 and contraction were significantly reduced in cells treated with MβCD. 
Similar decrease in contraction was also observed in muscle cells obtained from caveolin-1 KO 
mice. Thus, our results suggest that caveolin-1 is necessary for optimal G13/RhoA-dependent 
signaling in gastric smooth muscle. It is not clear, however, whether caveolin-1 targets RhoA or 
Rho kinase to facilitate the effect. Lack of m3 receptors in the caveolar fractions suggests that 
distal components of m3 receptor such as RhoA may be spatially associated with caveolin-1. 
RhoA is small GTP binding proteins and exists in active GTP-bound and inactive GDP-bound 
states. The inactive cytosolic pool is associated with Rho-dissociation inhibitor and the active 
plasma membrane pool is associated with caveolae. Previous studies by confocal microscopy in 
mesenteric arteries showed activation-induced colocalization of RhoA with caveolin-1, and 
MβCD treatment significantly decreased the colocalization and contraction (Dubroca, Loyer et 
al. 2007). Similar inhibition of agonist-induced RhoA translocation and contraction was obtained 
by blocking caveolin-1 scaffolding domain with a synthetic peptide in ferret aorta (Taggart, 
Leavis et al. 2000). In addition, sites of monoglycosylation and ADP ribosylation of RhoA, 
which inhibits RhoA translocation and muscle contraction, are located within the caveolin-1 
binding motif of RhoA (Dubroca, Loyer et al. 2007). Although, caveolin-1 is generally 
considered as negative regulator of signaling molecules, our studies using several complimentary 
approaches suggested that caveolin-1 positively regulates G13/RhoA-mediated signaling by m3 
receptors. The mechanisms governing the facilitation of RhoA activation by caveolin-1 are 
unknown. Activation of RhoA is dependent on the Rho guanine exchange factors (RhoGEFs). 
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There are several members in the RhoGEF family of proteins that include p115RhoGEF, PDZ-
RhoGEF, and LARG (leukemia associated RhoGEF). All the RhoGEF proteins harbor a 
common signature motif including RGS (regulator of G protein signaling), Db1 homology (DH), 
and pleckstrin homology (PH) domains that are responsible for the exchange of GDP for GTP 
after binding to inactivated Gα subunits. The role of RhoGEFs can be described that of a 
molecular link between heterotrimeric G proteins and monomeric G proteins. Further 
experiments are needed to identify the localization of RhoA and specific Rho GEFs involved in 
the activation of Rho kinase and ZIP kinase and muscle contraction in gastric muscle.  
It is important to note that downstream of m3 receptor activation, PKC, in addition to 
Rho kinase and ZIP kinase, play an important role in the inhibition of MLC phosphatase and 
regulation of muscle contraction. In the active GTP-bound conformation, RhoA physically 
interact with downstream effectors such as Rho Kinase and phospholipase D (PLD) and 
stimulates their activity. Phosphatidic acid formed as a hydrolytic product of phosphatidylcholine 
by PLD activity, leads to sustained activation of several PKC isozymes (Murthy, Grider et al. 
2000; Preininger, Henage et al. 2006). PKC, in turn, phosphorylates an endogenous MLC 
phosphatase inhibitor known as CPI-17 and phosphorylation greatly accelerates the ability of 
CPI-17 to inhibit MLC phosphatase and augment MLC20 phosphorylation (Li, Eto et al. 1998; 
Woodsome, Eto et al. 2001; Tazzeo, Bates et al. 2012). We did not examine the effect of 
caveolin-1 on this PKC/CPI-17 pathway in gastric muscle. Previous studies in vascular muscle 
have identified caveolae as regulators of PKC signaling. Studies by Je et al (Je, Gallant et al. 
2004) showed that chemical loading of caveolin-1 peptide that inhibits caveolin-1 function 
caused significant inhibition of contraction in response to phorbol esters. Understanding agonist-
induced, isoform(s)-specific translocation of PKC could lead to assess the singular contribution 
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of Rho kinase and ZIP kinase pathway to the decrease in muscle contraction in cells treated with 
MβCD or caveolin-1 siRNA or in cells isolated from caveolin-1 KO mice. 
In conclusion, the results described here indicate a significant role for caveolin-1 in 
regulation of G13-coupled RhoA-dependent pathway and muscle function. Further work 
examining the localization of RhoA and PKC isoforms in caveolae and their interaction with 
caveolin-1 may reveal more precise understanding of the mechanism regulating Rho kinase/ZIP 
kinase and sustained muscle contraction. 
 
IV. 2c. Regulation of Gi-coupled muscarinic m2 receptor signaling by caveolin-1. 
Since m2 receptors are coupled to PTx-sensitive Gi proteins, inhibition of forskolin-
stimulated cAMP formation, reflecting inhibition of AC activity was measured as readout of Gi-
coupled m2 receptor signaling. The effect of caveolae and caveolin-1 was analyzed using all 
three approaches described above. In contrast to the effect of caveolae and caveolin-1 on the 
Gq/G13-coupled m3 receptor signaling, disruption of caveolae with MβCD in freshly dispersed 
muscle cells or suppression of caveolin-1 in cultured muscle cells with caveolin-1 siRNA did not 
affect the inhibition of AC activity in response to CCh. Similar results were obtained using 
caveolin-1 KO mice. CCh-induced inhibition of AC activity was similar in gastric muscle cells 
from WT mice and caveolin-1 KO mice. The similarity of results with three distinct approaches 
strongly suggests that caveolin-1 has no effect on Gi-coupled m2 receptor signaling in gastric 
muscle cells.  
Taken together, our studies provide evidence that caveolin-1 differentially regulate m3 
and m2 receptor signaling in gastric muscle: m3-coupled Gαq and Gα13 signaling is facilitated, 
whereas m2-coupled Gαi signaling is not affected.  
 171 
Our studies also demonstrated that the increase in AC activity in response to direct 
activator forskolin was similar in control cells and in cells treated with MβCD or caveolin-1 
siRNA. Stimulation of AC activity by forskolin was also similar in gastric muscle from WT mice 
and caveolin-1 KO mice. These results suggest that caveolin-1 had no effect on AC activity. Our 
results differ with previous studies showing suppression of caveolin-1 in C6 glioma cells or lack 
of caveolin-1 in the brain of caveolin-1 KO mice significantly augmented forskolin-stimulated 
AC activity (Allen, Yu et al. 2009; Head, Hu et al. 2011). These studies suggest that the effect of 
caveolin-1 on AC activity varies within different tissues and/or with the expression of specific 
AC isoforms.  There are nine different isoforms of AC’s and their localization in caveolae seems 
to be isoforms-specific. AC3, AC5, AC6 and AC8 are expressed in lipid rafts while the other 
isoforms of AC are not (Ostrom, Liu et al. 2002). Localization of the AC isoforms in membrane 
microdomains play an important role in the coupling of G protein coupled receptors to discrete 
AC isoforms and differential regulation of AC isoforms by signaling molecules such as Ca2+ and 
PKC. Further experiments are sought to characterize the localization of AC isoforms in the 
caveolae to define the regulation of their activity by signaling molecules. In addition, given that 
cAMP signaling is compartmentalized by the expression of phosphodiesterases, we speculate 
that such intermolecular association with other signaling partners in caveolar microdomains is 
also relevant to understand the role of caveolin-1 in cAMP signaling. 
  In conclusion, the results described here indicate that m2 receptor signaling via Gi is 
not regulated by caveolae and caveolin-1 and this is in contrast to the positive regulation of m3 
receptor signaling via Gq/13. Further work examining the localization of AC isoforms and cAMP-
specific phosphodiesterases, and their regulation by signaling molecules may reveal more precise 
understanding of the mechanisms involved in cAMP signaling in gastric smooth muscle. 
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IV. 3. Regulation of m2 and m3 receptor internalization by caveolae and caveolin-1. 
Compelling evidences showing selective regulation of m3 receptor signaling by caveolin-
1 necessitated the importance to look into the probability of occurrence of muscarinic receptors 
in caveolar microdomains. Western blot analysis of m2 and m3 receptors in different fraction of 
sucrose density centrifugation showed that in basal state both m2 and m3 receptors are absent in 
caveolar fraction. However, upon treatment with CCh, there was translocation of m2 but not m3 
receptors to caveolar fractions raising the possibility that caveolae could facilitate m2, but not 
m3 receptor internalization.  
Multiple “turn off” signals operate in the cell to fine-tune the intensity of G protein 
coupled receptor signaling. The most important mechanism involved regulating the density of 
surface receptors through the process of receptor desensitization and subsequent internalization. 
Receptor desensitization can be broadly classified into two major categories: homologous 
desensitization that strictly target the agonist-bound receptors leaving the unbound non-activated 
receptor population to function, and heterologous desensitization that target ligand-free 
receptors. Homologous desensitization of agonist-occupied receptors is initiated by GRK (G 
protein coupled receptor kinase)-mediated phosphorylation of the receptor and binding of the 
scaffolding protein β-arrestin to the phosphorylated receptor, which uncouples the receptor from 
the G protein as a prelude to receptor internalization (Delom and Fessart 2011).   
The molecular events that drive the receptor internalization process can be either clathrin-
dependent or clathrin-independent, caveolae-dependent. Internalization via the clathrin-
dependent pathway triggers activation of signaling pathways (e.g., ERK1/2 and Src kinase) from 
early endosomes, whereas internalization via caveolae results in accelerated receptor 
degradation. Although the importance of clathrin-dependnet internalization in receptor 
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trafficking and activation of signaling pathways for several GPCRs is well established, the 
contribution of the caveolar-dependent pathway has been little explored. In clathrin-dependent 
model, binding of β-arrestins provides a scaffold for associating the receptor to clathrin and 
facilitates the formation of clathrin-coated pits. As the clathrin pits gets matured, they are 
invaginated and pinch off from the cell surface by the GTPase activity of dynamin and 
progressively released into the cytoplasm as free clathrin coated vesicles and the clathrin coat is 
removed (Bunemann, Lee et al. 1999). In the clathrin-independent, caveolar-dependent model, 
internalization of specific receptors through caveolae is strictly dependent on tyrosine kinase 
signaling. Ligand binding triggers receptor clustering in caveolar microdomains and activation of 
phosphorylation events. The essential step in the internalization process via caveolae involves 
activation of Src kinase following receptor clustering. Activation of Src causes phosphorylation 
of caveolar coat proteins such as caveolin-1 at Tyr14 (Sverdlov, Shajahan et al. 2007). The 
primary function of Src mediated phosphorylation of caveolar proteins is to regulate and stabilize 
the assembly of multi-protein complexes that finally leads to caveolae fission and internalization. 
Ectopic expression of phosphorylation-deficient caveolin-1 (Y14F) inhibits agonist-induced 
internalization of GPCRs via caveolae-dependent pathways (Shajahan, Timblin et al. 2003). 
  
IV. 3a. Regulation of m2 receptor internalization by caveolae and caveolin-1. 
 Internalization was measured as decrease in radioligand ([3H]Scopolamine) binding to 
surface receptors after treatment of cells with CCh for 20 min. Treatment of cells with CCh for 
20 min significantly inhibited the binding of [3H]Scopolamine, measured in the presence of 4-
DAMP, suggesting internalization of m2 receptors. Previous studies with radioligand binding 
studies showed that 20-min treatment is sufficient to cause maximum internalization of various 
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GPCRs. The role of caveolin-1 in the regulation of m2 and m3 receptor internalization was 
examined using MβCD in freshly dispersed muscle cells and in cultured muscle cells transfected 
with caveolin-1 siRNA Limited yield of muscle cells from mice precluded the use of caveolin-1 
KO mice for binding studies. Disruption of caveolae or suppression of caveolin-1 had no effect 
on the maximal binding of m2 receptors, but significantly attenuated m2 receptor internalization. 
Internalization of m2 receptors was also attenuated by the blockade of Src kinase. These results 
suggest that m2 receptor internalization was facilitated by caveolae or caveolin-1 and consistent 
with the translocation of m2 receptors to caveolar fractions. This is in contrast to the lack of 
effect of caveolin-1 on the rapid responses to m2 receptor activation such as inhibition of AC 
activity.  In our experiments, role of caveolin-1 in m2 receptor recycling or endocytosis remains 
to be clarified.  Future studies will also be necessary to identify signaling molecules involved in 
the activation of Src kinase by m2 receptors and regulation of m2 receptor internalization via the 
caveolar pathways. Previous studies demonstrated that activation of Src kinase via Gβγ is critical 
for internalization via caveolar pathways (Murthy, Mahavadi et al. 2008). These studies linked 
Gβγ signaling to the regulation of caveolae-mediated internalization and demonstrated that Src 
kinase is the downstream effector of the Gβγ heterodimer. Stimulation of Gi-coupled m2 
receptors is shown to activate Src kinase in gastrointestinal muscle (Murthy 2008), however, 
further studies are sought to understand the role of Gβγ in the activation of Src kinase and m2 
receptor internalization via caveolae-dependent pathways in gastric muscle.   
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IV. 3b.  Regulation of m3 receptor internalization by caveolae and caveolin-1. 
Treatment of cells with CCh for 20 min significantly inhibited the binding of 
[3H]Scopolamine, measured in the presence of methoctramine, suggesting internalization of m3 
receptors. The extent (~ 70%) of internalization of m3 receptors is similar to the m2 receptor 
internalization. Disruption of caveolae or suppression of caveolin-1 had no effect on the maximal 
binding of [3H]Scopolamine to m3 receptors and did not affect m3 receptor internalization.  
These results suggest that m3 receptor internalization is caveolae-independent and probably 
involves clathrin-dependent pathways. This is contrast to the positive effect of caveolin-1 on the 
rapid responses of m3 receptor signaling such as stimulation of PI hydrolysis, Rho kinase and 
ZIP kinase activity. These results also suggest that caveolae-dependent internalization is 
receptor-specific. Similar, caveolae-dependent pathway for internalization of vasoactive 
intestinal peptide receptor, VPAC2 was obtained in gastric muscle (Muthy, unpublished).   
Caveolin-binding motifs are present in many G protein coupled receptors (GPCRs) such 
as β-adrenergic receptor, endothelin receptors, muscarinic receptors, opioid receptors, and mGlu 
receptor 1α (Chini and Parenti 2004; BM 2012). Desensitization in response to angiotensin II in 
rat aorta was inhibited by MβCD suggesting that AT1 receptor internalization occurs via 
caveolae-dependent pathways. Caveolin-1 was coimmunoprecipitated with AT1 receptor after 
agonist stimulation, and this interaction was inhibited by MβCD (Linder, Thakali et al. 2007). 
Consensus caveolin binding motifs are also present in GRKs (G-protein receptor kinases) and 
interaction of GRKs with caveolin play an important role in agonist-induced internalization of 
GPCRs (Carman, Lisanti et al. 1999). In addition to GPCR internalization, tyrosine kinase-
coupled receptors are internalized via caveolae-dependent pathway (Mukherjee, Tessema et al. 
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2006). Caveolin-1 is a target of insulin-like growth factor I (IGF-I) receptor and plays a role in 
IGF-I receptor internalization and signaling. IGF stimulates caveolin-1 tyrosine phosphorylation 
and the IGF-I receptors co-localize with the caveolin-1 in the plasma membrane (Salani, 
Passalacqua et al. 2010).   
 In conclusion, our studies provide evidence that caveolin-1 positively regulates m2, 
but not m3 receptor internalization in gastric muscle. This is in contrast to the regulation by 
caveolin-1 of m2 and m3 receptor mediated rapid signaling pathways. 
 
VI. 4. Regulation of Excitation-transcription coupling by caveolin-1 
Unlike other cell types, such as cardiac and skeleton muscle cells smooth muscle (SM) 
cells do not undergo terminal differentiation, rather they switch between proliferative and 
differentiated phenotypes in response to various intrinsic and extrinsic signals. SM cells derive 
their characteristic contractile and physiological phenotype through the transcriptional activation 
of a distinct subset of SM-specific genes encoding for proteins such as SM-myosin heavy chain, 
SM-α actin, γ-actin, SM-myosin light chain kinase, calponin, and caldesmon (Wang and Olson 
2004).   
Serum response factor (SRF) a member of the MADS (MCM1, Agamous, Deficiens, 
SRF) family of transcription factors plays an important role in the regulation of SM gene 
expression and differentiation (Shore and Sharrocks 1995). SRF recognizes a consensus 
sequence of CC(A/T)6GG, also known as the CArG box or serum response element on the target 
genes to drive their transcription (Kim, Ip et al. 1997; Manabe and Owens 2001).  SRF associate 
with other transcription factors aptly termed as co-factors to control and regulate the expression 
of SRF target genes.  Myocardin constitute one of the most intimate coactivators of SRF that was 
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originally identified in a bioinformatics screen of cardiac gene expression profiling, and its 
expression is specific for cardiac myocytes and SM cells (Wang, Chang et al. 2001).  Myocardin 
binds and activate promoters containing multiple CArG elements along with stimulated SRF.  
The myocardin family of proteins contains two additional members and shares homology with 
myocardin-related transcription factor A (MRTF-A) and factor B (MRTF-B) (Wang, Li et al. 
2002). The critical role of myocardin and its family in SMC differentiation comes from the 
finding that showed that the differentiation process is severely compromised when dominant 
mutant form of myocardin and MRTFs or small interfering RNA targeted to myocardin was used 
to suppress its activity (Yoshida, Sinha et al. 2003).  
SRF/myocardin-mediated transcription of SM marker genes is regulated by actin 
dynamics and a decrease in G actin pool is critical for SRF-dependent activation of SM-specific 
genes (Copeland and Treisman 2002). Recently, Ca2+ and Rho family of small GTPases 
including RhoA has been shown to facilitate F-actin to G-actin ratio through multiple pathways 
that finally stimulate SRF activity (Wamhoff, Bowles et al. 2004). Overexpression of 
constitutively active RhoA stimulates transcription of SRF/myocardin-mediated genes such as 
SM-α actin, SM-MHC and the stimulation is dependent on Rho kinase activity. In addition, 
increase in cytosolic Ca2+ upregulates the expression of myocardin (Mack, Somlyo et al. 2001). 
These results suggest that the factors that regulate Ca2+ and RhoA-dependent pathways could 
modulate SM marker genes (excitation-transcription) long-term, in addition to modulating 
muscle contraction (excitation-contraction) short-term as shown above. Positive regulation of 
Ca2+ and RhoA signaling by caveolae and caveolin-1 prompted us to examine the role of 
caveolin-1 in the regulation of smooth muscle contractile phenotype. The present study 
significantly extends understanding the role of caveolin-1 in the regulation of smooth muscle 
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marker genes because our results demonstrate that caveolin-1 suppresses the proliferative signals 
and facilitates differentiated contractile phenotype in gastric smooth muscle. Our data reveal that 
caveolin-1 represses EGF receptor and ERK1/2 activity and promotes the expression of 
contractile proteins and their transcription factors. Suppression of caveolin-1 attenuated 
expression of SRF and myocardin and SM contractile proteins such as γ-actin and caldesmon, 
and augmented basal and agonist-induced EGF receptor phosphorylation and ERK1/2 activity. 
Mitogen-activated protein kinases such as ERK1/2 are recognized as important signaling 
molecules in cell proliferation.   
Our results are in line with previous studies indicating that vascular muscle cells, 
fibroblasts and epithelial cells isolated from caveolin-1 KO mice exhibit hyperproliferative 
phenotype (Cohen, Park et al. 2003). Studies in airway and vascular muscle demonstrated that 
expression of caveolin-1 was more than two fold higher in quiescent contractile muscle cells 
compared to proliferating muscle cells in culture (Gosens, Stelmack et al. 2011). Overexpression 
of caveloin-1 causes antiproliferative effects. Consistent with the antiproliferative role of 
caveolins, expression of receptors for growth factors such as EGF and PDGF, and constituent of 
growth factor signaling such as Src, Shc, Grb2 and Ras are localized in caveolae (Gosens, 
Stelmack et al. 2006). Interaction of these signaling proteins with caveolins suppresses their 
activity. Transactivation of growth factor signals by GPCRs is also associated with the decrease 
in the binding of growth factor receptors with caveolin-1 (Olivares-Reyes, Shah et al. 2005), 
however, the molecular mechanisms that causes disassociation of caveolin-1 from growth factor 
signal are not clear. In addition, it was demonstrated that non-phosphorylated, but not 
phosphorylated (activated) EGF receptor is associated with caveolin-1 (Matveev and Smart 
2002). Caveolin-1 KO mice do not develop tumors spontaneously, but are more susceptible to 
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tumor formation in response to carcinogens (Torres, Tapia et al. 2006). Thus, there is clear 
association between caveolae and growth factor signal. Our current findings in gastric muscle are 
highly reminiscent of these observations, and reveal the importance of caveolin-1 in regulating 
proliferative and contractile phenotype in gastrointestinal smooth muscle. It is interesting to note 
that the smooth muscle differentiation is not affected in caveolin-1 KO mice, suggesting 
functional compensation for the lack of caveolin-1.    
Although, our studies suggest a link between decrease in Ca2+ and RhoA signaling in the 
absence of caveolin-1 to decrease in contractile protein expression, they do not exclude the 
existence of additional, transcriptional and post-translational mechanisms downstream of 
caveolin-1 that control contractile proteins expression. Preliminary studies from our laboratory, 
using microarray analysis, compared of microRNA levels from gastric muscle expressing or not 
expressing caveolin-1. One of the striking changes detected in response to absence of caveolin-1 
expression was upregulation of microRNA133a. MicroRNAs play an important role in the 
regulation of gene expression by pairing to the mRNA targets. Searching for conserved targets of 
microRNA-133a by RNA hybrid analysis, we identified the transcription factor SRF, which 
regulates expression of contractile proteins. SRF expression is negatively regulated by 
microRNA-133a. In vascular smooth muscle, overexpression of microRNA-133a reduced SRF 
expression, whereas the effects were opposite when microRNA-133a was inhibited by anti-
microRNA-133a. Future studies are important to examine the mechanisms involved in the 
regulation of contractile protein expression by caveolin-1 in gastric smooth muscle involving 
mcroRNA-133a. It is also important to examine the expression profile of caveolins in 
gastrointestinal disorders with smooth muscle hyperproliferation. If caveolin-1 expression is 
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decreased, this could contribute to the smooth muscle proliferation and stricture formation in 
inflammatory diseases.   
In conclusion, our results provide evidence that caveolin-1 negatively regulates 
proliferative phenotype and positively regulates contractile phenotype in gastric muscle. Further 
studies examining the molecular mechanisms involved in the regulation of contractile protein 
expression by caveolin-1 may reveal more precise understanding of the mechanism regulating 
SM contractile phenotype.   
 
In summary, our studies demonstrated that CCh, acting via m3 receptors caused 
stimulation of PI hydrolysis and RhoA-dependent signaling (Rho kinase and ZIP kinase) and 
induced muscle contraction, and acting via m2 receptors caused inhibition of AC activity.  
Stimulation of PI hydrolysis, RhoA-dependent signaling and muscle contraction were attenuated 
in dispersed cells by the disruption of caveolae with MβCD, or by the suppression of caveolin-1 
in cultured muscle cells transfected with caveolin-1 siRNA. Similar inhibition of PI hydrolysis 
and RhoA-dependent signaling was obtained in gastric muscle from caveolin-1 KO mice 
compared to control mice. Inhibition of cAMP formation via m2 receptors, in contrast, was not 
affected in dispersed cells treated with MβCD or in cultured muscle cells transfected with 
caveolin-1 siRNA. Similarly, inhibition of AC activity was not affected in gastric muscle from 
caveolin-1 KO mice. In the basal state both m2 and m3 receptors are present in non-caveolar 
fractions and upon treatment with CCh, m2, but not m3 receptors are translocated to caveolar 
fractions. Pretreatment of muscle cells with CCh caused internalization of both m2 and m3 
receptors: internalization of m2, but not m3 receptors was blocked in dispersed cells treated with 
MβCD or in cultured muscle cells transfected with caveolin-1 siRNA. The possible physiological 
 181 
significance of this regulation of m2 receptor internalization is not clear. However, there exists 
the potential for regulation of m3 receptor signaling by m2 receptors; this should be investigated 
more rigorously. Thus, caveolin-1 selectively regulates m3/Gq-mediated PI hydrolysis, m3/G13-
mediated RhoA signaling and contraction, and m2 receptor internalization. Since, there was no 
change in the binding of [3H]Scopolamine to m2 and m3 receptors by caveolae and caveolin-1, 
we propose that caveolae and caveolin-1 promote m3 receptor signaling via enhanced receptor-
effector coupling rather than enhanced receptor affinity. Furthermore, expression of contractile 
proteins, γ-actin and caldesmon and the transcription factors SRF and myocardin that mediate the 
expression of contractile proteins are down regulated in cells transfected with caveolin-1 siRNA 
suggesting that caveolin-1 expression is also important for the maintenance of smooth muscle 
contractile phenotype. The study also suggests that caveolin-1 could be a marker of the mature, 
contractile smooth muscle cell phenotype, and is a determinant of functional characteristics of 
gastric muscle. In parallel, caveolin-1 suppresses the activity of proliferative signals.  
 In conclusion our studies using pharmacological, molecular and genetic approaches, 
provide conclusive evidence that caveolae and caveolin-1 play an important role in orchestrating 
G protein coupled receptor signaling to have dual pro-excitation-contraction and excitation-
transcription coupling, and anti-proliferative role in gastric smooth muscle. 
 
 
  
 
 
 
 
 182 
REFERENCES 
 
 
Abrahamsen, H., G. Baillie, et al. (2004). "TCR- and CD28-mediated recruitment of 
phosphodiesterase 4 to lipid rafts potentiates TCR signaling." J Immunol 173(8): 4847-4858. 
  
Allen, J. A., J. Z. Yu, et al. (2009). "Caveolin-1 and lipid microdomains regulate Gs trafficking 
and attenuate Gs/adenylyl cyclase signaling." Mol Pharmacol 76(5): 1082-1093. 
  
Andreeva, A. V., M. A. Kutuzov, et al. (2007). "Scaffolding proteins in G-protein signaling." J 
Mol Signal 2: 13. 
  
Arvidsson, U., M. Riedl, et al. (1997). "Vesicular acetylcholine transporter (VAChT) protein: a 
novel and unique marker for cholinergic neurons in the central and peripheral nervous systems." 
J Comp Neurol 378(4): 454-467. 
  
Baillie, G. S., J. D. Scott, et al. (2005). "Compartmentalisation of phosphodiesterases and protein 
kinase A: opposites attract." FEBS Lett 579(15): 3264-3270. 
  
Balijepalli, R. C. and T. J. Kamp (2008). "Caveolae, ion channels and cardiac arrhythmias." Prog 
Biophys Mol Biol 98(2-3): 149-160. 
  
Bayguinov, O., S. M. Ward, et al. (2007). "Voltage-gated Ca2+ currents are necessary for slow-
wave propagation in the canine gastric antrum." Am J Physiol Cell Physiol 293(5): C1645-1659. 
  
Belmonte, K. E. (2005). "Cholinergic pathways in the lungs and anticholinergic therapy for 
chronic obstructive pulmonary disease." Proc Am Thorac Soc 2(4): 297-304; discussion 311-
292. 
  
Bergdahl, A. and K. Sward (2004). "Caveolae-associated signalling in smooth muscle." Can J 
Physiol Pharmacol 82(5): 289-299. 
  
Berman, D. M. and A. G. Gilman (1998). "Mammalian RGS proteins: barbarians at the gate." J 
Biol Chem 273(3): 1269-1272. 
  
Bitar, K. N. (2003). "Function of gastrointestinal smooth muscle: from signaling to contractile 
proteins." Am J Med 115 Suppl 3A: 15S-23S. 
  
Bitar, K. N. and G. M. Makhlouf (1982). "Relaxation of isolated gastric smooth muscle cells by 
vasoactive intestinal peptide." Science 216(4545): 531-533. 
  
BM, C. (2012). "Structure-Based Reassessment of the Caveolin 
Signaling Model: Do Caveolae Regulate Signaling 
through Caveolin-Protein Interactions?" developmental cell 23 
 
  
 183 
Boehning, D. and S. H. Snyder (2003). "Novel neural modulators." Annu Rev Neurosci 26: 105-
131. 
  
Bohm, S. K., E. F. Grady, et al. (1997). "Regulatory mechanisms that modulate signalling by G-
protein-coupled receptors." Biochem J 322 ( Pt 1): 1-18. 
  
Borman, M. A., J. A. MacDonald, et al. (2002). "Smooth muscle myosin phosphatase-associated 
kinase induces Ca2+ sensitization via myosin phosphatase inhibition." J Biol Chem 277(26): 
23441-23446. 
  
Boulanger, C. M., K. J. Morrison, et al. (1994). "Mediation by M3-muscarinic receptors of both 
endothelium-dependent contraction and relaxation to acetylcholine in the aorta of the 
spontaneously hypertensive rat." Br J Pharmacol 112(2): 519-524. 
  
Brookes, S. J. (2001). "Classes of enteric nerve cells in the guinea-pig small intestine." Anat Rec 
262(1): 58-70. 
  
Bunemann, M., K. B. Lee, et al. (1999). "Desensitization of G-protein-coupled receptors in the 
cardiovascular system." Annu Rev Physiol 61: 169-192. 
  
Burgess, S. A., S. Yu, et al. (2007). "Structures of smooth muscle myosin and heavy meromyosin 
in the folded, shutdown state." J Mol Biol 372(5): 1165-1178. 
  
Buyukafsar, K. and A. Levent (2003). "Involvement of Rho/Rho-kinase signalling in the 
contractile activity and acetylcholine release in the mouse gastric fundus." Biochem Biophys Res 
Commun 303(3): 777-781. 
  
Camborova, P., P. Hubka, et al. (2003). "The pacemaker activity of interstitial cells of Cajal and 
gastric electrical activity." Physiol Res 52(3): 275-284. 
  
Cao, T. T., H. W. Deacon, et al. (1999). "A kinase-regulated PDZ-domain interaction controls 
endocytic sorting of the beta2-adrenergic receptor." Nature 401(6750): 286-290. 
  
Carey, H. V., H. J. Cooke, et al. (1985). "Mucosal responses evoked by stimulation of ganglion 
cell somas in the submucosal plexus of the guinea-pig ileum." J Physiol 364: 69-79. 
  
Carman, C. V., M. P. Lisanti, et al. (1999). "Regulation of G protein-coupled receptor kinases by 
caveolin." J Biol Chem 274(13): 8858-8864. 
  
Chess-Williams, R., C. R. Chapple, et al. (2001). "The minor population of M3-receptors 
mediate contraction of human detrusor muscle in vitro." J Auton Pharmacol 21(5-6): 243-248. 
  
Chidlow, J. H., Jr. and W. C. Sessa (2010). "Caveolae, caveolins, and cavins: complex control of 
cellular signalling and inflammation." Cardiovasc Res 86(2): 219-225. 
  
 184 
Chini, B. and M. Parenti (2004). "G-protein coupled receptors in lipid rafts and caveolae: how, 
when and why do they go there?" J Mol Endocrinol 32(2): 325-338. 
  
Chuang, T. T., L. Iacovelli, et al. (1996). "G protein-coupled receptors: heterologous regulation 
of homologous desensitization and its implications." Trends Pharmacol Sci 17(11): 416-421. 
  
Cohen, A. W., R. Hnasko, et al. (2004). "Role of caveolae and caveolins in health and disease." 
Physiol Rev 84(4): 1341-1379. 
  
Cohen, A. W., D. S. Park, et al. (2003). "Caveolin-1 null mice develop cardiac hypertrophy with 
hyperactivation of p42/44 MAP kinase in cardiac fibroblasts." Am J Physiol Cell Physiol 284(2): 
C457-474. 
  
Cohen, N. A., J. E. Brenman, et al. (1996). "Binding of the inward rectifier K+ channel Kir 2.3 to 
PSD-95 is regulated by protein kinase A phosphorylation." Neuron 17(4): 759-767. 
  
Collins, B. M., M. J. Davis, et al. (2012). "Structure-Based Reassessment of the Caveolin 
Signaling Model: Do Caveolae Regulate Signaling through Caveolin-Protein Interactions?" Dev 
Cell 23(1): 11-20. 
  
Collins, S. M. (1996). "The immunomodulation of enteric neuromuscular function: implications 
for motility and inflammatory disorders." Gastroenterology 111(6): 1683-1699. 
  
Copeland, J. W. and R. Treisman (2002). "The diaphanous-related formin mDia1 controls serum 
response factor activity through its effects on actin polymerization." Mol Biol Cell 13(11): 4088-
4099. 
  
Cornwell, T. L., K. B. Pryzwansky, et al. (1991). "Regulation of sarcoplasmic reticulum protein 
phosphorylation by localized cyclic GMP-dependent protein kinase in vascular smooth muscle 
cells." Mol Pharmacol 40(6): 923-931. 
  
Costa, M., S. J. Brookes, et al. (1996). "Neurochemical classification of myenteric neurons in the 
guinea-pig ileum." Neuroscience 75(3): 949-967. 
  
Couet, J., S. Li, et al. (1997). "Identification of peptide and protein ligands for the caveolin-
scaffolding domain. Implications for the interaction of caveolin with caveolae-associated 
proteins." J Biol Chem 272(10): 6525-6533. 
  
Couet, J., M. Sargiacomo, et al. (1997). "Interaction of a receptor tyrosine kinase, EGF-R, with 
caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities." 
J Biol Chem 272(48): 30429-30438. 
  
Cristofaro, V., C. A. Peters, et al. (2007). "Smooth muscle caveolae differentially regulate 
specific agonist induced bladder contractions." Neurourol Urodyn 26(1): 71-80. 
  
 185 
Darby, P. J., C. Y. Kwan, et al. (2000). "Caveolae from canine airway smooth muscle contain the 
necessary components for a role in Ca(2+) handling." Am J Physiol Lung Cell Mol Physiol 
279(6): L1226-1235. 
  
de Laurentiis, A., L. Donovan, et al. (2007). "Lipid rafts and caveolae in signaling by growth 
factor receptors." Open Biochem J 1: 12-32. 
  
Delom, F. and D. Fessart (2011). "Role of Phosphorylation in the Control of Clathrin-Mediated 
Internalization of GPCR." Int J Cell Biol 2011: 246954. 
  
Deng, M., W. Ding, et al. (2011). "MLCK-independent phosphorylation of MLC20 and its 
regulation by MAP kinase pathway in human bladder smooth muscle cells." Cytoskeleton 
(Hoboken) 68(3): 139-149. 
  
Diviani, D. and J. D. Scott (2001). "AKAP signaling complexes at the cytoskeleton." J Cell Sci 
114(Pt 8): 1431-1437. 
  
Drab, M., P. Verkade, et al. (2001). "Loss of caveolae, vascular dysfunction, and pulmonary 
defects in caveolin-1 gene-disrupted mice." Science 293(5539): 2449-2452. 
  
Drake, M. T., S. K. Shenoy, et al. (2006). "Trafficking of G protein-coupled receptors." Circ Res 
99(6): 570-582. 
  
Dreja, K., M. Voldstedlund, et al. (2002). "Cholesterol depletion disrupts caveolae and 
differentially impairs agonist-induced arterial contraction." Arterioscler Thromb Vasc Biol 
22(8): 1267-1272. 
  
Dubroca, C., X. Loyer, et al. (2007). "RhoA activation and interaction with Caveolin-1 are 
critical for pressure-induced myogenic tone in rat mesenteric resistance arteries." Cardiovasc Res 
73(1): 190-197. 
  
Ebrahimkhani, M. R., A. R. Mani, et al. (2005). "Hydrogen sulphide and the hyperdynamic 
circulation in cirrhosis: a hypothesis." Gut 54(12): 1668-1671. 
  
Eglen, R. M., H. Reddy, et al. (1994). "Muscarinic acetylcholine receptor subtypes in smooth 
muscle." Trends Pharmacol Sci 15(4): 114-119. 
  
Endo, A., H. K. Surks, et al. (2004). "Identification and characterization of zipper-interacting 
protein kinase as the unique vascular smooth muscle myosin phosphatase-associated kinase." J 
Biol Chem 279(40): 42055-42061. 
  
Engelman, J. A., C. Chu, et al. (1998). "Caveolin-mediated regulation of signaling along the 
p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain." FEBS Lett 
428(3): 205-211. 
  
 186 
Epand, R. M., B. G. Sayer, et al. (2005). "Caveolin scaffolding region and cholesterol-rich 
domains in membranes." J Mol Biol 345(2): 339-350. 
  
Fagerholm, S., U. Ortegren, et al. (2009). "Rapid insulin-dependent endocytosis of the insulin 
receptor by caveolae in primary adipocytes." PLoS One 4(6): e5985. 
  
Fanning, A. S. and J. M. Anderson (1999). "PDZ domains: fundamental building blocks in the 
organization of protein complexes at the plasma membrane." J Clin Invest 103(6): 767-772. 
  
Farrugia, G. (1999). "Ionic conductances in gastrointestinal smooth muscles and interstitial cells 
of Cajal." Annu Rev Physiol 61: 45-84. 
  
Faux, M. C. and J. D. Scott (1996). "Molecular glue: kinase anchoring and scaffold proteins." 
Cell 85(1): 9-12. 
  
Feng, W. and M. Zhang (2009). "Organization and dynamics of PDZ-domain-related 
supramodules in the postsynaptic density." Nat Rev Neurosci 10(2): 87-99. 
  
Ferguson, S. S. (2001). "Evolving concepts in G protein-coupled receptor endocytosis: the role in 
receptor desensitization and signaling." Pharmacol Rev 53(1): 1-24. 
  
Feron, O. and R. A. Kelly (2001). "The caveolar paradox: suppressing, inducing, and terminating 
eNOS signaling." Circ Res 88(2): 129-131. 
  
Francis, S. H., I. V. Turko, et al. (2001). "Cyclic nucleotide phosphodiesterases: relating 
structure and function." Prog Nucleic Acid Res Mol Biol 65: 1-52. 
  
Fujimoto, T., A. Miyawaki, et al. (1995). "Inositol 1,4,5-trisphosphate receptor-like protein in 
plasmalemmal caveolae is linked to actin filaments." J Cell Sci 108 ( Pt 1): 7-15. 
  
Fukata, Y., M. Amano, et al. (2001). "Rho-Rho-kinase pathway in smooth muscle contraction 
and cytoskeletal reorganization of non-muscle cells." Trends Pharmacol Sci 22(1): 32-39. 
  
Furness, J. B. (2006). "The Enteric Nervous System." Blackwell Publishing, Oxford. 
  
Furness, J. B., C. Jones, et al. (2004). "Intrinsic primary afferent neurons and nerve circuits 
within the intestine." Prog Neurobiol 72(2): 143-164. 
  
Gabella, G. (1987). "Innervation of airway smooth muscle: fine structure." Annu Rev Physiol 49: 
583-594. 
  
Gainetdinov, R. R., R. T. Premont, et al. (2004). "Desensitization of G protein-coupled receptors 
and neuronal functions." Annu Rev Neurosci 27: 107-144. 
  
Gainetdinov, R. R., R. T. Premont, et al. (2000). "Reply: receptor specificity of G-protein-
coupled receptor kinases." Trends Pharmacol Sci 21(10): 366-367. 
 187 
  
Ganitkevich, V., V. Hasse, et al. (2002). "Ca2+-dependent and Ca2+-independent regulation of 
smooth muscle contraction." J Muscle Res Cell Motil 23(1): 47-52. 
  
Garcia-Cardena, G., R. Fan, et al. (1996). "Endothelial nitric oxide synthase is regulated by 
tyrosine phosphorylation and interacts with caveolin-1." J Biol Chem 271(44): 27237-27240. 
  
Gericke, A., J. J. Sniatecki, et al. (2011). "Identification of the muscarinic acetylcholine receptor 
subtype mediating cholinergic vasodilation in murine retinal arterioles." Invest Ophthalmol Vis 
Sci 52(10): 7479-7484. 
  
Gershon, M. D. (1981). "The enteric nervous system." Annu Rev Neurosci 4: 227-272. 
  
Gerthoffer, W. T. (2005). "Signal-transduction pathways that regulate visceral smooth muscle 
function. III. Coupling of muscarinic receptors to signaling kinases and effector proteins in 
gastrointestinal smooth muscles." Am J Physiol Gastrointest Liver Physiol 288(5): G849-853. 
  
Gold, M. G., B. Lygren, et al. (2006). "Molecular basis of AKAP specificity for PKA regulatory 
subunits." Mol Cell 24(3): 383-395. 
  
Gomperts, S. N. (1996). "Clustering membrane proteins: It's all coming together with the PSD-
95/SAP90 protein family." Cell 84(5): 659-662. 
  
Good, M. C., J. G. Zalatan, et al. (2011). "Scaffold proteins: hubs for controlling the flow of 
cellular information." Science 332(6030): 680-686. 
  
Gosens, R., G. L. Stelmack, et al. (2011). "Caveolin-1 is required for contractile phenotype 
expression by airway smooth muscle cells." J Cell Mol Med 15(11): 2430-2442. 
  
Gosens, R., G. L. Stelmack, et al. (2006). "Role of caveolin-1 in p42/p44 MAP kinase activation 
and proliferation of human airway smooth muscle." Am J Physiol Lung Cell Mol Physiol 291(3): 
L523-534. 
  
Gosens, R., G. L. Stelmack, et al. (2007). "Caveolae facilitate muscarinic receptor-mediated 
intracellular Ca2+ mobilization and contraction in airway smooth muscle." Am J Physiol Lung 
Cell Mol Physiol 293(6): L1406-1418. 
  
Graves, P. R., K. M. Winkfield, et al. (2005). "Regulation of zipper-interacting protein kinase 
activity in vitro and in vivo by multisite phosphorylation." J Biol Chem 280(10): 9363-9374. 
  
Grider, J. R. (1989). "Tachykinins as transmitters of ascending contractile component of the 
peristaltic reflex." Am J Physiol 257(5 Pt 1): G709-714. 
  
Grider, J. R. (1993). "Interplay of VIP and nitric oxide in regulation of the descending relaxation 
phase of peristalsis." Am J Physiol 264(2 Pt 1): G334-340. 
  
 188 
Guo, Y., U. Golebiewska, et al. (2011). "Modulation of Ca(2)+ activity in cardiomyocytes 
through caveolae-Galphaq interactions." Biophys J 100(7): 1599-1607. 
  
Hakonarson, H. and M. M. Grunstein (1998). "Regulation of second messengers associated with 
airway smooth muscle contraction and relaxation." Am J Respir Crit Care Med 158(5 Pt 3): 
S115-122. 
  
Hall, R. A. and R. J. Lefkowitz (2002). "Regulation of G protein-coupled receptor signaling by 
scaffold proteins." Circ Res 91(8): 672-680. 
  
Hamm, H. E. and A. Gilchrist (1996). "Heterotrimeric G proteins." Curr Opin Cell Biol 8(2): 
189-196. 
  
Hardin, C. D. and J. Vallejo (2006). "Caveolins in vascular smooth muscle: form organizing 
function." Cardiovasc Res 69(4): 808-815. 
  
Harmar, A. J., J. Fahrenkrug, et al. (2012). "Pharmacology and functions of receptors for 
vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR 
review 1." Br J Pharmacol 166(1): 4-17. 
  
Hartshorne, D. J. (1998). "Myosin phosphatase: subunits and interactions." Acta Physiol Scand 
164(4): 483-493. 
  
Hausdorff, W. P., M. G. Caron, et al. (1990). "Turning off the signal: desensitization of beta-
adrenergic receptor function." FASEB J 4(11): 2881-2889. 
  
Head, B. P., Y. Hu, et al. (2011). "Neuron-targeted caveolin-1 protein enhances signaling and 
promotes arborization of primary neurons." J Biol Chem 286(38): 33310-33321. 
  
Head, B. P., H. H. Patel, et al. (2006). "Microtubules and actin microfilaments regulate lipid 
raft/caveolae localization of adenylyl cyclase signaling components." J Biol Chem 281(36): 
26391-26399. 
  
Hellstrom, P. M., K. S. Murthy, et al. (1994). "Coexistence of three tachykinin receptors coupled 
to Ca++ signaling pathways in intestinal muscle cells." J Pharmacol Exp Ther 270(1): 236-243. 
  
Hersch, E., J. Huang, et al. (2004). "Gq/G13 signaling by ET-1 in smooth muscle: MYPT1 
phosphorylation via ETA and CPI-17 dephosphorylation via ETB." Am J Physiol Cell Physiol 
287(5): C1209-1218. 
  
Hodgkinson, J. L. (2000). "Actin and the smooth muscle regulatory proteins: a structural 
perspective." J Muscle Res Cell Motil 21(2): 115-130. 
  
Holst, J. J., J. Fahrenkrug, et al. (1987). "VIP and PHI in the pig pancreas: coexistence, 
corelease, and cooperative effects." Am J Physiol 252(2 Pt 1): G182-189. 
  
 189 
Horman, S., N. Morel, et al. (2008). "AMP-activated protein kinase phosphorylates and 
desensitizes smooth muscle myosin light chain kinase." J Biol Chem 283(27): 18505-18512. 
  
Horowitz, A., C. B. Menice, et al. (1996). "Mechanisms of smooth muscle contraction." Physiol 
Rev 76(4): 967-1003. 
  
Hu, L. A., W. Chen, et al. (2002). "G protein-coupled receptor kinase 5 regulates beta 1-
adrenergic receptor association with PSD-95." J Biol Chem 277(2): 1607-1613. 
  
Hu, W., F. Li, et al. (2009). "Upregulation of RGS4 expression by IL-1beta in colonic smooth 
muscle is enhanced by ERK1/2 and p38 MAPK and inhibited by the PI3K/Akt/GSK3beta 
pathway." Am J Physiol Cell Physiol 296(6): C1310-1320. 
  
Huang, J., H. Zhou, et al. (2005). "Signaling pathways mediating gastrointestinal smooth muscle 
contraction and MLC20 phosphorylation by motilin receptors." Am J Physiol Gastrointest Liver 
Physiol 288(1): G23-31. 
  
Huang, J., H. Zhou, et al. (2007). "Inhibition of Galphaq-dependent PLC-beta1 activity by PKG 
and PKA is mediated by phosphorylation of RGS4 and GRK2." Am J Physiol Cell Physiol 
292(1): C200-208. 
  
Huizinga, J. D., L. Thuneberg, et al. (1995). "W/kit gene required for interstitial cells of Cajal 
and for intestinal pacemaker activity." Nature 373(6512): 347-349. 
  
Iino, S. and K. Horiguchi (2006). "Interstitial cells of cajal are involved in neurotransmission in 
the gastrointestinal tract." Acta Histochem Cytochem 39(6): 145-153. 
  
Imamura, T., J. Huang, et al. (2001). "beta -Arrestin-mediated recruitment of the Src family 
kinase Yes mediates endothelin-1-stimulated glucose transport." J Biol Chem 276(47): 43663-
43667. 
  
Insel, P. A., B. P. Head, et al. (2005). "Compartmentation of G-protein-coupled receptors and 
their signalling components in lipid rafts and caveolae." Biochem Soc Trans 33(Pt 5): 1131-
1134. 
  
Insel, P. A. and H. H. Patel (2007). "Do studies in caveolin-knockouts teach us about physiology 
and pharmacology or instead, the ways mice compensate for 'lost proteins'?" Br J Pharmacol 
150(3): 251-254. 
  
Isshiki, M. and R. G. Anderson (2003). "Function of caveolae in Ca2+ entry and Ca2+-
dependent signal transduction." Traffic 4(11): 717-723. 
  
Je, H. D., C. Gallant, et al. (2004). "Caveolin-1 regulates contractility in differentiated vascular 
smooth muscle." Am J Physiol Heart Circ Physiol 286(1): H91-98. 
  
 190 
JH., S. (1987). "Electrical basis for gastrointestinal motility." In Physiology of the 
Gastrointestinal Tract ed. LR Johnson,: pp. 383–422.New York: Raven. 
  
Kamm, K. E. and J. T. Stull (1989). "Regulation of smooth muscle contractile elements by 
second messengers." Annu Rev Physiol 51: 299-313. 
  
Kasparek, M. S., D. R. Linden, et al. (2008). "Gasotransmitters in the gastrointestinal tract." 
Surgery 143(4): 455-459. 
  
Kim, S., H. S. Ip, et al. (1997). "A serum response factor-dependent transcriptional regulatory 
program identifies distinct smooth muscle cell sublineages." Mol Cell Biol 17(4): 2266-2278. 
  
Kitazawa, T., M. Eto, et al. (2000). "Agonists trigger G protein-mediated activation of the CPI-
17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth 
muscle contractility." J Biol Chem 275(14): 9897-9900. 
  
Kitazawa, T., R. Hirama, et al. (2008). "Muscarinic receptor subtypes involved in carbachol-
induced contraction of mouse uterine smooth muscle." Naunyn Schmiedebergs Arch Pharmacol 
377(4-6): 503-513. 
  
Koh, S. D., K. M. Sanders, et al. (1996). "Regulation of smooth muscle delayed rectifier K+ 
channels by protein kinase A." Pflugers Arch 432(3): 401-412. 
  
Koh, S. D., K. M. Sanders, et al. (1998). "Spontaneous electrical rhythmicity in cultured 
interstitial cells of cajal from the murine small intestine." J Physiol 513 ( Pt 1): 203-213. 
  
Kuemmerle, J. F., K. S. Murthy, et al. (1995). "Coexpression of 5-HT2A and 5-HT4 receptors 
coupled to distinct signaling pathways in human intestinal muscle cells." Gastroenterology 
109(6): 1791-1800. 
  
Kunze, W. A. and J. B. Furness (1999). "The enteric nervous system and regulation of intestinal 
motility." Annu Rev Physiol 61: 117-142. 
  
Le Page, S. L., Y. Bi, et al. (2003). "CCK-A receptor activates RhoA through G alpha 12/13 in 
NIH3T3 cells." Am J Physiol Cell Physiol 285(5): C1197-1206. 
  
Lecci, A., M. Altamura, et al. (2008). "Tachykinin receptors and gastrointestinal motility: focus 
on humans." Eur Rev Med Pharmacol Sci 12 Suppl 1: 69-80. 
  
Lefkowitz, R. J., W. P. Hausdorff, et al. (1990). "Role of phosphorylation in desensitization of 
the beta-adrenoceptor." Trends Pharmacol Sci 11(5): 190-194. 
  
Lefkowitz, R. J. and E. J. Whalen (2004). "beta-arrestins: traffic cops of cell signaling." Curr 
Opin Cell Biol 16(2): 162-168. 
  
 191 
LePard, K. J., E. Messori, et al. (1997). "Purinergic fast excitatory postsynaptic potentials in 
myenteric neurons of guinea pig: distribution and pharmacology." Gastroenterology 113(5): 
1522-1534. 
  
Li, L., M. Bhatia, et al. (2006). "Hydrogen sulphide--a novel mediator of inflammation?" Curr 
Opin Pharmacol 6(2): 125-129. 
  
Li, L., M. Eto, et al. (1998). "Possible involvement of the novel CPI-17 protein in protein kinase 
C signal transduction of rabbit arterial smooth muscle." J Physiol 508 ( Pt 3): 871-881. 
  
Lin, S., M. Kajimura, et al. (1997). "Expression of muscarinic receptor subtypes in rat gastric 
smooth muscle: effect of M3 selective antagonist on gastric motility and emptying." Dig Dis Sci 
42(5): 907-914. 
  
Lincoln, T. M. (2007). "Myosin phosphatase regulatory pathways: different functions or 
redundant functions?" Circ Res 100(1): 10-12. 
  
Linden, D. R., M. D. Levitt, et al. (2010). "Endogenous production of H2S in the gastrointestinal 
tract: still in search of a physiologic function." Antioxid Redox Signal 12(9): 1135-1146. 
  
Linder, A. E., K. M. Thakali, et al. (2007). "Methyl-beta-cyclodextrin prevents angiotensin II-
induced tachyphylactic contractile responses in rat aorta." J Pharmacol Exp Ther 323(1): 78-84. 
  
Lisanti, M. P., P. E. Scherer, et al. (1994). "Characterization of caveolin-rich membrane domains 
isolated from an endothelial-rich source: implications for human disease." J Cell Biol 126(1): 
111-126. 
  
Lisanti, M. P., Z. L. Tang, et al. (1993). "Caveolin forms a hetero-oligomeric protein complex 
that interacts with an apical GPI-linked protein: implications for the biogenesis of caveolae." J 
Cell Biol 123(3): 595-604. 
  
Lohn, M., M. Furstenau, et al. (2000). "Ignition of calcium sparks in arterial and cardiac muscle 
through caveolae." Circ Res 87(11): 1034-1039. 
  
Lundgren, O. (2002). "Enteric nerves and diarrhoea." Pharmacol Toxicol 90(3): 109-120. 
  
Luttrell, L. M., S. S. Ferguson, et al. (1999). "Beta-arrestin-dependent formation of beta2 
adrenergic receptor-Src protein kinase complexes." Science 283(5402): 655-661. 
  
Luttrell, L. M. and R. J. Lefkowitz (2002). "The role of beta-arrestins in the termination and 
transduction of G-protein-coupled receptor signals." J Cell Sci 115(Pt 3): 455-465. 
  
Ma, L. and G. Pei (2007). "Beta-arrestin signaling and regulation of transcription." J Cell Sci 
120(Pt 2): 213-218. 
  
 192 
MacDonald, J. A., M. A. Borman, et al. (2001). "Identification of the endogenous smooth muscle 
myosin phosphatase-associated kinase." Proc Natl Acad Sci U S A 98(5): 2419-2424. 
  
MacDonald, J. A., L. A. Walker, et al. (2000). "Phosphorylation of telokin by cyclic nucleotide 
kinases and the identification of in vivo phosphorylation sites in smooth muscle." FEBS Lett 
479(3): 83-88. 
  
Mack, C. P., A. V. Somlyo, et al. (2001). "Smooth muscle differentiation marker gene expression 
is regulated by RhoA-mediated actin polymerization." J Biol Chem 276(1): 341-347. 
  
Maggio, J. E. (1988). "Tachykinins." Annu Rev Neurosci 11: 13-28. 
  
Maguy, A., T. E. Hebert, et al. (2006). "Involvement of lipid rafts and caveolae in cardiac ion 
channel function." Cardiovasc Res 69(4): 798-807. 
  
Mahavadi S, Z. H., Murthy KS (2004). "Distinctive signaling by cannabinoid CB1 receptors in 
smooth muscle cells: absence of Gβγ -dependent activation of PLC-β1." Gastroenterology 126: 
A275 (Abstr.) 
 
  
Makhlouf, G. M. and K. S. Murthy (1997). "Signal transduction in gastrointestinal smooth 
muscle." Cell Signal 9(3-4): 269-276. 
  
Manabe, I. and G. K. Owens (2001). "CArG elements control smooth muscle subtype-specific 
expression of smooth muscle myosin in vivo." J Clin Invest 107(7): 823-834. 
  
Marty, C., D. D. Browning, et al. (2003). "Identification of tetratricopeptide repeat 1 as an 
adaptor protein that interacts with heterotrimeric G proteins and the small GTPase Ras." Mol 
Cell Biol 23(11): 3847-3858. 
  
Matthews, L. C., M. J. Taggart, et al. (2005). "Effect of cholesterol depletion on mitogenesis and 
survival: the role of caveolar and noncaveolar domains in insulin-like growth factor-mediated 
cellular function." Endocrinology 146(12): 5463-5473. 
  
Matveev, S. V. and E. J. Smart (2002). "Heterologous desensitization of EGF receptors and 
PDGF receptors by sequestration in caveolae." Am J Physiol Cell Physiol 282(4): C935-946. 
  
Mercier, I., J. F. Jasmin, et al. (2009). "Clinical and translational implications of the caveolin 
gene family: lessons from mouse models and human genetic disorders." Lab Invest 89(6): 614-
623. 
  
Michel, J. J. and J. D. Scott (2002). "AKAP mediated signal transduction." Annu Rev Pharmacol 
Toxicol 42: 235-257. 
  
 193 
Migeon, J. C., S. L. Thomas, et al. (1995). "Differential coupling of m2 and m4 muscarinic 
receptors to inhibition of adenylyl cyclase by Gi alpha and G(o)alpha subunits." J Biol Chem 
270(27): 16070-16074. 
  
Miller, S. M., D. Reed, et al. (2001). "Haem oxygenase in enteric nervous system of human 
stomach and jejunum and co-localization with nitric oxide synthase." Neurogastroenterol Motil 
13(2): 121-131. 
  
Minshall, R. D., W. C. Sessa, et al. (2003). "Caveolin regulation of endothelial function." Am J 
Physiol Lung Cell Mol Physiol 285(6): L1179-1183. 
  
Misra, S., K. S. Murthy, et al. (2004). "Coexpression of Y1, Y2, and Y4 receptors in smooth 
muscle coupled to distinct signaling pathways." J Pharmacol Exp Ther 311(3): 1154-1162. 
  
Morel, J. L., N. Macrez, et al. (1997). "Specific Gq protein involvement in muscarinic M3 
receptor-induced phosphatidylinositol hydrolysis and Ca2+ release in mouse duodenal 
myocytes." Br J Pharmacol 121(3): 451-458. 
  
Morgan, K. G. and S. S. Gangopadhyay (2001). "Invited review: cross-bridge regulation by thin 
filament-associated proteins." J Appl Physiol 91(2): 953-962. 
  
Morgan, K. G., T. C. Muir, et al. (1981). "The electrical basis for contraction and relaxation in 
canine fundal smooth muscle." J Physiol 311: 475-488. 
  
Morini, G., J. F. Kuemmerle, et al. (1993). "Coexistence of histamine H1 and H2 receptors 
coupled to distinct signal transduction pathways in isolated intestinal muscle cells." J Pharmacol 
Exp Ther 264(2): 598-603. 
  
Mukherjee, S., M. Tessema, et al. (2006). "Vesicular trafficking of tyrosine kinase receptors and 
associated proteins in the regulation of signaling and vascular function." Circ Res 98(6): 743-
756. 
  
Muranyi, A., J. A. MacDonald, et al. (2002). "Phosphorylation of the myosin phosphatase target 
subunit by integrin-linked kinase." Biochem J 366(Pt 1): 211-216. 
  
Murray F, P. H., Suda R, Thistlethwaite P, Yuan J, Insel P. (2006). "Caveolar localization and 
caveolin-1 regulation of PDE5 in human pulmonary artery smooth muscle cells." FASEB J. 20:: 
A543. 
  
Murthy, K. S. (2001). "Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by 
cGMP-dependent protein kinase in smooth muscle." Biochem J 360(Pt 1): 199-208. 
  
Murthy, K. S. (2006). "Signaling for contraction and relaxation in smooth muscle of the gut." 
Annu Rev Physiol 68: 345-374. 
  
 194 
Murthy, K. S. (2008). "Inhibitory phosphorylation of soluble guanylyl cyclase by muscarinic m2 
receptors via Gbetagamma-dependent activation of c-Src kinase." J Pharmacol Exp Ther 325(1): 
183-189. 
  
Murthy, K. S., J. R. Grider, et al. (2000). "Sustained muscle contraction induced by agonists, 
growth factors, and Ca(2+) mediated by distinct PKC isozymes." Am J Physiol Gastrointest 
Liver Physiol 279(1): G201-210. 
  
Murthy, K. S., J. R. Grider, et al. (1991). "InsP3-dependent Ca2+ mobilization in circular but not 
longitudinal muscle cells of intestine." Am J Physiol 261(6 Pt 1): G937-944. 
  
Murthy, K. S., J. R. Grider, et al. (2000). "Heterologous desensitization of response mediated by 
selective PKC-dependent phosphorylation of G(i-1) and G(i-2)." Am J Physiol Cell Physiol 
279(4): C925-934. 
  
Murthy, K. S., S. Mahavadi, et al. (2008). "Phosphorylation of GRK2 by PKA augments GRK2-
mediated phosphorylation, internalization, and desensitization of VPAC2 receptors in smooth 
muscle." Am J Physiol Cell Physiol 294(2): C477-487. 
  
Murthy, K. S. and G. M. Makhlouf (1991). "Phosphoinositide metabolism in intestinal smooth 
muscle: preferential production of Ins(1,4,5)P3 in circular muscle cells." Am J Physiol 261(6 Pt 
1): G945-951. 
  
Murthy, K. S. and G. M. Makhlouf (1995). "Adenosine A1 receptor-mediated activation of 
phospholipase C-beta 3 in intestinal muscle: dual requirement for alpha and beta gamma subunits 
of Gi3." Mol Pharmacol 47(6): 1172-1179. 
  
Murthy, K. S. and G. M. Makhlouf (1997). "Differential coupling of muscarinic m2 and m3 
receptors to adenylyl cyclases V/VI in smooth muscle. Concurrent M2-mediated inhibition via 
Galphai3 and m3-mediated stimulation via Gbetagammaq." J Biol Chem 272(34): 21317-21324. 
  
Murthy, K. S. and G. M. Makhlouf (1998). "Coexpression of ligand-gated P2X and G protein-
coupled P2Y receptors in smooth muscle. Preferential activation of P2Y receptors coupled to 
phospholipase C (PLC)-beta1 via Galphaq/11 and to PLC-beta3 via Gbetagammai3." J Biol 
Chem 273(8): 4695-4704. 
  
Murthy, K. S. and G. M. Makhlouf (1998). "Differential regulation of phospholipase A2 (PLA2)-
dependent Ca2+ signaling in smooth muscle by cAMP- and cGMP-dependent protein kinases. 
Inhibitory phosphorylation of PLA2 by cyclic nucleotide-dependent protein kinases." J Biol 
Chem 273(51): 34519-34526. 
  
Murthy, K. S. and G. M. Makhlouf (1998). "Regulation of adenylyl cyclase type V/VI in smooth 
muscle: interplay of inhibitory G protein and Ca2+ influx." Mol Pharmacol 54(1): 122-128. 
  
Murthy, K. S. and G. M. Makhlouf (2000). "Heterologous desensitization mediated by G protein-
specific binding to caveolin." J Biol Chem 275(39): 30211-30219. 
 195 
  
Murthy, K. S. and H. Zhou (2003). "Selective phosphorylation of the IP3R-I in vivo by cGMP-
dependent protein kinase in smooth muscle." Am J Physiol Gastrointest Liver Physiol 284(2): 
G221-230. 
  
Murthy, K. S., H. Zhou, et al. (2003). Biochem J 374(Pt 1): 145-155. 
  
Murthy, K. S., H. Zhou, et al. (2003). "Differential signalling by muscarinic receptors in smooth 
muscle: m2-mediated inactivation of myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-
activated kinase 1 pathway, and m3-mediated MLC20 (20 kDa regulatory light chain of myosin 
II) phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and 
protein kinase C/CPI-17 pathway." Biochem J 374(Pt 1): 145-155. 
  
Murthy, K. S., H. Zhou, et al. (2001). "Sequential activation of heterotrimeric and monomeric G 
proteins mediates PLD activity in smooth muscle." Am J Physiol Gastrointest Liver Physiol 
280(3): G381-388. 
  
Murthy, K. S., H. Zhou, et al. (2003). "Inhibition of sustained smooth muscle contraction by 
PKA and PKG preferentially mediated by phosphorylation of RhoA." Am J Physiol Gastrointest 
Liver Physiol 284(6): G1006-1016. 
  
Murthy, K. S., H. Zhou, et al. (2002). "PKA-dependent activation of PDE3A and PDE4 and 
inhibition of adenylyl cyclase V/VI in smooth muscle." Am J Physiol Cell Physiol 282(3): C508-
517. 
  
Neal, K. B. and J. C. Bornstein (2008). "Targets of myenteric interneurons in the guinea-pig 
small intestine." Neurogastroenterol Motil 20(5): 566-575. 
  
Neubig, R. R. (2002). "Regulators of G protein signaling (RGS proteins): novel central nervous 
system drug targets." J Pept Res 60(6): 312-316. 
  
Niihashi, M., M. Esumi, et al. (2000). "Expression of muscarinic receptor genes in the human 
coronary artery." Angiology 51(4): 295-300. 
  
Niiro, N. and M. Ikebe (2001). "Zipper-interacting protein kinase induces Ca(2+)-free smooth 
muscle contraction via myosin light chain phosphorylation." J Biol Chem 276(31): 29567-29574. 
  
Nilsson, R., F. Ahmad, et al. (2006). "Plasma membrane cyclic nucleotide phosphodiesterase 3B 
(PDE3B) is associated with caveolae in primary adipocytes." Cell Signal 18(10): 1713-1721. 
  
Oh, P., D. P. McIntosh, et al. (1998). "Dynamin at the neck of caveolae mediates their budding to 
form transport vesicles by GTP-driven fission from the plasma membrane of endothelium." J 
Cell Biol 141(1): 101-114. 
  
 196 
Okamoto, T., A. Schlegel, et al. (1998). "Caveolins, a family of scaffolding proteins for 
organizing "preassembled signaling complexes" at the plasma membrane." J Biol Chem 273(10): 
5419-5422. 
  
Olivares-Reyes, J. A., B. H. Shah, et al. (2005). "Agonist-induced interactions between 
angiotensin AT1 and epidermal growth factor receptors." Mol Pharmacol 68(2): 356-364. 
  
Ortegren, U., M. Karlsson, et al. (2004). "Lipids and glycosphingolipids in caveolae and 
surrounding plasma membrane of primary rat adipocytes." Eur J Biochem 271(10): 2028-2036. 
  
Ostrom, R. S. and P. A. Insel (2006). "Methods for the study of signaling molecules in 
membrane lipid rafts and caveolae." Methods Mol Biol 332: 181-191. 
  
Ostrom, R. S., X. Liu, et al. (2002). "Localization of adenylyl cyclase isoforms and G protein-
coupled receptors in vascular smooth muscle cells: expression in caveolin-rich and noncaveolin 
domains." Mol Pharmacol 62(5): 983-992. 
  
Papoucheva, E., A. Dumuis, et al. (2004). "The 5-hydroxytryptamine(1A) receptor is stably 
palmitoylated, and acylation is critical for communication of receptor with Gi protein." J Biol 
Chem 279(5): 3280-3291. 
  
Parton, R. G. (2003). "Caveolae--from ultrastructure to molecular mechanisms." Nat Rev Mol 
Cell Biol 4(2): 162-167. 
  
Parton, R. G. and K. Simons (2007). "The multiple faces of caveolae." Nat Rev Mol Cell Biol 
8(3): 185-194. 
  
Patel, H. H., F. Murray, et al. (2008). "Caveolae as organizers of pharmacologically relevant 
signal transduction molecules." Annu Rev Pharmacol Toxicol 48: 359-391. 
  
Pelkmans, L., T. Burli, et al. (2004). "Caveolin-stabilized membrane domains as multifunctional 
transport and sorting devices in endocytic membrane traffic." Cell 118(6): 767-780. 
  
Penela, P., C. Murga, et al. (2006). "Mechanisms of regulation of G protein-coupled receptor 
kinases (GRKs) and cardiovascular disease." Cardiovasc Res 69(1): 46-56. 
  
Perry, S. J. and R. J. Lefkowitz (2002). "Arresting developments in heptahelical receptor 
signaling and regulation." Trends Cell Biol 12(3): 130-138. 
  
Pidoux, G. and K. Tasken (2010). "Specificity and spatial dynamics of protein kinase A 
signaling organized by A-kinase-anchoring proteins." J Mol Endocrinol 44(5): 271-284. 
  
Pierce, K. L., R. T. Premont, et al. (2002). "Seven-transmembrane receptors." Nat Rev Mol Cell 
Biol 3(9): 639-650. 
  
 197 
Pike, L. J. (2005). "Growth factor receptors, lipid rafts and caveolae: an evolving story." 
Biochim Biophys Acta 1746(3): 260-273. 
  
Pipes, G. C., E. E. Creemers, et al. (2006). "The myocardin family of transcriptional 
coactivators: versatile regulators of cell growth, migration, and myogenesis." Genes Dev 20(12): 
1545-1556. 
  
Pitcher, J. A., N. J. Freedman, et al. (1998). "G protein-coupled receptor kinases." Annu Rev 
Biochem 67: 653-692. 
  
Pompolo, S. and J. B. Furness (1988). "Ultrastructure and synaptic relationships of calbindin-
reactive, Dogiel type II neurons, in myenteric ganglia of guinea-pig small intestine." J 
Neurocytol 17(6): 771-782. 
  
Pouokam, E. and M. Diener (2012). "Modulation of ion transport across rat distal colon by 
cysteine." Front Physiol 3: 43. 
  
Predescu, S. A., D. N. Predescu, et al. (2007). "Molecular determinants of endothelial 
transcytosis and their role in endothelial permeability." Am J Physiol Lung Cell Mol Physiol 
293(4): L823-842. 
  
Preininger, A. M., L. G. Henage, et al. (2006). "Direct modulation of phospholipase D activity 
by Gbetagamma." Mol Pharmacol 70(1): 311-318. 
  
Puetz, S., L. T. Lubomirov, et al. (2009). "Regulation of smooth muscle contraction by small 
GTPases." Physiology (Bethesda) 24: 342-356. 
  
Ranganathan, R. and E. M. Ross (1997). "PDZ domain proteins: scaffolds for signaling 
complexes." Curr Biol 7(12): R770-773. 
  
Rapacciuolo, A., S. Suvarna, et al. (2003). "Protein kinase A and G protein-coupled receptor 
kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different 
pathways." J Biol Chem 278(37): 35403-35411. 
  
Rath, G., C. Dessy, et al. (2009). "Caveolae, caveolin and control of vascular tone: nitric oxide 
(NO) and endothelium derived hyperpolarizing factor (EDHF) regulation." J Physiol Pharmacol 
60 Suppl 4: 105-109. 
  
Rattan, S., R. N. Puri, et al. (2003). "Involvement of rho and rho-associated kinase in sphincteric 
smooth muscle contraction by angiotensin II." Exp Biol Med (Maywood) 228(8): 972-981. 
  
Razani, B. and M. P. Lisanti (2001). "Two distinct caveolin-1 domains mediate the functional 
interaction of caveolin-1 with protein kinase A." Am J Physiol Cell Physiol 281(4): C1241-1250. 
  
 198 
Razani, B., C. S. Rubin, et al. (1999). "Regulation of cAMP-mediated signal transduction via 
interaction of caveolins with the catalytic subunit of protein kinase A." J Biol Chem 274(37): 
26353-26360. 
  
Razani, B., S. E. Woodman, et al. (2002). "Caveolae: from cell biology to animal physiology." 
Pharmacol Rev 54(3): 431-467. 
  
Reed, D. E. and S. Vanner (2007). "Mucosal stimulation activates secretomotor neurons via long 
myenteric pathways in guinea pig ileum." Am J Physiol Gastrointest Liver Physiol 292(2): 
G608-614. 
  
Rensen, S. S., P. A. Doevendans, et al. (2007). "Regulation and characteristics of vascular 
smooth muscle cell phenotypic diversity." Neth Heart J 15(3): 100-108. 
  
Riento, K. and A. J. Ridley (2003). "Rocks: multifunctional kinases in cell behaviour." Nat Rev 
Mol Cell Biol 4(6): 446-456. 
  
Ruhl, A., Y. Nasser, et al. (2004). "Enteric glia." Neurogastroenterol Motil 16 Suppl 1: 44-49. 
  
Sabbatini, M. E., Y. Bi, et al. (2010). "CCK activates RhoA and Rac1 differentially through 
Galpha13 and Galphaq in mouse pancreatic acini." Am J Physiol Cell Physiol 298(3): C592-601. 
  
Salani, B., M. Passalacqua, et al. (2010). "IGF-IR internalizes with Caveolin-1 and PTRF/Cavin 
in HaCat cells." PLoS One 5(11): e14157. 
  
Sanders, K. M. (2000). "Postjunctional electrical mechanisms of enteric neurotransmission." Gut 
47 Suppl 4: iv23-25; discussion iv26. 
  
Sanders, K. M., S. D. Koh, et al. (2006). "Interstitial cells of cajal as pacemakers in the 
gastrointestinal tract." Annu Rev Physiol 68: 307-343. 
  
Sarna, S. K. (1999). "Tachykinins and in vivo gut motility." Dig Dis Sci 44(8 Suppl): 114S-
118S. 
  
Satake, H., T. Kawada, et al. (2003). "Insight into tachykinin-related peptides, their receptors, 
and invertebrate tachykinins: a review." Zoolog Sci 20(5): 533-549. 
  
Sathish, V., B. Yang, et al. (2011). "Caveolin-1 and force regulation in porcine airway smooth 
muscle." Am J Physiol Lung Cell Mol Physiol 300(6): L920-929. 
  
Sauzeau, V., H. Le Jeune, et al. (2000). "Cyclic GMP-dependent protein kinase signaling 
pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle." J 
Biol Chem 275(28): 21722-21729. 
  
Schemann, M., H. Sann, et al. (1993). "Identification of cholinergic neurons in enteric nervous 
system by antibodies against choline acetyltransferase." Am J Physiol 265(5 Pt 1): G1005-1009. 
 199 
  
Scherer, P. E., R. Y. Lewis, et al. (1997). "Cell-type and tissue-specific expression of caveolin-2. 
Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo." J Biol 
Chem 272(46): 29337-29346. 
  
Schicho, R., D. Krueger, et al. (2006). "Hydrogen sulfide is a novel prosecretory neuromodulator 
in the Guinea-pig and human colon." Gastroenterology 131(5): 1542-1552. 
  
Schlenz, H., W. Kummer, et al. (2010). "Muscarinic receptor-mediated bronchoconstriction is 
coupled to caveolae in murine airways." Am J Physiol Lung Cell Mol Physiol 298(5): L626-636. 
  
Schnitzer, J. E., J. Liu, et al. (1995). "Endothelial caveolae have the molecular transport 
machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, 
and GTPases." J Biol Chem 270(24): 14399-14404. 
  
Schnitzer, J. E., P. Oh, et al. (1995). "Caveolae from luminal plasmalemma of rat lung 
endothelium: microdomains enriched in caveolin, Ca(2+)-ATPase, and inositol trisphosphate 
receptor." Proc Natl Acad Sci U S A 92(5): 1759-1763. 
  
Schramm, C. M., N. C. Arjona, et al. (1995). "Role of muscarinic M2 receptors in regulating 
beta-adrenergic responsiveness in maturing rabbit airway smooth muscle." Am J Physiol 269(6 
Pt 1): L783-790. 
  
Schwencke, C., A. Schmeisser, et al. (2005). "Decreased caveolin-1 in atheroma: loss of 
antiproliferative control of vascular smooth muscle cells in atherosclerosis." Cardiovasc Res 
68(1): 128-135. 
  
Schwentner, C., J. Oswald, et al. (2005). "Loss of interstitial cells of Cajal and gap junction 
protein connexin 43 at the vesicoureteral junction in children with vesicoureteral reflux." J Urol 
174(5): 1981-1986. 
  
Sengupta, P., F. Philip, et al. (2008). "Caveolin-1 alters Ca(2+) signal duration through specific 
interaction with the G alpha q family of G proteins." J Cell Sci 121(Pt 9): 1363-1372. 
  
Shah, V. and P. S. Kamath (2003). "Nitric oxide in liver transplantation: pathobiology and 
clinical implications." Liver Transpl 9(1): 1-11. 
  
Shajahan, A. N., B. K. Timblin, et al. (2003). "Endocytosis of caveolae in endothelial cells by 
Src-dependent dynamin-2 phosphorylation." Faseb Journal 17(4): A198-A198. 
  
Shajahan, A. N., B. K. Timblin, et al. (2004). "Role of Src-induced dynamin-2 phosphorylation 
in caveolae-mediated endocytosis in endothelial cells." J Biol Chem 279(19): 20392-20400. 
  
Shajahan, A. N., C. Tiruppathi, et al. (2004). "Gbetagamma activation of Src induces caveolae-
mediated endocytosis in endothelial cells." J Biol Chem 279(46): 48055-48062. 
  
 200 
Shakirova, Y., J. Bonnevier, et al. (2006). "Increased Rho activation and PKC-mediated smooth 
muscle contractility in the absence of caveolin-1." Am J Physiol Cell Physiol 291(6): C1326-
1335. 
  
Shenoy, S. K. and R. J. Lefkowitz (2003). "Multifaceted roles of beta-arrestins in the regulation 
of seven-membrane-spanning receptor trafficking and signalling." Biochem J 375(Pt 3): 503-
515. 
  
Shore, P. and A. D. Sharrocks (1995). "The MADS-box family of transcription factors." Eur J 
Biochem 229(1): 1-13. 
  
Siehler, S. (2009). "Regulation of RhoGEF proteins by G12/13-coupled receptors." Br J 
Pharmacol 158(1): 41-49. 
  
Singer, C. A., S. Vang, et al. (2002). "Coupling of M(2) muscarinic receptors to Src activation in 
cultured canine colonic smooth muscle cells." Am J Physiol Gastrointest Liver Physiol 282(1): 
G61-68. 
  
Snow, B. E., R. A. Hall, et al. (1998). "GTPase activating specificity of RGS12 and binding 
specificity of an alternatively spliced PDZ (PSD-95/Dlg/ZO-1) domain." J Biol Chem 273(28): 
17749-17755. 
  
Snyder, S. H., S. R. Jaffrey, et al. (1998). "Nitric oxide and carbon monoxide: parallel roles as 
neural messengers." Brain Res Brain Res Rev 26(2-3): 167-175. 
  
Somlyo, A. P. and A. V. Somlyo (1994). "Signal transduction and regulation in smooth muscle." 
Nature 372(6503): 231-236. 
  
Somlyo, A. P. and A. V. Somlyo (2003). "Ca2+ sensitivity of smooth muscle and nonmuscle 
myosin II: modulated by G proteins, kinases, and myosin phosphatase." Physiol Rev 83(4): 
1325-1358. 
  
Stengel, P. W., M. Yamada, et al. (2002). "M(3)-receptor knockout mice: muscarinic receptor 
function in atria, stomach fundus, urinary bladder, and trachea." Am J Physiol Regul Integr 
Comp Physiol 282(5): R1443-1449. 
  
Suzuki, N., N. Hajicek, et al. (2009). "Regulation and physiological functions of G12/13-
mediated signaling pathways." Neurosignals 17(1): 55-70. 
  
Sverdlov, M., A. N. Shajahan, et al. (2007). "Tyrosine phosphorylation-dependence of caveolae-
mediated endocytosis." J Cell Mol Med 11(6): 1239-1250. 
  
Taggart, M. J. (2001). "Smooth muscle excitation-contraction coupling: a role for caveolae and 
caveolins?" News Physiol Sci 16: 61-65. 
  
 201 
Taggart, M. J., P. Leavis, et al. (2000). "Inhibition of PKCalpha and rhoA translocation in 
differentiated smooth muscle by a caveolin scaffolding domain peptide." Exp Cell Res 258(1): 
72-81. 
  
Tang, D. D. (2008). "Intermediate filaments in smooth muscle." Am J Physiol Cell Physiol 
294(4): C869-878. 
  
Tang, Z., P. E. Scherer, et al. (1996). "Molecular cloning of caveolin-3, a novel member of the 
caveolin gene family expressed predominantly in muscle." J Biol Chem 271(4): 2255-2261. 
  
Tansey, M. G., K. Luby-Phelps, et al. (1994). "Ca(2+)-dependent phosphorylation of myosin 
light chain kinase decreases the Ca2+ sensitivity of light chain phosphorylation within smooth 
muscle cells." J Biol Chem 269(13): 9912-9920. 
  
Tazzeo, T., G. Bates, et al. (2012). "Caffeine Relaxes Smooth Muscle through Actin 
Depolymerization." Am J Physiol Lung Cell Mol Physiol. 
  
Teng, B., K. S. Murthy, et al. (1998). "Expression of endothelial nitric oxide synthase in human 
and rabbit gastrointestinal smooth muscle cells." Am J Physiol 275(2 Pt 1): G342-351. 
  
Teng, B. Q., J. R. Grider, et al. (2001). "Identification of a VIP-specific receptor in guinea pig 
tenia coli." Am J Physiol Gastrointest Liver Physiol 281(3): G718-725. 
  
Tobin, G., D. Giglio, et al. (2009). "Muscarinic receptor subtypes in the alimentary tract." J 
Physiol Pharmacol 60(1): 3-21. 
  
Tonini, M. and M. Costa (1990). "A pharmacological analysis of the neuronal circuitry involved 
in distension-evoked enteric excitatory reflex." Neuroscience 38(3): 787-795. 
  
Torres, V. A., J. C. Tapia, et al. (2006). "Caveolin-1 controls cell proliferation and cell death by 
suppressing expression of the inhibitor of apoptosis protein survivin." J Cell Sci 119(Pt 9): 1812-
1823. 
  
Toya, Y., C. Schwencke, et al. (1998). "Inhibition of adenylyl cyclase by caveolin peptides." 
Endocrinology 139(4): 2025-2031. 
  
Tran, J. A., M. Matsui, et al. (2006). "Differential coupling of muscarinic M1, M2, and M3 
receptors to phosphoinositide hydrolysis in urinary bladder and longitudinal muscle of the ileum 
of the mouse." J Pharmacol Exp Ther 318(2): 649-656. 
  
Traub, L. M. (2003). "Sorting it out: AP-2 and alternate clathrin adaptors in endocytic cargo 
selection." J Cell Biol 163(2): 203-208. 
  
Turko, I. V., S. H. Francis, et al. (1998). "Binding of cGMP to both allosteric sites of cGMP-
binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation." Biochem 
J 329 ( Pt 3): 505-510. 
 202 
  
Uchiyama, T. and R. Chess-Williams (2004). "Muscarinic receptor subtypes of the bladder and 
gastrointestinal tract." J Smooth Muscle Res 40(6): 237-247. 
  
Unno, T., H. Matsuyama, et al. (2006). "Muscarinic cationic current in gastrointestinal smooth 
muscles: signal transduction and role in contraction." Auton Autacoid Pharmacol 26(3): 203-217. 
  
Valentine, C. D. and P. M. Haggie (2011). "Confinement of beta(1)- and beta(2)-adrenergic 
receptors in the plasma membrane of cardiomyocyte-like H9c2 cells is mediated by selective 
interactions with PDZ domain and A-kinase anchoring proteins but not caveolae." Mol Biol Cell 
22(16): 2970-2982. 
  
Venema, V. J., H. Ju, et al. (1997). "Interaction of neuronal nitric-oxide synthase with caveolin-3 
in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain." J Biol 
Chem 272(45): 28187-28190. 
  
Volonte, D., C. F. McTiernan, et al. (2008). "Caveolin-1 and caveolin-3 form heterooligomeric 
complexes in atrial cardiac myocytes that are required for doxorubicin-induced apoptosis." Am J 
Physiol Heart Circ Physiol 294(1): H392-401. 
  
Wamhoff, B. R., D. K. Bowles, et al. (2004). "L-type voltage-gated Ca2+ channels modulate 
expression of smooth muscle differentiation marker genes via a rho kinase/myocardin/SRF-
dependent mechanism." Circ Res 95(4): 406-414. 
  
Wang, D., P. S. Chang, et al. (2001). "Activation of cardiac gene expression by myocardin, a 
transcriptional cofactor for serum response factor." Cell 105(7): 851-862. 
  
Wang, D. Z., S. Li, et al. (2002). "Potentiation of serum response factor activity by a family of 
myocardin-related transcription factors." Proc Natl Acad Sci U S A 99(23): 14855-14860. 
  
Wang, D. Z. and E. N. Olson (2004). "Control of smooth muscle development by the myocardin 
family of transcriptional coactivators." Curr Opin Genet Dev 14(5): 558-566. 
  
Wang, H., H. Han, et al. (2001). "Expression of multiple subtypes of muscarinic receptors and 
cellular distribution in the human heart." Mol Pharmacol 59(5): 1029-1036. 
  
Wang, X. L., D. Ye, et al. (2005). "Caveolae targeting and regulation of large conductance 
Ca(2+)-activated K+ channels in vascular endothelial cells." J Biol Chem 280(12): 11656-11664. 
  
Wansink, D. G., R. E. van Herpen, et al. (2003). "Alternative splicing controls myotonic 
dystrophy protein kinase structure, enzymatic activity, and subcellular localization." Mol Cell 
Biol 23(16): 5489-5501. 
  
Ward, S. M., A. J. Burns, et al. (1994). "Mutation of the proto-oncogene c-kit blocks 
development of interstitial cells and electrical rhythmicity in murine intestine." J Physiol 480 ( Pt 
1): 91-97. 
 203 
  
Webb, R. C. (2003). "Smooth muscle contraction and relaxation." Adv Physiol Educ 27(1-4): 
201-206. 
  
Willets, J. M., R. A. Challiss, et al. (2003). "Non-visual GRKs: are we seeing the whole 
picture?" Trends Pharmacol Sci 24(12): 626-633. 
  
Williams, T. M. and M. P. Lisanti (2004). "The caveolin proteins." Genome Biol 5(3): 214. 
  
Willoughby, D. and D. M. Cooper (2007). "Organization and Ca2+ regulation of adenylyl 
cyclases in cAMP microdomains." Physiol Rev 87(3): 965-1010. 
  
Woodsome, T. P., M. Eto, et al. (2001). "Expression of CPI-17 and myosin phosphatase 
correlates with Ca(2+) sensitivity of protein kinase C-induced contraction in rabbit smooth 
muscle." J Physiol 535(Pt 2): 553-564. 
  
Wooldridge, A. A., J. A. MacDonald, et al. (2004). "Smooth muscle phosphatase is regulated in 
vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 
695 in response to cyclic nucleotides." J Biol Chem 279(33): 34496-34504. 
  
Wrana, J. and T. Pawson (1997). "Signal transduction. Mad about SMADs." Nature 388(6637): 
28-29. 
  
Wright, D. B., S. Tripathi, et al. (2012). "Regulation of GPCR-mediated smooth muscle 
contraction: Implications for asthma and pulmonary hypertension." Pulm Pharmacol Ther. 
  
Wu, C., S. Butz, et al. (1997). "Tyrosine kinase receptors concentrated in caveolae-like domains 
from neuronal plasma membrane." J Biol Chem 272(6): 3554-3559. 
  
Wu, L. and R. Wang (2005). "Carbon monoxide: endogenous production, physiological 
functions, and pharmacological applications." Pharmacol Rev 57(4): 585-630. 
  
Xu, J. Q., B. A. Harder, et al. (1996). "Myosin filament structure in vertebrate smooth muscle." J 
Cell Biol 134(1): 53-66. 
  
Xue, L., G. Farrugia, et al. (2000). "Carbon monoxide and nitric oxide as coneurotransmitters in 
the enteric nervous system: evidence from genomic deletion of biosynthetic enzymes." Proc Natl 
Acad Sci U S A 97(4): 1851-1855. 
  
Xue, L., G. Farrugia, et al. (1999). "ATP is a mediator of the fast inhibitory junction potential in 
human jejunal circular smooth muscle." Am J Physiol 276(6 Pt 1): G1373-1379. 
  
Yamamoto, M., S. Okumura, et al. (1999). "Downregulation of caveolin expression by cAMP 
signal." Life Sci 64(15): 1349-1357. 
  
 204 
Yoshida, T., S. Sinha, et al. (2003). "Myocardin is a key regulator of CArG-dependent 
transcription of multiple smooth muscle marker genes." Circ Res 92(8): 856-864. 
  
Zhang, L. B., B. Horowitz, et al. (1991). "Muscarinic receptors in canine colonic circular smooth 
muscle. I. Coexistence of M2 and M3 subtypes." Mol Pharmacol 40(6): 943-951. 
  
Zhang, Y., F. Li, et al. (2012). "MEKK1-MKK4-JNK-AP1 pathway negatively regulates Rgs4 
expression in colonic smooth muscle cells." PLoS One 7(4): e35646. 
  
Zhao, Y. Y., Y. Liu, et al. (2002). "Defects in caveolin-1 cause dilated cardiomyopathy and 
pulmonary hypertension in knockout mice." Proc Natl Acad Sci U S A 99(17): 11375-11380. 
  
Zhou, H., S. Das, et al. (2003). "Erk1/2- and p38 MAP kinase-dependent phosphorylation and 
activation of cPLA2 by m3 and m2 receptors." Am J Physiol Gastrointest Liver Physiol 284(3): 
G472-480. 
  
Zhou, H. and K. S. Murthy (2004). "Distinctive G protein-dependent signaling in smooth muscle 
by sphingosine 1-phosphate receptors S1P1 and S1P2." Am J Physiol Cell Physiol 286(5): 
C1130-1138. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 205 
VITA 
CONTACT INFORMATION 
 
SAYAK BHATTACHARYA 
300 West Franklin Street, APT 1206E, Richmond, Va-23220                                         
Tell: 804-868-9811                                                                                         
Email: bhattachars2@vcu.edu 
 
Education 
 
Master of Science (2006) 
Department of Physiology 
University of Calcutta, Kolkata, India 
 
Thesis/Dissertation 
 
Regulation of excitation-contraction and excitation-transcription coupling in gastrointestinal 
smooth muscle by caveolin-1. 
 
Key Areas of Research Experience 
• Cell culture • Cell signalling techniques 
(Radioactivity) 
• Confocal Microscopy 
• Cell and molecular Biology 
• Biochemical techniques 
• siRNA   
• Ligand binding studies 
• ELISA 
• Micrometry to measure smooth muscle 
contraction 
• Isolation of smooth muscle cells  
 
• Immuno-histochemistry 
• Basic electrophysiology 
• Ca2+ imaging (Fura dyes) 
• Two electrode voltage clamp 
• Protein expression and 
purification 
• Animal Handling 
• In vivo gastric emptying 
studies 
 
 
 
 206 
 
Experience 
 
GRADUATE RESEARCH ASSISTANT 
August 2008-present 
 
 
TEACHING EXPERIENCE 
Human Physiology Lab, 2011 
 
 
 
Advance coursework 
 
• Cellular Signalling, Fall 2010  
• Cell signalling and growth control. Spring 2011  
• Techniques in molecular biology and genetics, Fall 2009 
 
 
Fellowships/Awards 
 
1. Nominated member of Phi Kappa Phi Society of VCU's School of Medicine, 2012 
2. INDO-US Research Internship in Science and Technology, 2011-12 
3. Award for best oral presentation, Physiological society of India, 2011 
4. Best Poster Award, Graduate School Symposium, VCU, 2011 
5 Virginia Commonwealth University Teaching Assistant Award, 2008 
6. Lal Chand Mukherjee International Scholarship, University of Calcutta, 2008 
 
Publications  
 
1. Sayak Bhattacharya, Sunila Mahavadi, Othman Al-Shboul, Senthilkumar  
Rajagopal, John R. Grider. Karnam S. Murthy. Differential regulation of 
muscarinic m2 and m3 receptor signalling in gastrointestinal smooth muscle by 
caveolin-1. Manuscript submitted under review. 
 
2. Sayak Bhattacharya, Sunila Mahavadi, Ruiszhe Zhou, John R. Grider, Karnam S. 
Murthy. The role of caveolin-1 in the excitation-transcription coupling in 
gastrointestinal smooth muscle. Manuscript under review. 
 
 207 
3. Senthilkumar Rajagopal, Divya P. Kumar, Sunila Mahavadi, Sayak Bhattacharya, 
Ruizhe Zhou, Carlos Corvera, Nigel W. Bunnett, John R. Grider and Karnam S. 
Murthy. Activation of G protein-coupled bile acid receptor, TGR5 induces smooth 
muscle relaxation via PKA/Epac-mediated inhibition of RhoA/Rho kinase 
pathway. Manuscript submitted under review. 
 
4.  Rashad Ahmed, Sunila Mahavadi, Othman Al-Shboul, Sayak Bhattacharya, John 
R. Grider, Karnam S. Murthy. Characterizing the signalling pathways coupled to 
melatonin receptors in gastrointestinal smooth muscle. Manuscript submitted 
under review. 
 
 
Poster Presentation 
 
 
1. Sayak Bhattacharya, O. Al-Shboul, S. Mahavadi, J. R. Grider and K. S. Murthy. 
Role of Rho-A dependent sustained contraction by caveolin-1 in gastric smooth 
muscle. Experimental Biology, 2011. 
 
2. Sayak Bhattacharya, S. Mahavadi, J. R.Grider and K. S. Murthy. Caveolin-1 
differentially regulates muscarinic m3 and m2 receptor signalling in gastric 
smooth muscle. Experimental Biology, 2011. 
 
3. O. Al-Shboul, Sayak Bhattacharya, S. Mahavadi, s Rajagopal, R. Zhou, K. S. 
Murthy. Agonist induced Rho Kinase and ZIP kinase activity in different regions of the 
stomach. Experimental Biology, 2011. 
 
4. V.R. Joginapally, S Rajagopal, Sayak Bhattacharya, R Zhou. PCR amplification of a 
novel transcription initiation factor gene (TL-1) in smooth muscle cells of rabbit 
gastrointestinal tract and its phylogenetic analysis. Experimental Biology, 2011. 
 
5. Sayak Bhattacharya, S. Rajagopal, S. Mahavadi, R. Zhou, J. R. Grider, and K. S. 
Murthy. Regulation of muscarinic m2 and m3 receptor signaling and contractile 
protein expression by caveolin-1 in gastrointestinal smooth muscle. Keystone 
Symposia, Canada, 2012. 
 
6. Sayak Bhattacharya, S. Mahavadi, R. Zhou, J.R. Grider and K.S. Murthy. 
Regulation of excitation-contraction and excitation-transcription coupling by caveolin-1 
via microRNA-133a and transcription factors, FOX4 and Elk1 in gastrointestinal smooth 
muscle. Neurogastroenterology meeting, Bologna, Italy, 2012. 
 
7. S. Rajagopal, D.P. Kumar, Sayak Bhattacharya, S. Mahavadi, R. Zhou, C. Corvera, 
N. Bunnett, J.R. Grider, and K.S. Murthy. Activation of G protein-coupled bile acid 
receptor, TGR5 induces muscle relaxation via PKA- and Epac-mediated inhibition of 
RhoA/Rho kinase pathway. Keystone Symposia, Canada, 2012. 
 208 
 
8. S. Rajagopal, D.P. Kumar, Sayak Bhattacharya, J.R. Grider, and K.S. Murthy. 
Characterization of Gz-coupled dopamine D3 receptors in gastric smooth muscle. 
Experimental Biology, 2012. 
 
 
Memberships/Scholarly Societies 
 
AMERICAN PHYSIOLOGICAL SOCIETY 
 
 
 
 
 
  
